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 ABSTRACT   
 
As a result of improvement in survival after childhood cancer, there are now increasing 
numbers of long-term survivors of childhood cancer living in the United Kingdom and across 
Europe. Specific groups of these childhood cancer survivors experience substantial excess 
risks of adverse health and social outcomes.   
Using the population-based British Childhood Cancer Survivor Study (BCCSS) the following 
areas were investigated: (1) The proportion of survivors on regular long-term hospital follow-
up using risk stratification levels of care developed by the BCCSS in partnership with the 
National Cancer Survivorship Initiative. (2) The risks of adverse health and social outcomes 
using record-linkage and a self-reported questionnaire to assess which survivors of central 
nervous system tumours were at excess risk compared to the general population. (3) The risk 
of hospitalisation due to cerebrovascular conditions among childhood cancer survivors by 
electronic record linkage with Hospital Episode Statistics. Using the European 
PanCareSurFup cohort, the excess risks of genitourinary subsequent primary neoplasms were 
investigated among five-year survivors of childhood cancer.  
This thesis quantifies the risks experienced by childhood cancer survivors in four areas and 
provides an evidence-base for risk stratification by healthcare professionals caring for 
survivors.   
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CHAPTER 1 INTRODUCTION 
  
 2 
1.1 DEFINITION OF CHILDHOOD CANCER  
Cancer, which can also be termed neoplasm, is the uncontrolled growth of abnormal cells 
beyond their usual boundaries that can occur in any part of the body. According to the World 
Health Organisation (WHO) 'childhood cancer' is terminology used for the occurrence of a 
neoplasm in children before the age of 15 years (1). 
1.2 EPIDEMIOLOGY OF CHILDHOOD CANCER 
An overview of childhood cancer epidemiology will now be introduced focussing on the 
incidence and survival of childhood cancer in individuals aged between 0 to 14 years in the 
United Kingdom (UK), which takes into account the WHO definition (1). 
1.2.1 Incidence  
Childhood cancer is rare, accounting for less than 1% of all cancers diagnosed (2). In the UK, 
during the 2009 to 2011 period, there was on average 1,574 new cases of childhood cancer 
diagnosed per year between the ages of 0 to 14 years inclusive (2). The annual world age-
standardised incidence for childhood cancer diagnosed between the ages of 0 and 14 years 
from 2009 to 2011 in the UK was 144.9 per million children per year (2).     
From the late 1960s to the early 2000s, the incidence of childhood cancer has increased 0.9% 
on average per year in Great Britain (3). An increase in the incidence of childhood cancer 
over time is a trend that has been observed in other countries in Europe (4). It has been 
suggested that this temporal increase in childhood cancer incidence could be explained by a 
number of factors including: earlier detection of cancer through improved diagnostic 
techniques; changes in levels of environmental carcinogenic risk factors; improvements in 
ascertainment to cancer registration systems (4-6). However, there is still little known about 
the causes of childhood cancer, unlike several adult cancers for which there are well 
established environmental and/or lifestyle risk factors. 
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Incidence of childhood cancer is highest among individuals aged under five years, with 
almost half of all childhood cancers (47%) diagnosed in this age category (7). Between 1991 
and 2000, the total age-standardised annual incidence rate was highest in children aged less 
than a year (188 per million) and lowest in children aged between five and nine years (108 per 
million) respectively (3).  
1.2.2 Survival  
Overall survival from childhood cancer has increased substantially over time in developed 
countries. In the UK, the percentage surviving at least five years has increased over the past 
30 years from 28% for those diagnosed in the 1960s to 77% for those diagnosed in the 1996 
to 2000 period with a further increase to 82% among children diagnosed between 2000 and 
2010 (3, 8).  
Increases in survival after childhood cancer overall have led to substantial increases in the 
number of long-term survivors in the general population. For example, in 2012 there were 
approximately 33,000 survivors living in the UK compared to 26,000 survivors in 2005 (3, 7). 
Approximately one in 715 young adults is now a long-term survivor of childhood cancer in 
the UK (9). Improvement in survival after childhood cancer has been attributed to 
developments in several aspects of modern medicine including: diagnostic techniques (for 
example, computed tomography and magnetic resonance imaging), paediatric surgery, 
centralisation of treatment, treatment modalities including chemotherapy and radiotherapy, 
entry into clinical trials and supportive care (10, 11).     
1.3 TYPES OF CHILDHOOD CANCER   
Childhood cancers are classified into categories based on the International Classification of 
Childhood Cancer (ICCC), Third Edition (12) (see Appendix 8.1). The ICCC takes into 
account the fact that childhood tumours are histologically more diverse than adult cancers, 
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which are typically coded using the International Classification of Diseases (ICD), a largely 
site based classification (13). The ICCC relies on tumours being coded using the International 
Classification of Diseases for Oncology, third edition (ICD-O-3) (14). Therefore the ICCC is 
based on morphology (type), topography (site) and behaviour code relating to the neoplasm. 
The diagnostic groups of childhood cancer for all of the analysis in this thesis are thus based 
on specific groups as defined by the ICCC and those groups not detailed below form a 
category of 'other' in the analyses. Further descriptions of the diagnostic groups (which can be 
divided into the broad categories of leukaemia and lymphoma or solid cancers) used 
throughout the analysis will be presented in the next two sections. Figure 1.1 summarises the 
main types of childhood cancer diagnosed in the UK.  
Figure 1.1 Main types of childhood cancer diagnosed in children aged 0-14 years in the UK between 2001 and 
2010 based on data provided by the National Registry of Childhood Tumours (8, 15) 
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1.3.2 Leukaemia and lymphomas  
Leukaemia, a haematological cancer of the blood and bone marrow is the commonest type of 
childhood cancer, accounting for approximately a third of all childhood cancers (16). 
Leukaemia can be further classified into acute or chronic. Acute leukaemia, which typically 
develops and progresses rapidly includes acute lymphoblastic leukaemia (ALL) accounting 
for 80% of all leukaemia (17) and acute myeloid leukaemia (AML) accounting for 15% of all 
leukaemia (18). In contrast, chronic leukaemia develops slowly over time and is rarer in 
children, less than 15 new cases of chronic myeloid leukaemia (CML) are diagnosed annually 
in the UK (19). Lymphomas arising in the lymphatic system broadly comprise Hodgkin's 
lymphoma and Non-Hodgkin lymphoma (NHL) which together account for just over 11% of 
childhood cancers in the UK (17).  
1.3.3 Solid cancers 
Central nervous system (CNS) tumours of which there are many different subtypes are the 
second most frequently diagnosed childhood cancer, accounting for over a quarter of all 
childhood cancers in the UK (16). CNS tumours are usually named after the cell type from 
which they develop or site of the brain in which they develop, they can be malignant or 
benign. The most common subtypes of CNS tumours are astrocytomas, which typically 
account for 40% of all CNS tumours diagnosed. Embryonal tumours, which mainly comprise 
medulloblastomas or primitive neuroectodermal tumours (PNETs) are the second most 
common CNS subtypes in childhood and account for 20% of all CNS tumours diagnosed. 
Ependymomas account for 10% of all CNS tumours diagnosed (20). 
Embryonal tumours developing outside the CNS encompass several varieties and only the 
main types are described here. Neuroblastoma tumours are usually derived from primordial 
neural crest cells, which are involved in the development of the nervous system. Principally in 
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childhood they are found in the spine and account for 6% of all childhood cancers diagnosed 
(15, 21). Retinoblastoma is a malignant tumour of the embryonic neural retina, which can be 
hereditary (autosomal dominant) or non-hereditary in form and account for 3% of all 
childhood cancer diagnoses (22, 23). Wilms' tumour, also known as nephroblastoma, 
originates in the kidney from metanephric blastema cells and can either be unilateral, 
affecting one kidney or bilateral, affecting both kidneys (24). Wilms' tumour comprise 90% of 
all renal cancers in childhood and renal cancers collectively account for 5% of all childhood 
cancer diagnoses in the UK (25).   
Soft tissue sarcomas are tumours that arise in connective tissue such as tendons and soft tissue 
such as muscle and comprise 7% of all childhood cancer diagnoses in the UK (26). 
Rhabdomyosarcoma is the most prevalent type of soft tissue sarcoma (26). The main types of 
malignant bone tumours are osteosarcoma and Ewing's sarcoma. Ewing's sarcoma can also 
originate in the connective tissues (27). Osteosarcoma is more common than Ewing's sarcoma 
in childhood and together they comprise 4% of childhood cancer diagnoses in the UK (28).  
1.4 ESTABLISHED CHILDHOOD CANCER SURVIVOR COHORTS  
Various cohorts have been established to investigate childhood cancer survivors since there 
was a growing need to address survivorship issues, particularly the risks of adverse health and 
social outcomes, in this population. In Europe, the main cohorts that exist are the Adult Life 
after Childhood Cancer in Scandinavia (ALiCCS) (29), the British Childhood Cancer 
Survivor Study (BCCSS) (30), the Dutch Childhood Oncology Group Late Effect Registry 
(DCOG LATER) (31) and the Swiss Childhood Cancer Survivor Study (SCCSS) (32). In 
North America, three cohorts exist, the Childhood Cancer Survivor Study (CCSS) (33), the 
Childhood, Adolescent and Young Adult Cancer Survivor Research Program (CAYCAS) (34) 
and the St. Jude Lifetime (SJLIFE) Cohort study (35). Other childhood cancer survivor 
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cohorts exist such as the French Childhood Cancer Survivor Study (FCCSS) (36), Australian 
childhood cancer survivor cohort based on the New South Wales population (37) and the 
recently established French Childhood Cancer Survivor Study for Leukaemia (LEA) cohort 
(38). Two of the cohorts mentioned above have been extended to encompass more recently 
diagnosed survivors; these include a period of diagnosis which now spans from 1940 to 2006 
in the BCCSS and a period of diagnosis from 1971 to 1999 in the CCSS. Table 1.1 
summarises some of the key features of the main childhood cancer survivor cohorts that have 
been established.  
European studies investigating survival after childhood cancer such as EUROCARE-5 state 
that their age range criteria is between 0 and 14 years inclusive as "14 years is usually the cut-
off used in studies of childhood cancer" (39). The WHO definition of childhood cancer also 
takes into account this age range (1). The definition of childhood cancer throughout this thesis 
follows age at diagnosis of 0-14 years, unless stated otherwise.  
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Table 1.1 Main characteristics of the established childhood cancer cohorts 
 
  
Name of 
cohort  
Country/Countries 
involved 
Childhood Cancer types 
included 
Period of 
FPN 
diagnosis 
Age at FPN 
diagnosis 
(years) 
Entry criteria 
(years from 
diagnosis) 
Setting  
Adult Life after 
Childhood 
Cancer in 
Scandinavia 
(ALiCCS) 
Denmark 
Finland 
Iceland  
Norway 
Sweden 
 
Leukaemia, Hodgkin's 
lymphoma, NHL, CNS 
tumours, sympathetic 
nervous system, 
Retinoblastoma, Renal 
tumours, Hepatic tumours, 
malignant bone tumour, soft 
tissue sarcoma, germ cell 
and gonadal neoplasm, 
malignant epithelial 
neoplasm, other and 
unspecified neoplasm   
 
1943-2008 <20 ≥ 1 year  Population-
based  
British 
Childhood 
Cancer 
Survivor Study 
(BCCSS) 
England  
Scotland 
Wales 
Leukaemia, Hodgkin's 
lymphoma, NHL, CNS 
tumours, neuroblastoma, 
Retinoblastoma, Wilm's 
tumour, bone sarcoma, soft 
tissue sarcoma, other 
tumours  
 
1940-1991, 
recently 
extended to 
2006 
<15 ≥ 5 years Population-
based 
Childhood 
Cancer 
Survivor Study 
(CCSS) 
North America Leukaemia, Hodgkin's 
lymphoma, NHL, CNS 
tumours neuroblastoma,  
Wilm's tumour, soft tissue 
sarcoma, bone tumour 
 
1970-1986, 
recently 
extended to 
1999 
<21 ≥ 5 years Hospital-
based 
Childhood, 
Adolescent and 
Young Adult 
Cancer 
Survivors 
Research 
Program 
(CAYCAS) 
Canada - specifically 
British Columbia 
Leukaemia, lymphomas, 
CNS tumours, sympathetic 
nervous system, 
retinoblastoma, renal 
tumours, hepatic tumours, 
malignant bone tumours, 
soft tissue sarcomas, germ 
cell cancers, carcinomas 
and other cancers  
 
1970-1995 <25 ≥ 5 years Population-
based  
Dutch 
Childhood 
Oncology 
Group LAte 
Effect Registry 
(DCOG 
LATER) 
 
Netherlands  Leukaemia, Hodgkin's 
lymphoma, NHL, CNS 
tumours, neuroblastoma, 
Retinoblastoma, Wilm's 
tumour, bone sarcoma, soft 
tissue sarcoma, other 
tumours 
1963-2002 <18 ≥ 5 years Hospital-
based  
Swiss 
Childhood 
Cancer 
Survivor Study 
(SCCSS) 
Switzerland  Leukaemia, lymphomas, 
CNS tumours, 
neuroblastoma, 
retinoblastoma, renal 
tumours, hepatic tumours, 
bone tumours, soft tissue 
sarcomas, germ cell 
tumours, other malignant 
epithelial neoplasms, other 
and unspecified malignant 
neoplasms, langerhans cell 
histiocytosis 
1976-2010 <21 ≥ 5 years Population-
based  
FPN: first primary neoplasm 
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1.5 'LATE EFFECTS' OF CHILDHOOD CANCER AND ITS TREATMENT  
Treatments given for childhood cancer involve surgery, chemotherapy or radiotherapy. Each 
of these forms of therapy may increase the risk of adverse health and social outcomes. Such 
adverse effects, often termed 'late effects' may occur soon after treatment or many years, up to 
decades, after treatment has ended (17, 40).  
Due to the number of long-term survivors now living many years beyond their original cancer 
diagnosis, there is a need to investigate the potential long-term health consequences of 
treatment for cancer. Research has provided evidence that the risk of late effects varies 
depending on a spectrum of cancer related and demographic factors. It is important that 
survivors are risk-stratified in relation to the intensity of follow-up care required and that the 
intensity of follow-up care corresponds closely with the level of risk anticipated (41, 42). 
Although treatment regimens have changed over recent decades, it is important to estimate the 
risks of late effects following these evolving therapies to provide risk estimates for existing 
long-term survivors and to assess potential risks associated with proposed new treatment 
protocols (43). This is of particular relevance since many cytotoxic drugs and treatment 
modalities that were used in earlier treatment eras are still used in modern day therapeutic 
protocols (44, 45). 
1.5.1 Overall risk of chronic diseases 
In the CCSS, survivors and their siblings completing postal questionnaires resulted in the 
reported chronic health conditions of 10,397 survivors and 3,094 siblings which were graded 
using the Common Terminology Criteria for Adverse Events version 3 (CTCAE v3.0), 
developed by the National Cancer Institute (46). The CTCAE classifies conditions from grade 
1 (mild conditions) to grade 5 (fatal, i.e. death) (46). It was found that 62.3% survivors 
reported having at least one chronic health condition graded 1 to 4, by a mean age of 26.6 
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years compared to 36.8% of siblings (47). A greater proportion of survivors (27.5%) reported 
a severe (grade 3) or life-threatening or disabling condition (grade 4) by a mean age of 26.6 
years compared to 5.2% of siblings. In relative terms, survivors were three times more likely 
than their siblings to have a chronic health condition of any grade (47). The cumulative risk of 
developing at least one chronic condition of any grade by 30 years from diagnosis was 73.4% 
(47). The CCSS have also investigated the risk of chronic conditions, graded 3, 4 or 5 
according to the CTCAE v3.0 (46) in association with attained age (48). By age 50 years, the 
cumulative incidence of chronic conditions graded at least 3 was 53.6% for survivors 
compared to 19.8% for siblings (48). Increasing cumulative incidence of particular chronic 
conditions such as cardiac dysfunction, respiratory impairments and endocrine disease with 
increasing age of survivors has been reported (49). These findings reinforce the ongoing 
importance of monitoring survivors many years after their original childhood cancer diagnosis 
since a large proportion of the survivor population will experience a chronic condition related 
to their treatment. In a hospital-based Dutch study of 1,362 childhood cancer survivors, the 
total burden of adverse health outcomes associated with various treatments was investigated 
(50). Using the CTCAE v3.0 grade of events (46) and the number of events experienced, the 
survivors were categorised to low (one or more grade 1 event), medium (one or more grade 2 
and/or grade 3 event), high (two or more grade 3 events or one grade 4 event) or severe (more 
grade 3/4 events or grade 5 event) burden (50). This Dutch study found that 75% of survivors 
had at least one condition of any CTCAE grade by a median attained age of 24.4 years and of 
those survivors with chronic conditions, 37% of survivors had at least one severe health 
outcome by the same age (50). Among survivors treated with radiotherapy only, 55% had a 
high or severe burden of adverse health events by a median attained age of 24.4 years, 
compared with 25% of survivors treated with surgery alone and 15% of survivors treated with 
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chemotherapy alone by the same age (50). Among survivors treated with chemotherapy alone 
(either anthracyclines or alkylating agents or both combined) survivors treated with just 
anthracyclines had the highest risk (3-fold) of developing a high or severe burden score 
compared to treatment with other types of chemotherapy (50).   
 
The extent of late effects vary by childhood cancer type, for example, in a study by the CCSS, 
survivors of a CNS tumour, bone tumour or Hodgkin's disease were at highest risk of 
developing severe or life-threatening chronic health problems compared to their siblings (47). 
While in the Dutch hospital-based study which assessed burden of adverse health outcomes, 
bone tumour survivors were at the highest risk compared to other survivor groups (50).  
Thus it is important to consider the diagnostic type of the childhood cancer and the treatment 
given including types of surgery, chemotherapy and radiotherapy received by the survivor.  
The types of physical late effects survivors may experience have been documented as 
premature mortality (51-58), subsequent primary neoplasms (59-67) and chronic conditions 
such as cardiovascular (50, 68-73), endocrine (50, 70, 74-78), gastrointestinal (79, 80), 
genitourinary (70, 81-90), musculoskeletal (91), respiratory (50, 70, 92-96) and neurological 
(91, 97-102). The late effects affecting childhood cancer survivors which are the subject of 
particular focus in this doctoral research will now be detailed. 
1.5.2 Premature Mortality 
All-cause mortality as well as cause-specific mortality has been investigated in various large 
scale population-based and hospital-based cohorts; observed mortality rates in all of these 
cohorts were compared to that expected from age, calendar-period and sex-matched peers in 
the general population (52-55). Overall mortality among childhood cancer survivors in the 
BCCSS cohort was 11-times that expected (Standardised Mortality Ratio (SMR)=10.7) (55), 
in the CCSS cohort, it was 8-times that expected (SMR=8.4) (52) and in the Nordic countries 
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it was 8-times that expected (SMR=8.3) (54). However, the period of follow-up varies across 
these studies and as SMRs tend to decline with increased follow-up, one needs to be mindful 
of this when interpreting these differences. In the CCSS cohort, the cumulative risk of dying 
by 30 years from diagnosis was 18.1% (52) while in the BCCSS cohort by 50 years from 
diagnosis, the cumulative risk of dying was 31.4% compared to 6.3% expected from the 
general population (55). Within the BCCSS, survivors of leukaemia (SMR=21.5) and CNS 
tumours (SMR=12.9) were found to be at particular high risk of all-cause mortality compared 
to the general population (55). These findings are consistent with the CCSS who also found 
survivors of CNS tumours (SMR=12.9) and leukaemia (SMR=10.0) to be at the highest risk 
of mortality (52). The main causes of the excess number of deaths observed are recurrence or 
progression of primary cancer in the initial years after childhood diagnosis whereas with 
increasing time from diagnosis, non-neoplastic causes of death account for most of the excess 
number of deaths including respiratory, endocrine and cardiac diseases (52, 54, 55).   
1.5.3 Subsequent Primary Neoplasms   
A subsequent primary neoplasm (SPN) is by definition a neoplasm histologically distinct 
from the first primary neoplasm (i.e. the childhood cancer) (103). The risk of developing a 
SPN among childhood cancer survivors has been compared to age, calendar-period and sex-
matched underlying general populations (61, 63, 64, 104). In the BCCSS, the risk of survivors 
developing a SPN was 4-times that expected from the general population (63) while in the 
CCSS this was 2-times that expected from the relevant general population (104). Survivors in 
the Nordic countries had an overall risk of developing a SPN 3-times that expected from the 
relevant general population (64). The cumulative risk of SPNs at 30 years from childhood 
cancer diagnosis has been reported as 7.9% in the CCSS (60). In a Dutch hospital-based 
study, the cumulative incidence in five-year childhood cancer survivors at 30 years of follow-
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up was 11.1% (59). In the BCCSS, which has longer follow-up compared with the CCSS, the 
cumulative risk of SPNs at an attained age of 60 years was 13.8% compared to 8.4% expected 
from the general population (63). The risk of SPNs persist beyond 30 years from initial cancer 
diagnosis, with particular SPNs such as CNS and bone being more common in the short-term 
and breast and digestive SPNs being more common in the long-term (63, 64). Some SPNs are 
typically known to occur after a particular primary childhood cancer diagnosis, such as breast 
cancer after Hodgkin lymphoma, thyroid cancers after leukaemia or Hodgkin lymphoma and 
CNS SPNs after a childhood CNS tumour or leukaemia (104) but this is largely explained by 
treatment for the relevant childhood cancers. As survivors are increasing in numbers and 
reaching ages where common cancers of mature adulthood typically develop in the general 
population such as breast, bowel and genitourinary cancers, further investigation is needed 
(63, 64). The main risk factor for solid cancer is radiation, while for leukaemia it is 
chemotherapy (60, 61, 105).  
1.5.4 Cardiac diseases 
Cardiac diseases occurring among childhood cancer survivors include cardiomyopathy/heart 
failure, ischaemic heart disease, valvular abnormalities, pericardial disease and arrhythmia 
(49, 68). In the CCSS, survivors were between 5-and 6-times more likely to have an adverse 
cardiac condition compared to siblings; cardiac conditions included 
cardiomyopathy/congestive heart failure, myocardial infarction, pericardial disease and 
valvular abnormalities (68). Of the non-neoplastic causes of mortality observed among 
survivors, cardiac is the leading cause (51, 54, 55). By 30 years from cancer diagnosis, 
cardiac deaths accounted for a total of 6.9% of all causes of deaths in the CCSS cohort (51). 
By 50 years from cancer diagnosis in the BCCSS, the cumulative mortality due to circulatory 
causes was 3.9% (55). This latter study highlights that survivors remain at elevated risk of 
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cardiac conditions many years after their original childhood cancer diagnosis. Survivors of 
Hodgkin's disease are at particular increased risk of cardiac conditions (68, 106). In a clinical 
cohort, 56.4% of survivors classified as being at risk due to their childhood cancer treatment 
had cardiac abnormalities, one of the most prevalent chronic conditions among adult survivors 
of childhood cancer (70). Radiation has been shown to accelerate the atherosclerotic process 
which increases the risk of ischaemic heart disease (107) while anthracyclines increase the 
risk of cardiomyopathy and heart failure (108, 109). A hospital-based study in the 
Netherlands, which had a median follow-up of 17 years found childhood cancer survivors 
previously treated with anthracyclines in childhood to have a 3-fold risk of an adverse 
cardiovascular event compared to survivors treated with no chemotherapy (50).  
1.5.5 Stroke 
In a CCSS study of 14,358 childhood cancer survivors that were followed up for a mean of 
23.3 years, the overall relative risk of having a stroke among survivors was 8-times that 
among siblings (110). Survivors of CNS tumours and leukaemia had the highest risk of stroke 
among all types of childhood cancer as demonstrated by significantly increased relative risks 
of 29.0 and 6.4 compared to siblings in the CCSS cohort (111). Survivors of Hodgkin's 
disease also had elevated risk of stroke with a relative risk of 4.3 compared to siblings (112). 
Cranial radiation is a risk factor for stroke occurrence among childhood cancer survivors 
(110) as is treatment with mantle radiation (112). A study by the CCSS has investigated the 
risk of stroke over time among survivors who were treated with cranial irradiation (110). The 
cumulative incidence of stroke among CNS tumour survivors treated with cranial irradiation 
of 50+Gray (Gy) at 30 years after diagnosis was 14.2% compared with 1.3% at 10 years after 
diagnosis (110).  
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1.5.6 Respiratory diseases 
Respiratory problems investigated among survivors include; lung fibrosis, emphysema, 
pneumonia, bronchitis, recurrent sinus infections, asthma, hayfever, tonsilitis and shortness of 
breath (92). In a Dutch hospital-based study of all types of childhood cancer survivors except 
CNS tumours, 44% (n=85) of survivors had a developed a respiratory functional impairment 
after a median follow-up of 18 years (95). After five years from diagnosis, of the respiratory 
conditions investigated in a CCSS study among all types of childhood cancer, the highest 
estimated incidence rates were observed for bronchitis (13.7 per 1,000 person-years) and for 
recurrent sinus infections (11.9 per 1,000 person-years) (92). Also in the CCSS, the 
conditions among survivors associated with the highest relative risks compared with siblings 
were pneumonia (5-fold) and lung fibrosis (3-fold) (92). Respiratory conditions are one of the 
most common non-neoplastic causes deaths accounting for almost 3% of all deaths by 30 
years from diagnosis in a study by the CCSS (51). Among BCCSS survivors reaching at least 
45 years from diagnosis, 7% of all excess deaths were attributable to respiratory causes (55). 
Of 417 adult survivors of childhood cancer exposed to any of lung radiation, busulfan, 
carmustine, lomustine, bleomycin or thoracotomy, the prevalence of abnormal respiratory 
function was 62.5% by a median follow-up of 25.1 years (70). Childhood cancer survivors 
treated with both chest radiation and chemotherapeutic agents (bleomycin, busulfan, 
carmustine, cyclophosphamide or lomustine) have shown an increasing cumulative incidence 
over time of lung fibrosis, pleurisy, chronic cough and exercise exacerbated shortness of 
breath (92). Survivors at particular increased risk of respiratory complications include CNS 
tumour survivors (96) and leukaemia (113). 
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1.5.7 Endocrine 
Endocrine disorders are diverse and can be a driving factor for other health conditions to 
develop such as cardiovascular disease (114). Treatment-related endocrine disorders can have 
both a physical and psychological impact on a survivor, which can affect the quality of life a 
survivor leads (114). In a SJLIFE study, the prevalence of endocrine problems was 62.5% 
after a median follow-up of 25.1 years among adult survivors treated for childhood cancer 
with any of following: radiation to the hypothalamic-pituitary axis, neck, male or female 
reproductive organs or alkylating agents (70). Medical assessment of endocrine disorders that 
developed among childhood cancer survivors in a Dutch hospital-based study revealed 5.3% 
as severe, life-threatening or disabling or fatal by a median attained age of 24.4 years (50). 
Survivors at the greatest excess risk of hospital contact for endocrine disorders in an ALiCCS 
study included leukaemia (standardised hospitalisation rate ratio (SHRR)=7.3, 95%CI:6.7-
7.9), CNS tumours (SHRR=6.6, 95%CI:6.2-7.0) and Hodgkin's lymphoma (SHRR=6.2, 
95%CI:5.6-7.0) (75). The cumulative risk of endocrine disorders for survivors aged 60 years 
was 42% in the ALiCCS study (75). CNS tumour survivors (76), Hodgkin's disease survivors 
(115), neuroblastoma survivors (91) and leukaemia survivors (116) have all been reported to 
be at high risk of endocrine problems in various studies by the CCSS. Endocrine dysfunction 
can occur due to damage of the hypothalamic-pituitary axis as a result of either proximity of 
neoplastic development close to the axis or from cancer treatments close to the axis such as 
surgery or cranial radiotherapy (74). The hypothalamic-pituitary axis is critically important 
for the regulation of hormone production and impairment to this axis can cause hormonal 
imbalance and neuroendocrine abnormalities (114). A study from the Netherlands 
demonstrated survivors who received radiation directly exposing the head and neck to be at 8-
times the risk of developing an endocrine adverse event compared to survivors who had not 
been treated with radiotherapy (50). Radiation has been documented to elevate the risk of 
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hypothyroidism, hyperthyroidism and thyroid cancers among survivors of Hodgkin's disease 
and survivors of ALL (77, 115, 117). Total body irradiation and radioactive iodine are other 
modalities of treatment which are associated with an increased risk of endocrine conditions 
(50). Treatment with alkylating agents can cause gonadal problems such as testicular 
dysfunction (118), acute ovarian failure (119) or premature menopause (120). Adult survivors 
treated with radiation and/or alkylating agents for childhood cancer experienced a prevalence 
of 56.4% for disorders of the hypothalamic-pituitary axis, 13.8% for hypothyroidism, 66.4% 
for testicular dysfunction and 11.8% for primary ovarian failure by a median follow-up of 
25.1 years (70).  
1.5.8 Nervous system disorders   
Nervous system disorders include a spectrum of neurological and neurocognitive deficits (70). 
Neurological problems can include neurosensory deficits, seizures or convulsions or motor 
dysfunction (99). Neurocognitive problems can include deficits in executive function, 
memory, processing speed, sustained attention, visual motor integration, fine motor dexterity, 
diminished Intelligence Quotient or behavioural change (121). Nervous system disorders were 
one of the most prevalent conditions identified among adult survivors of childhood cancer 
investigated as part of the St. Jude Lifetime cohort with a prevalence greater than 20% for 
each neurocognitive or neurosensory condition by a median follow-up of 25.1 years (70). 
Risk factors for neurological and neurocognitive problems include previous treatment with 
cranial irradiation, total body irradiation, and a whole host of chemotherapeutic drugs such as 
platinum agents (cisplatin and carboplatin), antimetabolites (methotrexate) and alkylating 
agents (busulfan) (70, 98, 99). Childhood cancer survivors at particular increased risk of 
neurological and neurocognitive disorders include CNS tumour survivors (99, 100), 
leukaemia survivors (98) and neuroblastoma survivors (91). 
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1.5.9 Hospitalisations  
It is important to quantify the extent to which increased morbidity observed among survivors 
translates into excess use of healthcare and in particular hospital facilities. This is likely to be 
helpful for healthcare planning purposes as well as identifying groups of survivors who may 
need closer clinical monitoring (122). Both the CCSS and BCCSS have investigated the use 
of healthcare among survivors by using self-reported questionnaires (122, 123). In a study by 
the CCSS, the overall rate of hospitalisation among survivors was 1.6-times that expected 
from the general population (122). In the BCCSS, survivors were twice as likely to have been 
hospitalised as an inpatient with an overnight stay at least once in the last year compared to 
that expected from the general population (123). The CCSS found survivors of Hodgkin's 
disease had twice the rate of hospitalisation compared to that expected from the general 
population (Standardised Incidence Ratio (SIR)=2.2, 95%CI: 2.1-2.3) (122) while the BCCSS 
reported that CNS tumour survivors (Odds Ratio (OR) =2.4, 95%CI:2.0-2.8) and survivors of 
bone sarcoma (OR=2.3, 95% CI:1.6-3.2) were twice as likely to be hospitalised as an 
inpatient compared to the general population (123). Neuroblastoma survivors were also 
associated with higher risks of hospitalisations than expected from the general population in 
both studies (122, 123). In a Canadian study, CNS tumour survivors demonstrated the highest 
excess risk of developing multiple late conditions, graded 3 or above according to the CTCAE 
v3.0 (46) that lead to hospitalisation (124). 
1.5.10 Psychosocial outcomes  
Late effects are not solely restricted to those that impact of health but also include those that 
impact social aspects of life. Psychosocial outcomes can encompass education, employment, 
marriage and health related quality of life (125). Such outcomes are important to an 
individual's life course. Social outcomes of relevance to this thesis are summarised next.  
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Various studies have investigated educational attainment among childhood cancer survivors 
compared to underlying general populations, siblings or comparators selected from general 
practitioner registry lists (126-129). There is concordance from the UK, North America, 
Switzerland and Denmark that CNS tumour survivors had the lowest levels of educational 
attainment compared to the relevant comparator populations (126-129). Survivors of 
leukaemia, NHL and neuroblastoma have also shown deficits in their educational attainment 
compared to sibling controls (129). A population-based Canadian study reported that parents 
of survivors of CNS tumours, leukaemia and neuroblastoma were more likely to report poorer 
education outcomes such as failing or repeating a school grade compared to parents of 
controls who did not have cancer (130). In terms of cancer therapy, survivors treated with 
cranial irradiation have shown greater deficits in their educational attainment across a 
spectrum of education levels compared to those survivors who did not receive cranial 
irradiation (128). Cranial irradiation doses of  ≤25Gy was the strongest explanatory factor for 
lower educational levels among survivors in a study from the Netherlands (131). A possible 
explanation given for this finding is that almost a third of survivors that received this dose of 
cranial irradiation were aged 6 years or less and literature has reported younger age at 
treatment as a risk factor for cognitive impairment (131). Furthermore, survivors who 
received either cranial irradiation and/or intrathecal methotrexate were significantly more 
likely to use special education services compared to those survivors who had not received 
either of these treatment modalities (129).   
Lifestyle factors such as smoking and alcohol consumption are risk factors for various health 
conditions and illnesses such as cancers, cardiovascular disease, respiratory problems and 
liver disease (132, 133). Thus these behaviours should be discouraged in survivors who may 
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already be at increased risk of these chronic health conditions as a result of their original 
childhood cancer diagnosis and/or treatment.  
In the BCCSS, childhood cancer survivors of all types had half the odds (OR=0.52, 
99%CI:0.46-0.60) of being a current drinker compared to that expected from the general 
population (134). However, in the CCSS, childhood cancer survivors were slightly more 
likely to be current drinkers (OR=1.1, 95%CI:1.0-1.2) compared to national peers (135). CNS 
tumour survivors and leukaemia survivors were the least likely to be current drinkers 
compared with the general population while NHL survivors and bone sarcoma were closest to 
the general population in their odds of being a current drinker in the BCCSS (134). All 
childhood cancer survivors were less likely than the general population to consume alcohol 
over recommendations (OR=0.65, 99%CI:0.58-0.73) or harmful amounts of alcohol 
(OR=0.40, 99%CI:0.32-0.49) compared to the general population in the BCCSS (134). 
Childhood cancer survivors in the CCSS were less likely to be risky drinkers (OR=0.9, 
95%CI:0.8-1.0) or heavy drinkers (OR=0.8, 95%CI:0.7-1.0) compared to national peers 
(135). A Canadian study also reported childhood cancer survivors being less likely to be 
binge drinkers (OR=0.66, 95%CI:0.55-0.78) compared to population controls selected from 
provincial health insurance registries or random digit dialling (136). Survivors of Hodgkin's 
lymphoma, Wilms' tumour, NHL and soft tissue sarcoma were comparable to the general 
population in consuming alcohol above recommendations (134). Treatment with cranial 
irradiation (OR=0.46, 99%CI:0.39-0.55) showed even greater deficits than those who had not 
received such treatment (OR=0.71, 99%CI:0.61-0.83) in being a current drinker (134). Risk 
factors reported for survivors being a heavy drinker included being male (135-137) and low 
educational attainment (135, 136). A study by the SCCSS however found higher education 
achievement to be associated with frequent alcohol consumption among survivors (137). 
 21 
Drinking initiation at a young age has also been reported as being a risk factor for heavy 
drinking among childhood cancer survivors (135). 
In the BCCSS, survivors of all types of childhood cancer had half the odds of being a current 
regular smoker (OR=0.51, 99%CI:0.46-0.57) than expected from the general population 
(138). This finding is consistent with a Canadian study which reported survivors being less 
likely to be current smokers (OR=0.65, 95%CI:0.54-0.77) than population controls (136). 
Survivors closest to the general population in their odds of being a current regular smoker 
were non-heritable retinoblastoma survivors, Hodgkin lymphoma survivors and soft tissue 
sarcoma survivors (138). Some risk factors for smoking initiation among survivors have been 
identified as low income and low educational attainment (136, 139).  
Even though it is somewhat reassuring that survivors are not displaying worse health 
behaviours compared to underlying general populations, there are still survivors who are 
smoking regularly, consuming alcohol over recommended limits and consuming harmful 
quantities of alcohol, which is of concern given the types of treatment some of these survivors 
may have received. In a Canadian study, no difference was reported in being a current smoker 
among childhood survivors who had been treated with cardiac/pulmonary toxic therapy 
compared to those who had not received this therapy (136). Thus health promotion 
interventions and initiatives regarding smoking and alcohol consumption need to be an 
ongoing consideration for survivors of childhood cancer.  
The ability to form relationships is an important transition from adolescence into adulthood 
(140). Several studies investigating marriage reveal survivors being less likely to marry 
compared to their respective comparators, in particular survivors that were diagnosed with 
CNS tumours or treated with cranial irradiation (141-144). Male survivors in particular are 
less likely to marry when compared to underlying general populations (141, 144).     
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Investigation of the impact of treatment for childhood cancer on self-assessed health related 
quality of life is important as it may reveal problems not apparent from the investigation of 
adverse health and social outcomes alone.  
One measure that can be used to determine health related quality of life among childhood 
cancer survivors is the Medical Outcomes Short Form Survey (SF-36) (145-149). The SF-36 
consists of 36 questions, which are summarised into eight scales and two summary 
components; physical and mental (150). In studies conducted in the UK, North America and 
Switzerland, childhood cancer survivors scored lower on the physical component summary 
compared to population norms and siblings (145, 146, 149). In terms of the eight scales, lower 
scores were reported for physical functioning, role limitation physical and general health 
among CNS tumour survivors, soft tissue sarcoma, lymphoma and bone tumour survivors 
compared to siblings (145). Overall childhood cancer survivors compared to siblings did not 
differ in relation to the scale of bodily pain (149) while closer inspection of survivor groups in 
another study revealed bone tumour survivors reporting significantly worse bodily pain 
compared to siblings (145). With respect to the mental component summary, survivors either 
scored higher than siblings as shown by the SCCSS (149) or showed no difference compared 
to siblings as shown by the CCSS (145). Findings from the BCCSS also showed that there 
was no significant difference in the mental component summary scores between all childhood 
cancer survivors and the comparative normal population (146). However several studies 
found that upon inspection of survivor groups, CNS tumour survivors and bone tumour 
survivors scored lower than population norms in relation to the mental component summary 
scores (146). Treatment risk factors for scoring low on the physical component summary of 
the SF-36 include surgery, cranial or spinal irradiation, bone marrow transplant and 
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chemotherapy (145, 149). Other factors associated with poor health related quality of life 
include being female, older age and lower educational attainment (145).     
There are a whole host of late effects that can affect survivors. In providing survivorship care, 
it is critically important that healthcare providers take into account both medical and 
psychosocial late effects and the impact they have on general health, mental health and 
function (151).   
1.6 LONG-TERM CLINICAL FOLLOW-UP CARE OF CHILDHOOD CANCER SURVIVORS  
The extent of long-term clinical follow-up care survivors receive after their cancer treatment 
is complete should be evidence-based on their risks of adverse health outcomes. Until 
relatively recently many clinicians considered that clinical follow-up of childhood cancer 
survivors should be life-long in order to detect any potential late effects as well as providing 
advice and counselling to survivors (152, 153). Furthermore, most of the long-term clinical 
follow-up care of childhood cancer survivors in the UK is provided by medical consultants in 
hospitals (154). However as the number of long-term survivors continues to increase, it will 
not be feasible to sustain the practice of every childhood cancer survivor in the UK being on 
hospital follow-up (155). A survey of clinicians in the UK's Children Cancer Study Group 
(UKCCSG) centres revealed that long-term clinical follow-up in the UK was not evidence-
based but dependent on the treatment centre and clinician involved (156).   
The National Cancer Survivorship Initiative (NCSI) which was developed as a partnership 
between the Department of Health, National Health Service (NHS) Improvement and 
Macmillan Cancer UK aimed at improving the care and support of people living with and 
beyond cancer (157). In their Children and Young People Workstream, the NCSI investigated 
which survivors were at low, medium or high risk of late effects (known as risk stratification) 
as a consequence of their cancer and its treatment. Since survivors are known to have varying 
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risks of late effects, the proposal was to develop risk stratified levels of clinical follow-up 
care. The NCSI has also explored alternative models of follow-up care which could 
correspond to the risk survivors experience; those at highest risk would still receive medical 
consultant care in a hospital. Different models of follow-up care have been suggested that 
include postal follow-up or telephone follow-up (153, 158), supported self-management care 
(155), primary care-led follow-up (159), nurse-led follow-up (153, 159, 160) and shared care 
follow-up between primary and secondary or tertiary care (159, 161). Since some survivors 
have showed preference in receiving hospital follow-up care (162, 163), any proposed 
changes in long-term clinical follow-up care needs to involve consultation with this 
population so their requirements, concerns and any perceived barriers to alternative models of 
follow-up may be addressed. The future of long-term clinical follow-up care of childhood 
cancer survivors in the UK ought to be evidence-based as this has been previously lacking.  
1.7 LONG-TERM CLINICAL FOLLOW-UP GUIDELINES  
It is important that the extent and nature of clinical follow-up offered to survivors should 
relate to their long-term risk of adverse outcomes. Ideally guidelines should be evidence-
based and updated regularly as further evidence is produced. These evidence-based clinical 
guidelines aim to inform clinicians involved in the long-term clinical follow-up of childhood 
cancer survivors irrespective of whether these clinicians are practising in primary, secondary 
or tertiary care.  
Two clinical guidelines have been developed in the UK, these are the Children’s Cancer and 
Leukaemia Group (CCLG) (164) and Scottish Intercollegiate Guidance Network (SIGN) 
guidelines (17). From the United States, there are the Children's Oncology Group (COG) 
guidelines (121). These three clinical guidelines are updated regularly taking account of best 
evidence through publications and websites. Such updating is reflected in that all three current 
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guidelines were preceded by earlier published guidelines (165-167). Clinical guidelines in the 
Netherlands have also been developed, but are available in Dutch only (168). 
As the evidence base relating to the risks of late effects is expanding and various research 
groups across the world are conducting research among childhood cancer survivors, more 
independent guidelines are being published. Since these guidelines do not always demonstrate 
consistency in their recommendations whether it be whom to screen, when to screen or other 
tests that may be appropriate, ambiguity arises as to which guideline is best to follow (169). 
Thus an International Late Effects of Childhood Cancer Guideline Harmonization Group 
(IGHG) was founded in 2010 with the goal of developing guidelines through collaborative 
efforts in order for survivors to a) receive the best care possible to reduce the consequences of 
late effects and b) improve their quality of life (170). It is anticipated that there will be less 
duplication of work; resources will be used more efficiently and there will be pooling of 
expert knowledge. The first two guidelines from the IGHG have been published, which 
proves that the goal of an integrated, collaborative strategy is working (171, 172). There are 
other guidelines in the process of being formulated that include the topics of thyroid cancer 
and male and female gonadal dysfunction (170). 
There will be an ongoing programme of updating such guidelines as the evidence base 
increases.      
1.7.1 PanCare and PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up 
Studies (PanCareSurFup) 
PanCare is a European Network for the Care of Survivors after Childhood and Adolescent 
Cancer that was founded in 2008 (173). Thirteen countries across Europe are involved in this 
network. Six questionnaire surveys were conducted to better understand the current landscape 
of childhood and adolescent cancer research within Europe. Surveys included assessing the 
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follow-up care after childhood cancer and assessing the process of establishing guidelines for 
long-term follow-up care for survivors of childhood and adolescent cancer in Europe (174). 
The findings from these surveys provided an evidence-base for countries across Europe to 
work collaboratively towards the common goal of providing optimal care for all childhood 
and adolescent cancer survivors. One project that was set up to meet the aims of PanCare was 
Pancare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies 
(PanCareSurFup) which included evaluating long-term risks of childhood cancer treatment, 
developing evidence-based guidelines and providing education and dissemination of 
information to survivors and clinicians.  
PanCareSurFup was established in 2011, a Seventh Framework Programme funded by the 
European Union (Grant Agreement Number: 257505). PanCareSurFup is arranged into eight 
Work Packages (WP) and each WP assumes responsibility for a part of the project. There are 
WPs which aim to provide risk estimates through cohort and case-control studies with regards 
to cardiac disease (WP3), SPNs (WP4) and late mortality (WP5) with the intention of 
improving existing clinical guidelines.  
1.8 RATIONALE OF PHD RESEARCH  
There is growing evidence to inform childhood cancer survivorship guidelines and it is 
imperative that these guidelines are evidence-based. The BCCSS is one of the few childhood 
cancer survivor cohorts that is population-based in nature and thus able to provide unbiased, 
reliable risk estimates of adverse health and social outcomes. As the date of diagnosis of 
childhood cancer dates as far back as 1940 in the BCCSS, the length of follow-up is 
substantial compared to other childhood cohorts such as the CCSS (33), SCCSS (32) and 
DCOG LaTER study (31) which enables investigation of late effects up to 50 years after 
initial cancer diagnosis (see Table 1.1 for a comparison of these cohorts). Childhood cancer 
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survivors are a heterogeneous population in terms of the risk of late effects they will 
encounter thus it is essential to provide an evidence base to guide which survivors need closer 
monitoring with regards to each specific late effect. The focus of research presented in this 
thesis should lead to improvements in existing clinical follow-up guidelines by providing new 
quantitative evidence of risks of adverse health outcomes and variation in such risks with 
factors relating to the cancer, its treatment and demographic characteristics.  
1.9 OBJECTIVES 
The objectives of this thesis are:  
1. Investigate which survivors in the BCCSS are on long-term hospital follow-up in relation 
to the proposed levels of risk stratification developed by the BCCSS in collaboration with the 
NCSI (157).     
2. Explore which subgroups of survivors of CNS tumours within the BCCSS are at risk of 
adverse health and social outcomes using record-linkage and questionnaire data and compare 
excess risks to the general population.  
3. Investigate which groups of survivors within the extended BCCSS cohort are at excess risk 
of hospitalisations for cerebrovascular events in England using record linkage with the 
national Hospital Episode Statistics (HES) database.  
4. Quantify the excess risk of genitourinary subsequent primary neoplasms in the 
PanCareSurFup European cohort of survivors of childhood cancer.   
1.10 THESIS OUTLINE  
Chapter Two concerns the assessment of survivors that are on regular long-term hospital 
follow-up in the UK and the willingness of General Practitioners (GPs) to provide advice to 
survivors in relation to personal medical questions and late effects. Chapter Three reports on 
the risk of adverse health and social outcomes among survivors initially diagnosed with a 
CNS tumour within the BCCSS compared to that expected from the general UK population. 
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Chapter Four concerns the risk of cerebrovascular hospitalisations among BCCSS survivors 
using record linkage with HES. Chapter Five describes the risk of genitourinary subsequent 
primary neoplasms among childhood cancer survivors using the PanCareSurFup cohort. 
Finally, Chapter Six provides a discussion of the main findings of the research conducted for 
this thesis with implications for current long-term clinical follow-up guidelines and 
recommendations for future research.  
 
For Chapters Two and Three, the data had already been collected and I was not involved in 
study questionnaire send outs, data coding or data entry. The dataset was essentially prepared 
and I carried out some data cleaning before conducting analysis. For Chapter Four, the 
BCCSS cohort was linked externally with the Hospital Episode Statistics Data by Northgate 
Solutions. However extensive data cleaning was conducted by myself and other members of 
the research team independently before analysis was initiated. For Chapter Five, I was 
involved in extensive cleaning of the data once the dataset had been transferred from the 
University of Mainz in Germany, assisted with ICD-O conversions and ICD conversions 
through the IARC programme and liaised with data providers in terms of queries that arose 
from ICD-O conversions alongside other members of the research team in Birmingham.   
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CHAPTER 2 NATIONWIDE LONG-TERM CLINICAL 
FOLLOW-UP OF ADULT SURVIVORS OF CHILDHOOD 
CANCER: EVIDENCE OF GROUPS WHO NEED THEIR 
NHS CARE PLAN REVIEWED 
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2.1 ABSTRACT 
Background: Restructuring of clinical long-term follow-up within the National Health 
Service (NHS) in England has been proposed as part of the National Cancer Survivorship 
Initiative (NCSI), a key element of the Improving Outcomes: A Strategy for Cancer of the 
Department of Health for England. Objectives were to investigate the proportion of adult 
survivors of childhood cancer throughout Britain who are regularly followed-up in a hospital 
clinic and to explore variation in this proportion with age of survivor and the survivor's 
estimated long-term risk of serious adverse health outcomes as defined by the National 
Cancer Survivorship Initiative Level of care: LEVEL 1(low risk); LEVEL 2 (intermediate 
risk); LEVEL 3 (high risk).    
Methods: The British Childhood Cancer Survivor Study (BCCSS) is a population-based 
cohort of 17,980 five-year survivors of childhood cancer diagnosed <15 years between 1940-
1991 in Great Britain. 14,836 of 17,980 survivors were eligible to receive a postal 
questionnaire. By means of a postal survey, 14,223 General Practitioners (GPs) were 
contacted for consent to approach survivors; 12,978 GPs returned a completed consent form 
with information relating to the survivor's clinical follow-up status. Main outcome measures 
were percentages of childhood cancer survivors on regular hospital follow-up, and GPs 
willing to provide advice to survivors, in relation to demographic, cancer and treatment 
factors. 
Results: Among LEVEL 3 survivors of non-leukaemic cancer only 31% were on regular 
hospital follow-up, despite the NCSI recommendation for all LEVEL 3 survivors to be on 
regular hospital multi-disciplinary team review, furthermore this percentage declined from 
57% to 16% among survivors aged under 20 years to survivors aged at least 50 years, 
respectively. Among LEVEL 1 survivors of non-leukaemia cancers 12% were on regular 
hospital follow-up, whilst the NCSI recommendation for all LEVEL 1 survivors is self-care 
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with support. GPs returns indicated that 74% (9595/12978) were willing to discuss 
survivorship issues with survivors. 
Conclusion: Consideration needs to be given to the potential recall of both NCSI LEVEL 3 
survivors who are not on regular hospital follow-up for possible establishment of such follow-
up, and NCSI LEVEL 1 survivors who are on such follow-up for possible discharge to self-
care with support. 
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2.2 INTRODUCTION  
Comprehensive reorganisation of the clinical follow-up of survivors of cancer within the 
National Health Service (NHS) has been proposed by the National Cancer Survivorship 
Initiative (NCSI), an important element of the Improving Outcomes: A Strategy for Cancer, 
produced by the Department of Health for England, and of which this research was part. 
Before the NCSI, our survey of Children's Cancer and Leukaemia Group Centres, revealed 
considerable variation in clinical long-term follow-up practices between Centres (156). The 
NCSI proposes that the level of clinical follow-up care offered to each survivor should be 
stratified and correspond to their anticipated level of risk of serious adverse health outcomes 
(154, 155). Such risk stratification is based principally on type of cancer and treatment 
received and ranges from LEVEL 1 (self-care with support and open access to the healthcare 
system, with or without reference to a General Practitioner (GP)) to LEVEL 3 (regular 
hospital multi-disciplinary team review). Intermediate is LEVEL 2 (shared care with planned 
reviews potentially involving medical and/or nursing specialists in hospitals, and/or GPs with 
either face-to-face or telephone contact).  
 
As part of the BCCSS, GPs throughout Britain were contacted who were responsible for the 
care of most adult survivors of childhood cancer in Britain. The GPs were asked whether their 
patient was still on regular long-term hospital follow-up in relation to their childhood cancer 
and whether they would be prepared to discuss personal medical questions which might arise 
from the survivor completing the BCCSS questionnaire (see Appendix 8.2).  
Our novel contribution here relates to our investigation of the clinical follow-up status of the 
entire population-based group of adult survivors of childhood cancer throughout Britain. We 
explore the percentage of survivors on regular long-term hospital follow-up in relation to their 
childhood cancer, how this varies with age of the survivor and other characteristics; also 
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whether there is evidence of individuals not on hospital follow-up who may be at increased 
risk of serious adverse health outcomes.  
2.2.1 Objectives  
Our objectives were: (1) Quantify the percentage of the national population of adult survivors 
of childhood cancer who were regularly seen in a hospital clinic in relation to their childhood 
cancer prior to the NCSI and explore factors related to variations in this percentage. (2) After 
assigning each survivor to the appropriate LEVEL 1, 2 or 3 of clinical follow-up care 
proposed by the NCSI, using type of childhood cancer and treatment information available to 
the BCCSS, explore the extent of regular long-term hospital follow-up experienced by 
survivors with increasing attained ages. In particular determine the extent to which LEVEL 3 
survivors were not on regular long-term hospital follow-up and the extent to which LEVEL 1 
survivors were on such hospital follow-up. (3) Quantify the percentage of GPs who were 
willing to discuss personal medical questions with survivors relating to survivorship and late 
consequences of treatment, generated by the BCCSS questionnaire, and investigate factors 
related to variations in this percentage. 
2.3 METHODS 
2.3.1 British Childhood Cancer Survivor Study cohort 
The British Childhood Cancer Survivor Study (BCCSS) was based on a cohort of 17,980 
individuals who were diagnosed with cancer when aged 0-14 years inclusive, between 1940 
and 1991, in Britain, and who survived at least five years from diagnosis. The BCCSS cohort 
of survivors was identified using the population-based National Registry of Childhood 
Tumours. The BCCSS objectives, study population and methodology have been described in 
detail previously (30). Ethical approval for the study was obtained from the Multi-Centre 
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Research Ethics Committee (MREC) in the West Midlands and every Local Research Ethics 
Committee (LREC) in Britain.  
2.3.2 Regular long-term hospital follow-up and associated outcome measures 
The BCCSS postal questionnaire was designed to ascertain adverse health and social 
outcomes occurring among survivors. A total of 14,836 adult survivors were eligible to 
receive a postal questionnaire, in that they were aged at least 16 years and alive. The GP of 
each survivor was identified through record linkage with the National Health Service Central 
Registers. GPs were contacted initially in this study with a consent form as they were 
considered the key 'gatekeepers' to the survivors. In addition to seeking consent to contact 
their patient, the GPs were also asked: "Is your patient still on regular long-term hospital 
follow-up in relation to their childhood neoplastic disease?; YES or NO"; "Would you be 
prepared to discuss with the patient personal medical questions which might arise as a result 
of completing the questionnaire?; YES or NO". From the 14,223 GPs for whom contact 
details were obtained, 12,978 (91% response rate) completed and returned the consent forms 
with these additional questions completed.  
2.3.3 Statistical methods 
Multivariable logistic regression was used to examine potential explanatory factors associated 
with two outcomes: whether survivors were on such regular long-term hospital follow-up; 
whether the GP was willing to discuss such medical questions with the survivor. Explanatory 
factors investigated in relation to each outcome were sex; attained age; childhood cancer type; 
age at childhood cancer diagnosis; whether treatment involved surgery, chemotherapy or 
radiotherapy with the latter being coded according to anatomical site of direct exposure; area 
of residence within Great Britain. Decade of treatment and period of follow-up were not 
included in the multivariable models due to strong collinearity with attained age. Within each 
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model and for each specific factor, likelihood ratio tests were used to assess the statistical 
significance. The strength of association was quantified using the Odds Ratio (OR). Statistical 
significance was taken at the 5% level (two sided tests). Analyses were carried out using Stata 
statistical software (version 12.0; Stata Corp., College Station, TX). 
For the outcome of whether survivors were on regular long-term hospital follow-up, the effect 
of an additional potential explanatory factor, classification of each childhood cancer survivor 
according to their NCSI level of clinical follow-up (155), was investigated. The NCSI levels 
of follow-up for acute lymphoblastic leukaemia (ALL) survivors were defined as follows: 
LEVEL 1- no radiotherapy; LEVEL 2- radiotherapy under 24 Gray (Gy); LEVEL 3 - 
radiotherapy of at least 24 Gy or relapsed or bone marrow transplant (BMT) as part of their 
initial treatment. For survivors of childhood cancers other than leukaemia, the NSCI Levels of 
follow-up were defined on the basis of childhood cancer type and the treatment received ─ 
see Figure 2.1. For both ALL survivors and survivors of childhood cancers other than 
leukaemia, histograms were created to investigate the percentage of survivors on regular long-
term hospital follow-up across different specific attained ages, for survivors allocated to each 
of the NCSI Levels of clinical care 1, 2 and 3. 
2.4 RESULTS  
2.4.1 Factors related to the percentage of survivors on regular long-term hospital follow-
up 
Overall, 36% (4,707 of 12,978 survivors for whom consent forms were returned), were on 
regular long-term hospital follow-up (Table 2.1). Table 2.1 reveals that age is the strongest 
explanatory factor with the percentage of survivors on such follow-up declining from 62% 
among those aged under 20 years, to 9% among those aged at least 50 years.  
The percentage of survivors on regular long-term hospital follow-up varied substantially by 
type of childhood cancer (P<0.001). Compared to Wilms' tumour survivors, a significantly 
  36 
higher odds ratio (OR) of being on follow-up was observed for survivors of leukaemia 
(OR=1.21, 95% confidence interval (CI):1.04-1.41) and Hodgkin's lymphoma (OR=1.28, 
95%CI:1.04-1.57), and significantly lower ORs were observed for neuroblastoma (OR=0.69, 
95%CI:0.55-0.88), non-heritable retinoblastoma (OR=0.23, 95%CI:0.17-0.31) and other 
neoplasms (OR=0.69, 95%CI:0.56-0.84).   
The OR of survivors being on such follow-up increased with age of diagnosis (Ptrend<0.001) 
from 1.00 for the referent group of survivors aged 0-4 years at diagnosis to 1.49 (95%CI:1.32-
1.68) for survivors aged 10-14 years at diagnosis in a linear fashion (Pnon-linearity=0.42).  
Survivors treated with chemotherapy were more likely to be on such follow-up than those 
survivors who had not been treated with chemotherapy. Compared to survivors not treated 
with any radiotherapy, survivors treated with cranial irradiation were more likely to be on 
such follow-up (OR=1.76, 95%CI:1.54-2.03) and to a lesser extent, survivors treated with 
radiotherapy which excluded the head and abdomen were more likely to be on follow-up 
(OR=1.45, 95%CI:1.23-1.71).  
In terms of geographical location, survivors residing in the North West (OR=1.86, 
95%CI:1.58-2.21), West Midlands (OR=1.37, 95%CI:1.15-1.64), Scotland (OR=1.32, 
95%CI:1.10-1.58) and Yorkshire and Humber (OR=1.19, 95%CI:0.99-1.42), were more likely 
to be on such follow-up than survivors in London.       
2.4.2 Factors related to general practitioners willingness to provide medical advice to 
survivors 
Overall, 74%, 9,595 of 12,978 GPs returning consent forms were willing to provide medical 
advice to survivors in relation to their childhood cancer. GPs were more willing to provide 
medical advice to female survivors (OR=1.20, 95%CI:1.10-1.30) than male survivors.  
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Although there was statistical evidence of variation (P=0.036) across type of cancer, 
inspection of specific values of odds ratios revealed that the effect was not strong. 
GPs were more willing to provide advice (P<0.001) to survivors residing in the North East 
(OR=1.50, 95%CI:1.19-1.88), Scotland (OR=1.40, 95%CI:1.17-1.69), South East (OR=1.37, 
95%CI:1.16-1.61), South West (OR=1.29, 95%CI:1.08-1.54), Wales (OR=1.26, 95%CI:1.02-
1.57) and North West (OR=1.19, 95%CI:1.00-1.40), than to survivors residing in London.  
2.4.3 Extent of regular long-term hospital follow-up among survivors by age for each 
National Cancer Survivorship Initiative Level of clinical care  
In Figures 2.2a and 2.2b we provide the extent of regular long-term hospital follow-up among 
survivors in relation to the NCSI Levels of clinical follow-up care and attained age of the 
survivor. Figures 2.2a and 2.2b relate to survivors of all childhood cancers except leukaemia 
and survivors of ALL, respectively. There are two clear patterns apparent from Figure 2.2a: 
within age groups, the percentage on hospital follow-up increases with increasing NCSI Level 
of clinical follow-up care; between age groups, there is a substantial decline in the percentage 
of survivors on hospital follow-up with increasing age for each NCSI Level of clinical follow-
up care. From Figure 2.2b there is also evidence of a substantial decline in the percentage on 
hospital follow-up with increasing age for each NCSI Level of clinical follow-up care.  
2.4.4 NCSI LEVEL 1 survivors  
Overall, 118 (12%) of the 1,026 survivors of non-leukaemic childhood cancers assigned to 
NCSI LEVEL 1 were still on regular hospital follow-up even though the type of follow-up 
associated with this Level is self-care with support and open access to the healthcare system, 
but the survivors were widely spread across a broad spectrum of types of childhood cancer. 
This percentage of survivors on follow-up declined with age from 22% to 3% among 
survivors aged under 20 years to those survivors aged at least 50 years, respectively. The 
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corresponding overall figure for survivors of ALL was 103 (66%) of 156, but 127 (81%) of 
the 156 were still aged under 20 years.  
2.4.5 NCSI LEVEL 2 survivors  
Overall, 601 (24%) of the 2,469 survivors of non-leukaemic childhood cancers assigned to 
NCSI LEVEL 2 were still on regular hospital follow-up. The percentage of survivors on 
follow-up declined with age from 49% to 9% among survivors aged under 20 years, to those 
aged at least 50 years, respectively. Overall among survivors of ALL, 472 (48%) of the 974 
were on hospital follow-up and this percentage of ALL survivors on follow-up declined with 
age from 64% among survivors aged under 20 years to 37% among survivors aged at least 30 
years.  
2.4.6 NCSI LEVEL 3 survivors 
Of the non-leukaemic childhood cancer survivors, only 809 (31%) of the 2,578 survivors 
assigned to NCSI LEVEL 3 were on regular hospital follow-up even though the 
recommended type of follow-up associated with this Level is regular hospital multi-
disciplinary team review. This percentage declined with age from 57% to 16% among 
survivors aged under 20 years to survivors aged at least 50 years, respectively. 1,388 (79%) of 
the 1,769 not on hospital follow-up were survivors of a CNS tumour (40%), Hodgkin's 
lymphoma (20%) and Wilms' tumour (19%). The decline in the percentage on regular long-
term hospital follow-up with increased attained age for survivors of each of these three 
childhood cancers is provided in Figures 2.3a, 2.3b, 2.3c; in particular the percentage for CNS 
tumour declined from 61% to 19% for those aged under 20 years to those aged at least 50 
years, respectively. Overall, 453 (52%) of 874 of ALL survivors were on hospital follow-up 
and this percentage declined with age from 75% to 27% among those aged under 20 years to 
those survivors aged at least 30 years, respectively. 
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2.5 DISCUSSION  
2.5.1 Principal findings  
This first large scale and population-based assessment of the long-term clinical follow-up 
status of most adult survivors of childhood cancer in Britain revealed that among survivors 
within each NCSI Level of care there was a substantial decline in the percentage still on 
regular hospital follow-up as age of survivor increased. This decline was strongest among 
survivors within NCSI LEVEL 3, all of whom should be on regular hospital follow-up 
according to NCSI guidelines: among survivors of all non-leukaemic neoplasms considered 
together the percentage on hospital follow-up declined from 57% among those aged under 20 
years to 16% among those aged at least 50 years; among survivors of acute lymphoblastic 
leukaemia the percentage on regular long-term hospital follow-up declined from 75% among 
those aged under 20 years to 27% among those aged at least 30 years. There is a need for 
clinical review of those NCSI LEVEL 3 survivors who are not on hospital follow-up with 
consideration given to potential recall to the NHS and we give a detailed justification for this 
proposal below.  
Others have observed that among survivors of adult cancer the level of long-term clinical 
follow-up of cancer survivors should involve consideration of risk stratification (175).  
Other studies of survivors of childhood cancer in North America (176), Sweden (177), 
Switzerland (178) and in the UK (156, 162) have shown that older age and longer time from 
diagnosis were associated with a decline in survivors being on regular hospital follow-up or a 
decrease in reporting an outpatient cancer related visit or a visit to a cancer centre. 
Conversely, there is evidence from one study of the likelihood of seeing an oncologist being 
elevated with increasing age of childhood, adolescent and young adult survivor, although the 
survivors in this study are on average comparatively young (mean age 25.5 years) (179). 
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When looking at the variation of survivors on long-term hospital follow-up by geographical 
region, childhood cancer survivors were more likely to be on follow-up in the North West 
than in London. Historically the North West is known to have principal treatment centres with 
clinicians actively involved in the long-term hospital follow-up of childhood cancer survivors 
once childhood cancer survivors have completed their treatment and reached five-year 
survival. Yorkshire and Humber, the West Midlands and Scotland are also regions where 
childhood cancer research is particularly active which may be a possible explanation as to 
survivors being more likely than childhood cancer survivors in London of being on long-term 
hospital follow-up.   
The variation of long-term hospital follow-up by cancer diagnosis may be explained by 
several reasons; the number of leukaemia survivors began to increase considerably from 1975 
and as a group are much younger and diagnosed more recently than other survivor groups in 
the BCCSS thus this would increase the extent to which they are followed-up in a hospital 
(156). Another possible reason could be the complexity of care required by the survivor group 
and the risk of adverse late effects, for instance CNS tumour survivors often require specialist 
care not only by oncologists but from neurosurgeons, endocrinologists and neurologists as 
well. Thus such survivors may be discharged from paediatric oncologists but then followed-
up by other specialist consultants within a hospital setting.  
 
2.5.2 NCSI LEVEL 3 survivors not on hospital follow-up  
Of the non-leukaemic survivors assigned to NCSI LEVEL 3, only 31% were on regular long-
term hospital follow-up. For leukaemia survivors 52% of those assigned to NCSI LEVEL 3 
were on hospital follow-up, but relatively few were aged over 30 years. A recent Scottish 
study, which assigned childhood cancer survivors to levels of clinical follow-up using the 
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Scottish Intercollegiate Guidelines Network (SIGN), found that the percentage of survivors on 
regular hospital follow-up rose with increasing SIGN level of follow-up assigned: 34%, 50% 
and 66% for those assigned to Level 1, 2 and 3, respectively. The considerable difference 
between the results for this one Scottish centre and the whole of England, Wales and Scotland 
could be explained by a number of factors including that their survivors were much younger 
(median age 19 years), treated more recently, and this centre has a long history of research in 
survivorship issues and therefore it would not be surprising if their levels of clinical follow-up 
were higher than average across Britain (180).  
Exploring the composition of the non-leukaemic survivors assigned to NCSI follow-up 
LEVEL 3 revealed that 79% of the survivors not on regular long-term hospital follow-up had 
been treated for a CNS neoplasm (40%), Hodgkin lymphoma (20%) or Wilms' tumour (19%). 
Similarly, Edgar et al (2012), reported that of the childhood cancer survivors not on regular 
hospital follow-up, survivors of a CNS neoplasm were one of the most frequent primary 
diagnoses (180). There is evidence that survivors of a CNS neoplasm, Wilms' tumour, and 
Hodgkin's lymphoma, especially if treated with radiotherapy, are at an increased risk of 
adverse physical health late effects (121, 164). CNS tumour survivors who have received 
radiotherapy, for example, are at increased risk from late death due to recurrence (100), 
subsequent primary neoplasms (63, 181), stroke (110, 182) and endocrine problems such as 
those relating to growth (76), sexual development (183) and thyroid function (77, 78). 
Hodgkin lymphoma survivors who have received radiotherapy are at an increased risk of 
developing breast cancer (63, 184-187), heart disease (72, 188) and pulmonary conditions 
(93). Wilms' tumour survivors who have received radiotherapy are at increased risk of 
cardiovascular disease such as hypertension and cardiac problems (73, 189), subsequent 
primary neoplasms (63) and infertility (88, 190). Previously irradiated female Wilms' tumour 
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survivors are also at increased risk of reproductive problems and adverse pregnancy outcomes 
(88, 191). In addition to physical health outcomes survivors of CNS tumours treated with 
radiotherapy, also experience excess risks of psychosocial problems including higher levels of 
cognitive problems than survivors of other childhood cancer types (97) and achieve lower 
than expected educational attainment (128). Such evidence justifies that serious consideration 
be given to systems for the recall to the NHS of such LEVEL 3 survivors who are not on 
regular long-term hospital follow-up.  
2.5.3 NCSI LEVEL 1 survivors on follow-up who may not need to be on follow-up 
Of the survivors assigned to NCSI LEVEL 1, 12% of non-leukaemia survivors and 66% of 
leukaemia survivors were still on regular long-term hospital follow-up. The NCSI proposes 
that survivors assigned to LEVEL 1 are likely to be safe to self-manage their own care (155) 
thus an assessment needs to be made as to whether less intrusive clinical follow-up for 
survivors within NCSI LEVEL 1 would be justified. Other studies have also suggested that 
many survivors receive more intense follow-up than necessary given their estimated level of 
risk (42).  
2.5.4 GPs willingness to be involved in long-term follow-up of childhood cancer survivors 
The overall proportion of general practitioners who were willing to discuss personal medical 
questions with childhood cancer survivors relating to survivorship and late consequences of 
treatment was relatively high at 74%. This finding is encouraging as it is anticipated that GPs 
are likely to be one of the groups of health care professionals who might take on more 
responsibility for the long-term clinical care of increasing numbers of childhood cancer 
survivors, particularly those survivors assigned to NCSI LEVEL 2 (155). In support of such a 
change, a Dutch study has shown the willingness of GPs to participate in the follow-up care 
of survivors when there was a shared model of care between hospital clinicians and 
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community doctors; 97% of the GPs surveyed agreed to participate (192). The CCSS reported 
that 85% of primary care physicians whom they surveyed with respect to their preference of 
model of care of childhood cancer survivors preferred to care for such survivors alongside a 
cancer-based physician or within a well-defined long-term follow-up program (193). These 
findings of others taken together with those reported here relating to GP willingness to be 
involved in follow-up care of childhood cancer survivors are encouraging from the 
perspective of their increased involvement. An advantage that has been noted by clinicians is 
that long-term follow-up care provided by GPs would enable cancer specialists to focus more 
on acute care; additionally GPs could refer a survivor back to specialist centres with relative 
ease should this be required (194). However some childhood cancer survivors have reported 
that they feel that GP-led follow-up is not appropriate as they lack specialist knowledge and 
have been considered less favourably to hospital-based forms of follow-up (162, 195). It is 
critically important that there needs to be improved communication between primary and 
secondary care providers and child and adult services for follow-up to work in the primary 
care setting; in addition to improved training of GPs in survivorship issues, as already 
observed by others (156, 193, 196-200).  
2.5.5 Study limitations 
As well as the considerable strengths of having an underlying population-based cohort, large 
numbers relating to almost all adult survivors of childhood cancer in Britain and reliable 
estimates of risk relating to survivors aged up to 50 years, there are some limitations inherent 
in our investigation. There are potential uncertainties in the replies generated from the GPs 
who completed the questionnaire in being representative of all such GPs within the UK. 
However the high response rate from the GPs approached with the survey at 91% suggests 
that this may not be too much of an issue here. Another limitation of our study is the way in 
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which the question of willingness was put to GPs, the question asked whether GPs would be 
prepared to discuss with the patient medical questions which might arise from the BCCSS 
questionnaire and not whether they would be content to become involved in survivor follow-
up on a regular basis.  
2.5.6 Conclusions 
The NCSI has proposed substantial changes to clinical follow-up practices within the NHS for 
the future, but until now there was no evidence relating to the clinical follow-up status of 
most adult survivors of cancer in childhood or young adulthood throughout Britain. Changes 
proposed are a move away from a one-size fits all model of follow-up towards risk 
stratification, whereby the level of care to be offered corresponds to the anticipated level of 
risk of serious adverse health outcomes (155). The excess risks of serious adverse health 
outcomes in childhood cancer survivors still persist 45 years from diagnosis of the original 
cancer, such as premature mortality and the development of a subsequent primary neoplasm 
(55, 63). Our study demonstrates that there is need for consideration of a call back to the NHS 
of NCSI LEVEL 3 survivors who are not currently on long-term hospital follow-up. In 
contrast survivors assigned to NCSI LEVEL 1 who are still on long-term hospital follow-up 
should be reviewed for consideration of whether less intensive clinical follow-up would be 
safe and more appropriate to their estimated risks of adverse health outcomes. 
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Table 2.1 Number (%) of childhood cancer survivors on hospital follow-up and General Practitioners willing to 
provide advice to childhood cancer survivors; with odds ratios and 95% confidence intervals from logistic 
regression models associated with specified demographic, cancer and treatment potential explanatory factors 
 Factor No.  No. of survivors 
on follow-up (%) 
Unadjusted OR 
(95%CI) 
OR (95% CI) No. of GPs willing 
to provide advice 
(%) 
Unadjusted OR 
(95%CI) 
OR (95% CI) 
Overall totals  12978 4707 (36.3)    9595 (73.9)   
Sex Male 7045 2562 (36.4) 1.00 (referent) 1.00 (referent) † 5100 (72.4) 1.00 (referent) 1.00 (referent) † 
 Female 5933 2145 (36.2) 0.99 (0.92 to 1.06) 1.05 (0.97 to 1.14) 4495 (75.8) 1.19 (1.10 to 1.29) 1.20 (1.10 to 1.30) 
 P heterogeneity   0.802 0.206  <0.001 <0.001 
Attained age, y <20 2620 1635 (62.4) 1.00 (referent) 1.00 (referent) † 1956 (74.7) 1.00 (referent) 1.00 (referent) † 
 20-29 4603 1929 (41.9) 0.43 (0.39 to 0.48) 0.36 (0.32 to 0.40) 3421 (74.3) 0.98 (0.88 to 1.10) 0.97 (0.86 to 1.09) 
 30-39 3664 912 (25.0) 0.20 (0.18 to 0.22) 0.15 (0.14 to 0.17) 2679 (73.1) 0.92 (0.82 to 1.04) 0.93 (0.82 to 1.05) 
 40-49 1487 175 (11.8) 0.08 (0.07 to 0.10) 0.06 (0.05 to 0.08 ) 1086 (73.0) 0.92 (0.80 to 1.06) 0.95 (0.81 to 1.11) 
 ≥50 604 56  (9.3) 0.06 (0.05 to 0.08) 0.04 (0.03 to 0.06) 453 (75.0) 1.02 (0.83 to 1.25) 1.06 (0.85 to 1.32) 
 P trend   <0.001∆ <0.001∆  0.296∆ 0.753∆ 
Childhood  Wilms' tumour 1177 429 (36.5) 1.00 (referent)    1.00 (referent)† 877 (74.5) 1.00 (referent) 1.00 (referent) † 
cancer Leukaemia 3531 1664(47.1) 1.55 (1.35 to 1.78) 1.21 (1.04 to 1.41) 2666 (75.5) 1.05 (0.91 to 1.23) 1.05 (0.90 to 1.23) 
type Hodgkin’s lymphoma 936 330 (35.2) 0.95 (0.79 to 1.13) 1.28 (1.04 to 1.57) 684 (73.0) 0.92 (0.76 to 1.12) 0.98 (0.80 to 1.21) 
 NHL 690 266 (38.5) 1.09 (0.90 to 1.32) 1.21 (0.98 to 1.51) 506 (73.2) 0.94 (0.76 to 1.16) 0.98 (0.79 to 1.23) 
 CNS neoplasms 2667 919 (34.5) 0.92 (0.79 to 1.06) 1.14(0.97 to 1.34) 1916 (71.9) 0.87 (0.75 to 1.02) 0.87 (0.74 to 1.03) 
 Neuroblastoma 549 179 (32.6) 0.84 (0.68 to 1.05) 0.69 (0.55 to 0.88) 405 (73.8) 0.96 (0.76 to 1.21) 0.99 (0.78 to 1.25) 
 Retinoblastoma 
(heritable) 
385 108 (28.1) 0.70 (0.53 to 0.87) 0.85 (0.64 to 1.12) 269 (70.0) 0.79 (0.62 to 1.02) 0.81 (0.63 to 1.05) 
 Retinoblastoma (non-
heritable) 
531 59 (11.1) 0.22 (0.16 to 0.29) 0.23 (0.17 to 0.31) 393 (74.0) 0.97 (0.77 to 1.23) 0.97 (0.77 to 1.23) 
 Bone sarcoma 472 170 (36.2) 0.98 (0.79 to 1.22) 1.23 (0.95 to 1.58) 370 (78.4) 1.24 (0.96 to 1.60) 1.30 (0.99 to 1.70) 
 STS  897 272 (30.3) 0.76 (0.63 to 0.91) 0.82(0.67 to 1.01) 665 (74.1) 0.98 (0.80 to 1.20) 1.00(0.82 to 1.23) 
 Other neoplasms 1143 311 (27.2) 0.65 (0.55 to 0.78) 0.69 (0.56 to 0.84) 844 (73.9) 0.97 (0.80 to 1.17) 0.98 (0.80 to 1.19) 
 P heterogeneity   <0.001 <0.001  0.0347 0.036 
Age at childhood  0-4 6118 2368 (38.7) 1.00 (referent) 1.00 (referent) † 4516 (73.8) 1.00 (referent) 1.00 (referent) † 
cancer 5-9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                3436 1265 (36.8) 0.92 (0.85 to 1.00) 1.17 (1.06 to 1.30) 2580 (75.1) 1.07 (0.97 to 1.18) 1.08 (0.97 to 1.20)
diagnosis, y 10-14  3424 1074 (31.4) 0.72 (0.66 to 0.79) 1.49 (1.32 to 1.68) 2499 (73.0) 0.96 (0.87 to 1.05) 0.97 (0.86 to 1.09) 
 P trend   <0.001∆ <0.001∆  0.544∆ 0.720∆ 
Chemotherapy No 4056 821 (20.2) 1.00 (referent) 1.00 (referent)* 3005 (74.1) 1.00 (referent) 1.00 (referent)* 
 Yes  4702 1760 (37.4) 2.36 (2.14 to 2.60) 1.40 (1.23 to 1.61) 3489 (74.2) 1.01 (0.91 to 1.11) 1.00 (0.87 to 1.13) 
 P heterogeneity    <0.001 <0.001  0.903 0.947 
Surgery No 4162 1519 (36.5) 1.00 (referent) 1.00 (referent)* 3095 (74.4) 1.00 (referent) 1.00 (referent)* 
 Yes 5152 1148 (22.3) 0.50 (0.46 to 0.55) 1.02 (0.89 to 1.16) 3788 (73.5) 0.96 (0.87 to 1.05) 0.93 (0.82 to 1.06) 
 P heterogeneity    <0.001 0.819  0.360 0.302 
Radiotherapy No RT 2796 625 (22.4) 1.00 (referent) 1.00 (referent)* 2081 (74.4) 1.00 (referent) 1.00 (referent)* 
 RT which excluded the 
head and abdomen 
1602 418 (25.8) 1.21 (1.05 to1.39) 1.45 (1.23 to 1.71) 1197 (73.8) 0.97 (0.84 to 1.11) 0.97 (0.83 to 1.13) 
 RT to an abdominal 
site 
1123 235 (20.9) 0.92 (0.78 to 1.09) 1.00 (0.83 to 1.22) 831 (74.0) 0.98 (0.83 to 1.15) 0.99 (0.83 to 1.18) 
 RT to the head 3591 1408 (39.2) 2.24 (2.00 to 2.50) 1.76 (1.54 to 2.03) 2655 (73.9) 0.97 (0.87 to1.09) 0.96 (0.84 to 1.09) 
 P heterogeneity    <0.001 <0.001  0.963 0.930 
Region  London 1247 424 (34.0) 1.00 (referent) 1.00 (referent)† 879 (70.5) 1.00 (referent) 1.00 (referent)† 
 North East 607 210 (34.6) 1.03 (0.84 to 1.26) 0.99 (0.80 to 1.24) 474 (78.1) 1.49 (1.19 to1.87) 1.50 (1.19 to 1.88) 
 North West 1543 711 (46.1) 1.66 (1.42 to 1.94) 1.86 (1.58 to 2.21) 1138 (73.8) 1.18 (1.00 to 1.39) 1.19 (1.00 to 1.40) 
 Yorkshire and Humber  1138 459 (40.3) 1.31 (1.11 to 1.55) 1.19 (0.99 to 1.42) 823 (72.3) 1.09 (0.92 to 1.31) 1.09 (0.91 to 1.31) 
 East Midlands 969 330 (34.1) 1.00 (0.84 to 1.20) 0.97 (0.80 to 1.18) 702 (72.5) 1.10 (0.91 to 1.33) 1.09 (0.91 to 1.32) 
 West Midlands 1218 496 (40.7) 1.33 (1.13 to 1.57) 1.37 (1.15 to 1.64) 875  (71.8) 1.07 (0.90 to 1.27) 1.07 (0.90 to 1.27) 
 East England 1304 408 (31.3) 0.88 (0.75 to 1.04) 0.91 (0.76 to 1.09) 937 (71.9) 1.07 (0.90 to 1.27) 1.08 (0.91 to 1.28) 
 South East 1809 571 (31.6) 0.90 (0.77 to 1.04) 0.87 (0.74 to 1.03) 1383 (76.5) 1.36 (1.15 to 1.60) 1.37 (1.16 to 1.61) 
 South West 1269 397 (31.3) 0.88 (0.75 to 1.04) 0.87 (0.72 to 1.04) 956 (75.3) 1.28 (1.07 to 1.53) 1.29 (1.08 to 1.54) 
 Wales 663 230 (34.7) 1.03 (0.85 to 1.26) 1.03 (0.83 to 1.28) 498 (75.1) 1.26 (1.02 to 1.57)  1.26 (1.02 to 1.57) 
 Scotland  1128 444 (39.4) 1.26 (1.07 to 1.49) 1.32 (1.10 to 1.58) 867 (76.9) 1.39 (1.16 to 1.67) 1.40 (1.17 to 1.69) 
 P heterogeneity    <0.001 <0.001  <0.001 <0.001 
NCSI Levels NCSI Level 1 1182 221 (18.7) 1.00 (referent) 1.00 (referent)§ 917 (77.6) 1.00 (referent) 1.00 (referent)§ 
 NCSI Level 2 3443 1073 (31.2) 1.97 (1.67 to 2.32) 1.88 (1.57 to 2.25) 2550 (74.1) 0.83 (0.71 to 0.97) 0.82 (0.70 to 0.96) 
 NCSI Level 3 8077 1262 (36.6) 2.51 (2.13 to 2.95) 2.68 (2.24 to 3.20) 2515 (72.9) 0.78 (0.66 to 0.91) 0.77 (0.66 to 0.91) 
 P heterogeneity  <0.001 <0.001 <0.001  0.005 0.006 
CNS = central nervous system; CI = confidence interval;  NCSI= National Cancer Survivorship Initiative, NHL= Non-Hodgkin's Lymphoma; OR = odds ratio; STS = soft tissue sarcomas; RT= radiotherapy, y= 
years 
† The multivariate model for these factors included the following; sex; attained age; childhood cancer type; age at childhood cancer diagnosis; region (main model without treatment). 
* The multivariate model for these factors included the following; sex, attained age, age at childhood cancer diagnosis, chemotherapy, surgery, radiotherapy according to site of treatment (treatment model). 
§ The multivariate model for these factors included the following; sex, attained age, age at childhood cancer diagnosis, region, NCSI Levels (model excluding treatment and cancer diagnosis)  
∆The p value for test for trends are reported here, in addition tests for non-linearity were conducted.    
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Figure 2.1 National Cancer Survivorship Initiative Levels of clinical follow-up defined in terms of type of 
childhood cancer and treatment received  
Type of Childhood Cancer 
 
HODG NHL CNS NEURO 
RETINO 
(HER) 
RETINO 
(NON-
HERITAB
LE) WILMS BONE STS OTHER 
S alone 1 1 2 1 2 1 1 1 1 1 
R alone 3 2 3 2 3 2 2 2 2 2 
C alone 2 2 2 2 2 1 2 2 2 2 
S + R 3 2 3 2 3 2 2 2 2 2 
S + C 2 2 2 2 2 1 2 2 2 2 
R + C 3 2 3 3 3 2 3 3 3 2 
S + R + C 3 2 3 3 3 2 3 3 3 2 
CNS - Central Nervous System; C - Chemotherapy; HODG - Hodgkin's lymphoma; NHL - Non-Hodgkin's lymphoma; NEURO - Neuroblastoma ; RETINO - Retinoblastoma; STS 
- Soft tissue sarcoma; S - Surgery; R - Radiotherapy; 
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Figure 2.2 Extent of regular long-term hospital follow-up among survivors by age for each National Cancer 
Survivorship Initiative Levels of clinical follow-up a) among all childhood cancers except leukaemia, b) among 
acute lymphoblastic leukaemia survivors  
a)     
b)  
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Figure 2.3 Extent of regular long-term hospital follow-up among survivors of specific types of childhood cancer 
assigned to the National Cancer Survivorship Initiative LEVEL 3 of clinical follow-up care in relation to attained 
age, a) CNS neoplasms survivors b) Hodgkin's tumour survivors, c) Wilm's tumour survivors  
a)  
b)  
c)  
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CHAPTER 3 ADVERSE HEALTH AND SOCIAL OUTCOMES 
IN LONG-TERM SURVIVORS OF A CENTRAL NERVOUS 
SYSTEM TUMOUR: THE BRITISH CHILDHOOD CANCER 
SURVIVOR STUDY 
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3.1 ABSTRACT  
Background: To our knowledge, no study has investigated the risks of adverse health 
outcomes beyond 30 years from diagnosis of specific childhood Central Nervous System 
(CNS) tumours. We investigated such risks, specifically following craniopharyngioma, 
medulloblastoma and astrocytoma.  
Methods: The BCCSS included 4,111 five-year survivors of a CNS tumour. We investigated 
cause-specific mortality and risk of subsequent primary neoplasms (SPNs). Among survivors 
who returned a questionnaire, smoking, drinking, education, marriage, body mass index, 
health care use and health-status (SF-36) were compared to that expected from the general 
population.      
Results: Between 30 and 50 years from diagnosis the principal causes of death accounting for 
most of the total excess deaths observed were: after craniopharyngioma, recurrence (28%) and 
circulatory (35%); after medulloblastoma, recurrence (20%) and SPN (48%); after 
astrocytoma, recurrence (35%), SPN (13%) and respiratory (13%). Consequently, CNS 
subtype was a strong risk stratification factor, as was cranial/craniospinal radiotherapy in that, 
of the total excess number of deaths observed beyond 30 years from diagnosis among those 
exposed (unexposed) to radiotherapy 21% (3%) and 11% (0%) were attributable to SPN and 
stroke respectively. The cumulative risks of developing a meningioma by 35 years from 
diagnosis among those exposed (unexposed) to radiotherapy were 3.9% (0.6%). Educational 
attainment and marriage showed greater deficits among those CNS tumour survivors who had 
received cranial/craniospinal irradiation.  
Conclusion: CNS subtype and cranial irradiation provide strong risk stratification factors 
which may be used in long-term follow-up clinics to powerfully discriminate between groups 
of survivors in terms of anticipated risk of serious adverse health outcomes. 
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3.2 INTRODUCTION   
Previous studies have reported increased risks of a range of adverse health and social 
outcomes among long-term central nervous system (CNS) tumour survivors including 
premature mortality, subsequent primary neoplasms (SPNs) and a spectrum of non-neoplastic 
conditions (61, 76, 97, 99, 100, 183, 201). However, previous studies have either investigated 
outcomes of all CNS tumours considered together and quantified risks beyond 30 years from 
diagnosis, or have investigated specific CNS tumour subtypes (subsequently referred to as 
CNS subtype) and quantified risks up to 30 years from diagnosis.  
The objective of this study was to quantify the risks of adverse health and social outcomes 
amongst CNS tumour survivors overall and by CNS subtype, specifically craniopharyngioma, 
medulloblastoma and astrocytoma, both before and after 30 years from diagnosis. 
3.3 METHODS 
3.3.1 British Childhood Cancer Survivor Study 
The British Childhood Cancer Survivor Study (BCCSS) is a large scale population-based 
cohort study established to investigate the long-term adverse health and social outcomes of 
childhood cancer and its treatment (30). The BCCSS cohort includes 17,980 individuals 
diagnosed with childhood cancer between 1940 and 1991 inclusive, before age 15 years, in 
Great Britain and who survived for at least five years. This includes 4,111 (22.9%) survivors 
diagnosed with a CNS neoplasm. The BCCSS cohort was identified using the population-
based National Registry of Childhood Tumours. Ethical approval for the BCCSS was 
obtained from the relevant Multi-Centre Research Ethics Committee and every Local 
Research Ethics Committee in Britain.  
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3.3.2 Ascertainment of deaths and subsequent primary neoplasms  
Death ascertainment was through electronic record linkage of the BCCSS cohort, via the 
Health and Social Care Information Centre (HSCIC), to the national population-based death 
registration system which enables ascertainment of vital and emigration status of each cohort 
member (55). SPN ascertainment was through record linkage with the population-based 
national cancer registry via HSCIC. All SPNs were validated by obtaining copies of 
diagnostic reports, particularly pathology reports confirming site, type and date of diagnosis 
(63). 
3.3.3 BCCSS Questionnaire 
All survivors who were alive and aged at least 16 years were sent a 40-page BCCSS 
questionnaire via their general practitioner: 3,054 CNS survivors were thus eligible and 2,222 
(72.8%) returned a completed BCCSS questionnaire (30). This questionnaire is shown in 
Appendix 8.2.    
3.3.4 CNS neoplasm classification 
CNS neoplasms were classified into subtypes: craniopharyngioma, medulloblastoma, 
astrocytoma and other diagnoses using the morphology classification of the International 
Classification of Diseases for Oncology (ICD-O-3) (14). 
3.3.5 Statistical methods 
Cause-specific mortality 
Follow-up started at five years after diagnosis of the CNS tumour and ended on 31st 
December 2010 with earlier exits at death or emigration. Standardised mortality ratios 
(SMRs) and absolute excess risks (AERs) were calculated for specific causes of death. The 
SMR was defined as the ratio of the observed to expected number of deaths, the AER as the 
observed minus expected number of deaths divided by the person-years at risk multiplied by 
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10,000. Cumulative mortality for specific causes of death after specific CNS subtypes was 
estimated, with other causes of death treated as competing risks.  
 
Subsequent Primary Neoplasms  
Entry to risk was again at five-year survival and ended at the first occurrence of diagnosis of a 
SPN, emigration, death or reaching 31st December 2006. Standardised incidence ratios (SIRs) 
and AERs were calculated as for SMRs and AERs above.   
 
Educational attainment, smoking history and alcohol consumption  
Educational attainment, smoking and alcohol consumption comparisons were undertaken 
between CNS tumour survivors and the national General Household Survey (GHS) (202). 
Odds Ratios (ORs) were calculated using a logistic regression model with a generalised 
estimating equation (GEE) modification, which took into account the clustering present 
within the GHS sample. Confounding factors were identified a priori and adjustments made as 
specified in Table 3.6. Four levels of educational attainment were evaluated: degree, teaching 
qualification, 'A'-level and 'O'-level. The outcome investigated for smoking was the 
proportion who were current regular smokers. Three outcomes were assessed for alcohol 
consumption: the prevalence of current drinkers, drinking over weekly recommendations (>21 
units/week for men and >14 units/week for women) and consuming harmful amounts of 
alcohol (>50 units/week for men and >35 units/week for women) (203, 204). 
 
Marital status 
The marital status of CNS tumour survivors was compared to that expected from the general 
population by pooling age-specific ORs using the Mantel-Haenszel method. National 
marriage registration statistics from the Office for National Statistics (ONS) were used for 
comparison (205). 
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Healthcare utilisation 
The extent of healthcare utilisation reported by CNS tumour survivors was compared to that 
expected from the general population using the GHS in relation to four outcomes: (1) talked 
to a doctor in the last 2 weeks; (2) attended a hospital outpatient department in the last 3 
months; (3) hospitalised as a day patient in the last year and; (4) hospitalised as an inpatient in 
the last year. For each outcome, the OR comparing survivors to the GHS was calculated using 
a logistic regression model with a GEE modification adjusted for age at questionnaire 
completion, sex and educational attainment.  
 
Body Mass Index (BMI) 
Self-reported height and weight were used to calculate BMI. Overweight was defined as a 
BMI of ≥25. The BMI of CNS tumour survivors was compared to the general population 
using the national ONS Omnibus Survey, which involved the collection of self-reported 
weight and height data for 1804 individuals by interview (206). Separate logistic regressions 
to calculate ORs of being at least overweight were conducted for males and females, adjusted 
for age and socio-economic status. A weighting factor was used to take account of the 
sampling technique used in the Omnibus Survey since only one adult from each selected 
household was interviewed. 
 
Health status (SF-36) 
Functional health and well-being of CNS survivors were investigated using the Short Form 
(SF-36) health status survey (150). The SF-36 consists of eight scales; physical function, role-
physical, role-emotional, social functioning, mental health, vitality, pain and general health 
perception. The Oxford Healthy Life Survey (OHLS) was used as the general population 
comparison group (207). For each SF-36 scale, linear regression (adjusted for sex and age at 
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questionnaire completion) was used to compare the mean scale score of survivors to that of 
the OHLS population. Direct standardisation was used to compare the percentage of CNS 
tumour survivors that reported a specific problem or limitation with that expected from the 
general population. 
All analyses were undertaken using Stata 12.1 (Stata Corp, College Station, Texas). Statistical 
significance was defined as a two-sided p-value less than 0.05. 
3.4 RESULTS 
3.4.1 Cohort characteristics 
Of the 4,111 CNS tumour survivors, 345 (8.4%) had been treated for craniopharyngioma, 632 
(15.4%) for medulloblastoma, 2,107 (51.3%) for astrocytoma and 1,027 (25%) for other CNS 
tumours. The composition of the cohort overall and for those returning a questionnaire, in 
relation to sex, age at diagnosis, age at questionnaire completion, decade of diagnosis and 
whether treated with radiotherapy, chemotherapy or surgery is provided in Table 3.1. 
3.4.2 Mortality 
Deaths after all CNS tumours 
Observed mortality after all CNS tumours was 13-times that expected, with an excess of 118 
deaths per 10,000 person-years. Substantial excesses (observed≥50 and SMR≥5) were 
observed for deaths from SPN, circulatory and respiratory disease (Table 3.2). Prior to 30 
years from diagnosis, 75% of excess deaths were attributable to recurrence, whilst beyond 30 
years from diagnosis only 31% of excess deaths were attributable to recurrence (Table 3.3). 
Comparing CNS tumour survivors who had (had not) received cranial/craniospinal 
radiotherapy, revealed that beyond 30 years from diagnosis 21% (3%) of excess deaths were 
attributable to SPN and 11% (0.2%) were attributable to stroke (Table 3.3). Beyond 30 years 
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from diagnosis 12 to 13% of excess deaths were attributable to respiratory causes, irrespective 
of treatment with radiotherapy.  
 
Deaths after medulloblastoma 
Survivors of a medulloblastoma had the highest overall excess mortality of the three CNS 
subtypes, 21-times that expected (Table 3.2). Before 30 years from diagnosis, 75% of excess 
deaths were attributable to recurrence compared to 20% after 30 years, when the largest 
proportion of excess deaths was attributable to SPNs (48%) (Table 3.4). The cumulative risk 
of death from SPN and non-neoplastic causes were both substantial by 50 years from 
diagnosis at 16% and 17% respectively, Figure 3.1. The expected cumulative risk from all 
causes was 7% at 50 years of follow-up.    
 
Deaths after craniopharyngioma 
Mortality among survivors of a craniopharyngioma was 20-times that expected (Table 3.2). 
Before 30 years from diagnosis 69% of the total excess deaths were attributable to recurrence, 
whereas beyond 30 years only 28% of excess deaths were attributable to recurrence and 35% 
were attributable to circulatory causes (Table 3.4). Cumulative risk of a non-neoplastic death 
by 50 years was 33.3%, whilst the corresponding risk of SPN death was only 2%, as shown in 
Figure 3.1. The expected cumulative risk from all causes was 8% at 50 years of follow-up.  
 
Deaths after astrocytoma  
Among astrocytoma survivors, the SMR for all causes of death was 11-times that expected 
(Table 3.2). Beyond 30 years of follow-up, the main causes of death that accounted for the 
greatest excess numbers observed were recurrence (35%), SPN (13%) and respiratory (13%) 
(Table 3.4). Astrocytoma survivors had a similar cumulative risk of non-neoplastic death by 
50 years of follow-up to medulloblastoma survivors (15% compared to 17%). However, in 
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contrast corresponding risks of SPN death were dissimilar at 6% and 16%, respectively, 
Figure 3.1. The cumulative risk of death from recurrence by 50 years of follow-up was 19.8%. 
The expected cumulative risk for all causes was 7.4% at 50 years of follow-up.    
3.4.3 Incidence of Subsequent Primary Neoplasms 
Overall, CNS tumour survivors were 3-times more likely than expected to develop a SPN: 
with an excess of 12 SPNs per 10,000 person-years (Table 3.5). The cumulative risk of 
developing any SPN by 35 years from CNS tumour diagnosis was 4.5% (Figure 3.2). By the 
same time, the cumulative risk of developing a meningioma SPN was greater for survivors 
exposed to cranial/craniospinal irradiation (3.9%) than among those unexposed (0.6%) 
P<0.0001 (Figure 3.2). The cumulative risk of developing a glioma SPN by 35 years from 
CNS tumour diagnosis was 2.1% among those survivors treated with cranial/craniospinal 
radiotherapy, whilst 0.6% among those not so treated P<0.0001 (Figure 3.2). 
Medulloblastoma survivors had an 8-fold increased risk of developing any SPN. The excess 
risk was particularly high for developing a glioma (SIR=43.4, 95%CI:24.6-76.4). The risk of 
developing any SPN among astrocytoma survivors was 2-fold (SIR=2.3, 95%CI:1.9-2.9) 
(Table 3.5).  
3.4.4 Education attainment, smoking, alcohol consumption, marriage, health care use and 
BMI (Table 3.6) 
CNS tumour survivors were found to experience large deficits in their educational attainment 
at all levels compared to that expected. The ORs compared with expected educational 
attainment across the four levels was 0.3-0.5 in CNS survivors who received 
cranial/craniospinal radiotherapy; and 0.6-0.7 in CNS survivors who did not. Of all subtypes, 
medulloblastoma survivors were least likely to attain any of the four qualifications (ORs=0.3-
0.4), but all subtypes had substantial deficits in some levels of educational attainment. The 
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above ORs may be approximately interpreted as relative risks, but because the outcome is 
common ( >10%) the relative risks may be exaggerated somewhat (208).  
Compared to the general population, CNS subtypes were significantly less likely to be current 
regular smokers (medulloblastoma and craniopharyngioma, both OR=0.2, 95%CI:0.1-0.3; 
astrocytoma, OR=0.4, 95%CI:0.3-0.5) or consume alcohol over the weekly recommendations 
(craniopharyngioma: OR=0.4, 95%CI:0.2-0.8; medulloblastoma: OR=0.2, 95%CI:0.1-0.4; 
astrocytoma: OR=0.6, 95%CI:0.5-0.7).  
CNS tumour survivors, particularly male survivors (OR=0.2, 95%CI:0.2-0.3), were 
significantly less likely to have married compared to the general population. Male 
medulloblastoma survivors were the least likely to have married (OR=0.1, 95%CI:0.1-0.2) 
compared to the general population.  
Compared to the general population, CNS tumour survivors were more likely to have used 
healthcare as: an outpatient (OR=3.1, 95%CI:2.7-3.5), inpatient (OR=2.4, 95%CI:2.1-2.8) and 
day patient (OR=1.6, 95%CI:1.3-1.8). Craniopharyngioma survivors in particular were 
significantly more likely than expected to visit a hospital as an outpatient (OR=7.0, 
95%CI:5.0-9.7) and significantly more likely to be hospitalised as an inpatient (OR=3.6, 
95%CI:2.4-5.6). 
Each of male and female CNS tumour survivors separately were 2-times more likely than 
expected to be overweight. Female CNS tumour survivors treated with cranial radiotherapy 
were 4-times more likely than expected to be overweight. Female craniopharyngioma 
survivors were 12-times more likely than expected to be overweight, with 84% being 
classified as overweight.   
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3.4.5 Health status (SF-36) 
CNS tumour survivors overall and within each subtype reported in Table 3.7 scored less 
favourably than expected on each separate scale of the SF-36; the greatest differences were 
observed in the physical function, role-physical, social functioning and general health 
perception scales.  
Investigation of the individual items, comprising the physical function scale - Table 3.8, 
revealed that 48%, 45% and 34% of medulloblastoma, craniopharyngioma and astrocytoma 
survivors respectively, were limited in ‘moderate activities’ compared to the 8% expected 
from the general population. Corresponding percentages for 'climbing one flight of stairs’ 
were 44%, 23% and 24%, respectively, compared with 5% expected and, for 'bathing and 
dressing yourself' were 20%, 24% and 18%, respectively, compared with 3% expected. 
3.5 DISCUSSION 
This is the first epidemiological study to have quantified adverse health and social outcomes 
among survivors of specific types of childhood CNS tumour between 30 and 50 years from 
the original cancer diagnosis. CNS subtype was a strong risk stratification factor in that it 
provides strong discrimination in relation to the risk of outcome(s). The cumulative risk of 
death from all non-neoplastic causes after craniopharyngioma, medulloblastoma and 
astrocytoma were 33%, 17% and 15%, respectively, by 50 years from diagnosis. The 
corresponding risks of SPN were 2%, 16% and 6%, respectively. The expected cumulative 
risk of death from all causes by 50 years from diagnosis was 7 to 8% in relation to each CNS 
subtype. Beyond 30 years from diagnosis the principal causes of death accounting for most of 
the total excess numbers observed were: recurrence (28%) and circulatory (35%) after 
craniopharyngioma; recurrence (20%) and SPN (48%) after medulloblastoma; recurrence 
(35%), SPN (13%) and respiratory (13%) after astrocytoma. In a previous study, survivors of 
an astrocytoma were at highest risk of late recurrence 20 years after their original diagnosis 
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while this study shows that the risk extends beyond 20 years as the cumulative mortality at 50 
years was 19.8% (209). 
 
Cranial/craniospinal radiotherapy also emerged as a powerful risk stratification factor. Of the 
total excess number of deaths observed beyond 30 years from diagnosis among those exposed 
(unexposed) to cranial/craniospinal radiotherapy, 21% (3%) were attributable to SPN and 
11% (0%) to stroke. The cumulative risk of developing a meningioma (the commonest 
secondary intracranial second neoplasm in this study) by 35 years from diagnosis among 
those exposed (unexposed) to cranial/craniospinal radiotherapy was 3.9% (0.6%); the 
corresponding figures for glioma were 2.1% (0.6%). After craniopharyngioma only 3 SPNs 
were observed and 4.3 were expected. Similar to a previous study, CNS tumour survivors had 
a 3-fold risk of developing a SPN compared to the general population (100). After 
medulloblastoma, 50 SPNs were observed, 8-fold expected, while after astrocytoma, 78 SPNs 
were observed, 2-fold expected. Previous studies have shown an increased risk of SPN 
development following cranial radiation exposure (60, 61, 210).   
 
Female survivors of craniopharyngioma were almost 12-times more likely than the general 
population to be overweight or obese. Obesity has been recognised among survivors of 
craniopharyngioma although this has not been previously quantified in relation to the general 
population (211-215). Hypothalamic damage with hormonal imbalance is associated with 
obesity and can also occur as a result of direct invasion by the craniopharyngioma or from 
surgery or (to a less extent) radiotherapy used in treatment (216-218). Both neurosurgery and 
cranial radiation for treatment of craniopharyngioma have been identified as risk factors for 
obesity (121).   
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In terms of education, all CNS subtypes attained a substantially lower level than expected and 
medulloblastoma survivors were the most impaired. In a previous study, cranial irradiation 
has been shown to be the strongest prognostic factor of educational attainment; survivors who 
had received cranial irradiation were approximately 9-times more likely to have a lower 
educational level than survivors without cranial irradiation (131). Since medulloblastoma 
tumours were largely treated with cranial irradiation in this study, this factor is likely to have 
been influential on their educational attainment. Cranial irradiation could also explain the 
lowest likelihood of marriage compared to that expected among medulloblastoma survivors 
compared to other subtypes in our study as the adverse effects of cranial irradiation have been 
demonstrated in previous studies (100, 142).  
CNS tumour survivors overall and by subtype report substantial excess limitations across the 
SF-36 scale, particularly in the domains of physical function, role-physical, social functioning 
and general health perception. CNS tumour survivors treated with cranial irradiation had 
appreciably greater deficits than those not treated with this modality and such deficits have 
been reported before (219).  
3.5.1 Study limitations 
Potential limitations of our study include: (i) the level of treatment information available: 
YES, NO or  NO RECORD  for each of radiotherapy, chemotherapy and surgery. However, 
cranial irradiation for brain tumour usually exceeds 30Gy and so having exposed/unexposed 
is useful for risk stratification. Chemotherapy is rarely used in the treatment of brain tumours 
except medulloblastoma, but it only became standard care in the mid to late 1990s and such 
survivors are not included in the present cohort.(ii) Our study questionnaire contained self-
reported height and weight, educational attainment, smoking, alcohol consumption, marriage 
and hospitalisations. However, the general population control data was obtained similarly so 
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there should be no bias in the comparison. (iii) Survivors were only eligible to receive a study 
questionnaire if they were alive and aged at least 16 thus there would be a proportion of 
survivors who were not eligible to receive the questionnaire in the first instance. Survivors 
who had died before the questionnaire send out may have been treated more aggressively than 
those survivors who remained alive to receive a questionnaire. Thus caution ought to be 
exercised in interpreting adverse health and social outcomes ascertained from the BCCSS 
study questionnaire because of potential selection bias. (iii) Our findings may not be 
generalisable to children diagnosed with cancer after 1991, but with recent extensions to the 
BCCSS cohort including those diagnosed from 1992 until 2006 inclusive there will be the 
opportunity to examine the outcomes addressed in this study in survivors diagnosed in more 
recent decades who received more modern forms of treatment.    
3.5.2 Conclusions 
We report the first study to quantify the risks of adverse health and social outcomes among 
survivors of specific CNS subtypes between 30 and 50 years from diagnosis. In this period of 
follow-up the principal causes of death accounting for most of the total excess deaths 
observed were: after craniopharyngioma, recurrence (28%) and circulatory (35%); after 
medulloblastoma, recurrence (20%) and SPN (48%); after astrocytoma, recurrence (35%), 
SPN (13%) and respiratory (13%). Consequently CNS subtype is a strong risk stratification 
factor. Cranial/craniospinal radiotherapy also emerged as a powerful risk stratification factor 
in that of the total excess number of deaths observed beyond 30 years from diagnosis among 
those exposed (unexposed) to radiotherapy, 21% (3%) and 11% (0%) were attributable to 
SPN and stroke respectively. The cumulative risks of developing a meningioma by 35 years 
from diagnosis among those exposed (unexposed) to radiotherapy were 3.9% (0.6%). 
Educational attainment and marriage showed greater deficits among those CNS tumour 
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survivors treated with cranial/craniospinal irradiation. CNS subtype and cranial irradiation 
provide strong risk stratification factors which may be used in long-term follow-up clinics to  
discriminate between groups of survivors in terms of anticipated risks of serious adverse 
health and social outcomes. 
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Table 3.1 Composition of the CNS cohort overall and for those returning a questionnaire 
  Overall BCCSS cohort, n (%)  Questionnaire completed, n (%) 
Characteristic  All  
CNS 
Craniopha- 
ryngioma 
Medullo- 
blastoma 
Astro- 
cytoma 
 
 
All  
CNS 
Craniopha- 
ryngioma 
Medullo- 
blastoma 
Astro- 
cytoma 
Overall  4111 345 632 2107  2222 168 306 1203 
Sex Male  2190 (53.3) 197 (57.1) 385 (60.9) 1044 (49.6)  1156 (52.0) 92 (54.8) 186 (60.8) 590 (49.0) 
 Female  1921 (46.7) 148 (42.9) 247 (39.1) 1063 (50.5)  1066 (48.0) 76 (45.2) 120 (39.2) 613 (51.0) 
Age at 16-24 n/a n/a n/a n/a  577 (26.0) 39 (23.2) 95 (31.1) 335 (27.9) 
Questionnaire 25-34 n/a n/a n/a n/a  721 (32.5) 59 (35.1) 115 (37.6) 370 (30.8) 
Completion (y) 35-44 n/a n/a n/a n/a  580 (26.1) 42 (25.0) 64 (20.9) 305 (25.4) 
 45-54 n/a n/a n/a n/a  278 (12.5) 22 (13.1) 28 ( 9.2) 152 (12.6) 
 ≥55 n/a n/a n/a n/a  66 ( 3.0) 6 ( 3.6) 4 ( 1.3) 41 ( 3.4) 
Age at  0-4 1210 (29.4) 62 (18.0) 190 (30.1) 672 (31.9)  628 (28.3) 25 (14.9) 100 (32.7) 359 (29.8) 
Diagnosis (y) 5-9 1510 (36.7) 152 (44.1) 269 (42.6) 738 (35.0)  814 (36.6) 70 (41.7) 131 (42.8) 434 (36.1) 
 10-14 1391 (33.8) 131 (38.0) 173 (27.4) 697 (33.1)  780 (35.1) 73 (43.5) 75 (24.5) 410 (34.1) 
Decade of  <1970 1218 (29.6) 116 (33.6) 166 (26.3) 610 (29.0)  551 (24.8) 43 (25.6) 60 (19.6) 303 (25.2) 
Diagnosis (y) 1970-1979 1243 (30.2) 99 (28.7) 174 (27.5) 635 (30.1)  700 (31.5) 54 (32.1) 92 (30.1) 358 (29.8) 
 1980-1991 1650 (40.1) 130 (37.7) 292 (46.2) 862 (40.9)  971 (43.7) 71 (42.3) 154 (50.3) 542 (45.1) 
Surgery No 529 (12.9) 27 ( 7.8) 43 (6.8) 331 (15.7)  251 (11.3) 14 ( 8.3) 17 ( 5.6) 166 (13.8) 
 Yes 2897 (70.5) 262 (75.9) 477 (75.4) 1398 (66.4)  1581 (71.1) 124 (73.8) 229 (74.8) 807 (67.1) 
 No record  685 (16.7) 56 (16.2) 112 (17.7) 378 (17.9)  390 (17.6) 30 (17.9) 60 (19.6) 230 (19.1) 
Chemotherapy No 2797 (68.0) 251 (72.8) 316 (50.0)  1498 (71.1)  1498 (67.4) 124 (73.8) 134 (43.8) 847 (70.4) 
 Yes 291 (7.1) 2 ( 0.6) 167 (26.4)  61 ( 2.9)  150 ( 6.8)  0 ( 0.0) 88 (28.8) 30 ( 2.5)  
 No record  1023 (24.9) 92 (26.7) 149 (23.6) 548 (26.0)  574 (25.8) 44 (26.2) 84 (27.5) 326 (27.1) 
Radiotherapy No 1115 (27.1) 128 (37.1) 10 ( 1.6) 720 (34.2)  668 (30.1) 56 (33.3) 7 ( 2.3)  455 (37.8) 
 Yes 2192 (53.3) 143 (41.5) 510 (80.7)  935 (44.4)  1097 (49.4) 77(45.8) 240 (78.4)  469 (39.0) 
 No record 804 (19.6) 71 (21.5) 112 (17.7) 452 (21.5)  457 (20.6) 35 (20.8) 59 (19.3) 279 (23.2)  
BCCSS: British Childhood Cancer Survivor Study; CNS: central nervous system;  NA: not applicable, n: number; y: years  
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Table 3.2 Standardised Mortality Ratios for CNS tumour survivors overall and CNS subgroups by cause of death 
 Obs/Exp SMR (95%CI) AER (95%CI) 
CNS Overall*    
All causes 1249/98.5 12.7 (12.0-13.4) 117.8 (110.7-124.9) 
Infection 12/1.8 6.6 (3.4-11.5) 1.0 (0.3-1.7) 
Recurrence∆ 776/0.0 NA 79.4 (73.8-85.0) 
SPN 149/26.8 5.6 (4.7-6.5) 12.5 (10.1-15.0) 
Endocrine 12/2.0 6.1 (3.2-10.7) 1.0 (0.3-1.7) 
Nervous system 44/4.1 10.6 (7.7-14.3) 4.1 (2.7-5.4) 
Circulatory§ 81/17.4 4.7 (3.7-5.8) 6.5 (4.7-8.3) 
Cardiac 28/12.5 2.2 (1.5-3.2) 1.6 (0.5-2.6) 
Stroke 39/3.4 11.3 (8.1-15.5) 3.6 (2.4-4.9) 
Respiratory  70/5.0 14.0 (10.9-17.7) 6.7 (5.0-8.3) 
Digestive 13/6.2 2.1 (1.1-3.6) 0.7 (-0.0-1.4) 
External  58/28.3 2.1 (1.6-2.7) 3.0 (1.5-4.6) 
Other¥ 34/6.8 4.9 (3.4-6.9) 2.8 (1.6-3.9) 
    
Craniopharyngioma*    
All causes 149/7.6 19.6 (16.6-23.0) 189.4 (157.4-221.5) 
Infection 6/0.1 41.1 (15.1-89.6) 7.8 (1.4-14.3 ) 
Recurrence∆ 86/0.0 NA 115.2 (90.9-139.6) 
Circulatory§ 21/1.3 15.9 (9.8-24.2) 26.4 (14.3-38.4) 
Cardiac 6/1.0 6.2 (2.3-13.6) 6.7 (0.3-13.2) 
Stroke 9/0.3 35.4 (16.2-67.2) 11.7 (3.8-19.6) 
Respiratory  14/0.4 37.6 (20.6-63.1) 18.3 (8.4-28.1) 
    
Medulloblastoma*    
All causes 239/11.1 21.4 (18.8-24.3) 178.3 (154.6-202.0) 
Recurrence∆ 152/0.0 NA 118.9 (100.0-137.8) 
SPN 49/2.5 19.7 (14.5-26.0) 36.4 (25.7-47.1) 
Circulatory§ 12/1.7 7.0 (3.6-12.2) 8.0 (2.7-13.4) 
Respiratory  12/0.5 23.7 (12.3-41.4) 9.0 (3.7-14.3) 
    
Astrocytoma*    
All causes 553/52.9 10.5 (9.6-11.4) 96.0 (87.1-104.8) 
Recurrence∆ 336/0.0 NA 64.5 (57.6-71.4) 
SPN 67/15.1 4.4 (3.4-5.6) 10.0 (6.9-13.0) 
Nervous system 23/2.0 10.4 (6.6-15.6) 4.0 (2.2-5.8) 
Circulatory§ 32/9.5 3.4 (2.3-4.8) 4.3 (2.2-6.4) 
Cardiac 14/6.8 2.1 (1.1-3.5) 1.4 (-.0.0-2.8) 
Stroke 16/1.9 8.4 (4.8-13.7) 2.7 (1.2-4.2) 
Respiratory  27/2.8 9.8 (6.4-14.2) 4.7 (2.7-6.6) 
Digestive 8/3.3 2.4 (1.0-4.8) 0.9 (-0.2-2.0) 
Perinatal 7/0.9 7.5 (3.0-15.5) 1.2 (0.2-2.2) 
External  31/14.4 2.2 (1.5-3.1) 3.2 (1.1-5.3) 
AER: absolute excess risks, CNS: central nervous system,  CI: confidence interval, Exp: expected, NA: 
not applicable, Obs: observed, SMR: standardised mortality ratio, SPN: second primary neoplasm 
*The causes of death were only included for CNS overall if the number of observed events was >10 
and for CNS subtypes if the number of observed events was >5 
§For circulatory, this category consists of cardiac, stroke and other cardiovascular conditions; the latter 
conditions have not been reported  
∆Calculation of SMR for deaths due to recurrence would be inappropriate since the expected mortality 
rate in the general population would be 0. AER for recurrence was calculated as the mortality rate per 
10,000 person years 
¥ comprises deaths due to blood, mental disorders, musculoskeletal, genitourinary, perinatal and other 
causes 
  66 
Table 3.3 Cause of death specific absolute excess risks for CNS tumour survivors overall and by treatment received 
Cause of death   Years 
from 
diagnosis 
CNS overall CNS overall Cranial RT yes CNS overall cranial RT no 
  O/E AER (95%CI) % O/E AER (95%CI) % O/E AER (95%CI) % 
All causes <30 996/49.6 119.9 (112.1,127.7) 100.0 625/26.2 150.8 (138.5,163.2) 100.0 222/16.5 81.2 (69.7,92.8) 100.0 
 ≥30 253/48.9 108.8 (92.2,125.4) 100.0 184/26.9 150.4 (125.0,175.9) 100.0 66/19.6 64.5 (42.4,86.6) 100.0 
Recurrence <30 713/0.0 90.3 (83.7,97.0) 75.3 457/0.0 115.1 (104.6,125.7) 76.3 155/0.0 61.3 (51.6,70.9) 75.4 
 ≥30 63/0.0 33.6 (25.3,41.9) 30.9 51/0.0 48.8 (35.4,62.2) 32.5 12/0.0 16.7 (7.2,26.1) 25.9 
SPN <30 96/8.5 11.1 (8.7,13.5) 9.2 66/4.5 15.5 (11.5,19.5) 10.3 16/2.9 5.2 (2.1,8.3) 6.4 
 ≥30 53/18.3 18.5 (10.9,26.1) 17.0 43/9.8 31.8 (19.5,44.1) 21.2 9/7.6 1.9 (-6.3,10.1) 3.0 
Circulatory§ <30 37/4.9 4.1 (2.6,5.6) 3.4 24/2.7 5.4 (3.0,7.8) 3.6 7/1.7 2.1 (0.0,4.1) 2.6 
 ≥30 44/12.5 16.8 (9.9,23.7) 15.4 30/7.0 22.0 (11.8,32.3) 14.6 13/5.0 11.2 (1.3,21.0) 17.3 
Cardiac <30 10/3.2 0.9 (0.1,1.6) 0.7 2/1.7 0.1 (-0.6,0.8) 0.0 3/1.1 0.8 (-0.6,2.1) 0.9 
 ≥30 18/9.3 4.6 (0.2,9.0) 4.2 8/5.3 2.6 (-2.7,7.9) 1.7 9/3.7 7.4 (-0.8,15.6) 11.5 
Stroke <30 19/1.3 2.2 (1.2,3.3) 1.9 16/0.7 3.9 (1.9,5.8) 2.6 3/0.4 1.0 (-0.3,2.4) 1.2 
 ≥30 20/2.2 9.5 (4.8,14.2) 8.7 19/1.2 17.1 (8.9,25.2) 11.3 1/0.9 0.2 (-2.6,2.9) 0.2 
Respiratory <30 41/2.1 4.9 (3.3,6.5) 4.1 21/1.1 5.0 (2.7,7.3) 3.3 13/0.7 4.9 (2.1,7.7) 6.0 
 ≥30 29/2.9 13.9 (8.3,19.5) 12.8 21/1.6 18.6 (10.0,27.2) 12.4 7/1.2 8.1 (0.8,15.3) 12.5 
External <30 40/22.8 2.2 (0.6,3.8) 1.8 21/12.1 2.2 (-0.0,4.5) 1.5 12/7.4 1.8 (-0.9,4.5) 2.2 
  ≥30 18/5.5 6.7 (2.2,11.1) 6.1 10/3.2 6.5 (0.6,12.5) 4.3 8/2.0 8.3 (0.6,16.0) 12.9 
Other∆  <30 69/11.4 7.3 (5.2,9.4) 6.1 36/5.9 7.6 (4.6,10.6) 5.0 19/3.8 6.0 (2.6,9.4) 7.4 
 ≥30 46/9.7 19.4 (12.3,26.4) 17.8 29/5.4 22.6 (12.5,32.7) 15.0 17/3.8 18.4 (7.2,29.6) 28.5 
AER: absolute excess risks, CNS: central nervous system, CI: confidence interval, O/E: observed/ expected, RT: radiotherapy, SPN: subsequent primary neoplasm   
∆ comprises deaths due to blood, infection, endocrine, mental, nervous system disease, digestive, musculoskeletal, genitourinary, perinatal and other 
§  category consists of cardiac, stroke and other cardiovascular conditions; the latter conditions have not been reported 
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Table 3.4 Cause of death specific absolute excess risks for CNS tumour subtype 
Cause of death   Years 
from 
diagnosis 
Craniopharyngioma Medulloblastoma Astrocytoma 
  O/E AER (95%CI) % O/E AER (95%CI) % O/E AER (95%CI) % 
All causes 
<30 117/4.2 181.8 (147.6,216.0) 100.0 200/6.6 180.1 (154.3,206.0) 100.0 436/25.4 98.2(88.4,108.0) 100.0 
                             ≥30 32/3.4 226.9 (138.9,314.9) 100.0 39/4.5 168.6 (108.7,228.4) 100.0 117/27.5 86.8(66.3,107.4) 100.0 
Recurrence <30 78/0.0 125.7 (97.8,153.6) 69.1 145/0.0 135.1 (113.1,157.1) 75.0 305/0.0 73.0 (64.8,81.2) 74.3 
 ≥30 8/0.0 63.5 (19.5,107.5) 28.0 7/0.0 34.2 (8.9,59.6) 20.3 31/0.0 30.1 (19.5,40.7) 34.6 
SPN <30 2/0.7 2.1 (-2.4,6.6) 1.2 31/1.0 28.0 (17.8,38.1) 15.5 45/4.5 9.7 (6.6,12.8) 9.9 
 ≥30 1/1.2 -1.7 (-17.3,13.9) -0.7 18/1.5 80.7 (40.0,121.3) 47.9 22/10.6 11.0 (2.1,20.0) 12.7 
Circulatory§ <30 10/0.4 15.4 (5.4,25.4) 8.5 6/0.6 5.0 (0.6,9.5) 2.8 17/2.5 3.5 (1.5,5.4) 3.5 
 ≥30 11/0.9 80.2 (28.6,131.8) 35.3 6/1.1 23.8 (0.3,47.3) 14.1 15/7.0 7.8 (0.4,15.1) 9.0 
Cardiac <30 3/0.3 4.4 (-1.1,9.9) 2.4 1/0.4 0.6 (-1.3,2.4) 0.3 6/1.6 1.0 (-0.1,2.2) 1.1 
 ≥30 3/0.7 18.4 (-8.5,45.3) 8.1 3/0.9 10.5 (-6.1,27.1) 6.2 8/5.2 2.7 (-2.6,8.1) 3.2 
Stroke <30 5/0.1 7.9 (0.8,15.0) 4.3 3/0.1 2.7 (-0.5,5.8) 1.5 9/0.7 2.0 (0.6,3.4) 2.0 
 ≥30 4/0.1 30.6 (-0.5,61.7) 13.5 3/0.2 13.7 (-2.9,30.3) 8.2 7/1.2 5.6 (0.6,10.6) 6.4 
Respiratory <30 11/0.2 17.4 (7.0,27.9) 9.6 8/0.3 7.2 (2.0,12.4) 4.0 14/1.1 3.1 (1.3,4.8) 3.1 
 ≥30 3/0.2 22.3 (-4.7,49.2) 9.8 4/0.2 18.4 (-0.8,37.6) 10.9 13/1.7 11.0 (4.1,17.8) 12.7 
External <30 3/2.0 1.7 (-3.8,7.2) 0.9 2/3.2 -1.2 (-3.7,1.4) -0.6 21/11.5 2.3 (0.1,4.4) 2.3 
  ≥30 1/0.4 4.7 (-10.8,20.3) 2.1 3/0.7 11.4 (-5.2,28.0) 6.8 10/2.9 6.9 (0.9,12.9) 7.9 
Other∆  <30 13/0.9 19.4 (8.0,30.8) 10.7 8/1.5 6.0 (0.9,11.2) 3.3 34/5.9 6.7 (4.0,9.5) 6.9 
 ≥30 8/0.7 57.9 (13.9,101.9) 25.5 1/1.0 0.1 (-9.5,9.7) 0.0 26/5.3 20.1 (10.4,29.8) 23.1 
AER: absolute excess risks, CNS: central nervous system, CI: confidence interval, O/E: observed/ expected, SPN: subsequent primary neoplasm   
∆ comprises deaths due to blood, infection, endocrine, mental, nervous system disease, digestive, musculoskeletal, genitourinary, perinatal and other 
§  category consists of cardiac, stroke and other cardiovascular conditions; the latter conditions have not been reported 
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Figure 3.1 Cumulative mortality for causes of death among all childhood cancer survivors diagnosed with a CNS neoplasm overall and more specifically by CNS 
subtypes of astrocytoma, craniopharyngioma and medulloblastoma 
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Table 3.5 Overall and site specific Standardised Incidence Ratios and Absolute Excess Risks for Subsequent 
Primary Neoplasms developing in CNS tumour survivors  
 
 
 SPN Obs/Exp SIR (95% CI)† AER (95% CI)‡ 
All CNS† Any Cancer Site 165/60.1 2.7 (2.4-3.2) 12.2 (9.3-15.1) 
Survivors Glioma 50/2.3 21.8 (16.6-28.8) 5.5 (4.1-7.4) 
 Digestive 25/6.9 3.6 (2.5-5.4) 2.1 (1.0-3.2) 
 Genitourinary 23/14.3 1.6 (1.1-2.4) 1.0 (-0.1-2.1) 
 Thyroid 11/1.2 9.5 (5.2-17.1) 1.1 (0.4 -1.9) 
 Breast 10/13.1 0.8 (0.4-1.4) 0 (-1.1-0.4) 
  
   
Cranial RT – No Glioma 7/0.74 9.5 (4.5-19.7) 2.4 (0.4-4.3) 
Cranial RT – Yes Glioma 41/1.2 33.6 (24.7-45.6) 8.8 (6.0-11.6) 
  
   
Craniopharyngioma Any Cancer Site 3/4.3 0.7 (0.2-2.1)  0 (-7.2-3.1) 
Medulloblastoma§ Any Cancer Site 50/5.9 8.4 (6.4-11.1) 39.3 (27.0-51.7) 
 Glioma 12/0.3 43.4 (24.6-76.4) 10.5 (4.45-16.5) 
Astrocytoma Any Cancer Site 78/33.7 2.3 (1.9-2.9) 9.7 (5.9-13.4) 
 Glioma 22/1.2 18.0 (11.9-27.4)  4.5 (2.5-6.5) 
AER: absolute excess risk, CNS: central nervous system, CI: confidence interval, Obs/Exp: observed/expected, RT: radiotherapy, SIR: standardised 
incidence ratio  
† Other SPNs include: 8 connective & soft tissue, 7 Leukaemia, 6 respiratory, 6 bone & articular cartilage, 5 oral cavity & pharynx, 5 melanoma skin cancer, 
2 Hodgkin Lymphoma, 2 Non-Hodgkin Lymphoma, 2 other endocrine, 1 other lymphoid, 1 eye and 1 others   
§ SPNs include: 12 CNS, 12 digestive and peritoneum, 6 female genital organs, 6 thyroid, 4 leukaemia, 2 breast, 2 oral cavity & pharynx, 2 bone & articular 
cartilage, 1 respiratory & intrathoracic, 1 melanoma skin cancer, 1 male genital organs, 1 eye  
‡AER is shown per 10,000 person years 
  70 
Figure 3.2 Observed Cumulative Incidence of Subsequent Primary Neoplasms among all CNS childhood cancer survivors, cumulative incidence of specific CNS 
subsquent primary neoplasms and cumulative incidence of SPNs after an astrocytoma and medulloblastoma respectively.  
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Table 3.6 Odds ratios of the different health and social outcomes for all survivors of a CNS tumour combined, 
for survivors treated with cranial radiotherapy and for survivors of specific types of CNS tumours relative to the 
general population 
  
Outcome CNS overall 
 
CNS overall 
Cranial RT yes 
CNS overall 
Cranial RT no 
Craniopharyn- 
gioma 
Medullo- 
blastoma 
Astrocy- 
toma 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Educationa       
University degree  0.4 (0.3-0.5) 0.3 (0.2-0.4) 0.6 (0.5-0.7) 0.4 (0.2-0.7)  0.3 (0.2-0.4) 0.5 (0.4-0.6)  
Teaching qualification  0.5 (0.5-0.6) 0.5 (0.4-0.6) 0.6 (0.5-0.8) 0.5 (0.4-0.8) 0.3 (0.2-0.5)  0.6 (0.5-0.7) 
A levels or higher  0.5 (0.5-0.6) 0.5 (0.4-0.5) 0.7 (0.6-0.8) 0.8 (0.6-1.9) 0.3 (0.2-0.4) 0.5 (0.5-0.6) 
O levels or higher  0.5 (0.4-0.5) 0.4 (0.6-0.5) 0.7 (0.6-0.9) 0.9 (0.6-1.4) 0.4 (0.2-0.3)  0.5 (0.4-0.7) 
       
Smokingb       
Current regular smoker 0.3 (0.3-0.4) 0.3 (0.2-0.3) 0.5 (0.4-0.7) 0.2 (0.1-0.3) 0.2 (0.1-0.3) 0.4 (0.3-0.5) 
       
Alcohol consumptionb       
Current drinker 0.3 (0.3-0.4) 0.3 (0.3-0.4)  0.5 (0.4-0.6) 0.2 (0.1-0.2) 0.3 (0.2-0.4) 0.4 (0.3-0.5) 
Consuming over 
recommendation 
0.5 (0.4-0.6) 0.4 (0.3-0.5) 0.8 (0.6-1.0) 0.4 (0.2-0.8) 0.2 (0.1-0.4) 0.6 (0.5-0.7) 
Consuming harmful amounts  0.3 (0.2-0.5) 0.3 (0.2-0.5) 0.4 (0.2-0.6) 0.4 (0.1-1.4) 0.3 (0.1-0.7) 0.4 (0.3-0.6) 
       
Marriagec       
Males 0.2 (0.2-0.3)            0.2 (0.1-0.2) 0.3 (0.3-0.4) 0.2 (0.2-0.4)           0.1 (0.1-0.2)            0.3 (0.2-0.3)                  
Females 0.3 (0.3-0.4) 0.2 (0.2-0.3) 0.5 (0.4-0.7) 0.2 (0.1-0.3) 0.2 (0.1-0.4) 0.4 (0.3-0.4) 
       
Health care utilisationd       
Talked to a doctor 1.2 (1.1-1.4) 1.1 (0.9-1.3) 1.3 (1.1-1.6) 2.2 (1.5-3.1) 1.2 (0.9-1.7) 1.1 (0.9-1.3) 
Attended hospital outpatient  3.1 (2.7-3.5) 3.1 (2.6-3.6) 2.6 (2.1-3.1) 7.0 (5.0-9.7) 3.1 (2.4-4.1) 2.7 (2.3-3.1) 
Hospitalised as a day patient 1.6 (1.3-1.8) 1.4 (1.2-1.8) 1.4 (1.1-1.9)   3.1 (2.1-4.5) 1.6 (1.1-2.3) 1.4 (1.2-1.8) 
Hospitalised as an inpatient 2.4 (2.1-2.8) 2.4 (1.9-3.0) 2.1 (1.6-2.8) 3.6 (2.4-5.6) 2.9 (2.0-4.1) 2.1 (1.7-2.6) 
       
BMIe       
Male 1.6 (1.3-2.1) 1.8 (1.4-2.4) 1.3 (0.9-1.7) 3.9 (2.2-7.0) 1.3 (0.9-1.9) 1.5 (1.2-2.0) 
Female 2.4 (1.9-3.1) 3.5 (2.6-4.7) 1.7 (1.3-2.3) 11.9 (5.7-24.6) 3.1 (1.9-5.2) 2.4 (1.8-3.1) 
BMI: body mass index, CNS: central nervous system, CI confidence interval, OR: odds ratio, RT: radiotherapy 
 a  From a generalised estimating equation logistic regression model, taking into account the General Household Survey weighting factor, controlling for age 
and sex. Population data from the General Household Survey (2002) was used for the reference group 
b From a generalised estimating equation logistic regression model controlling for age at questionnaire completion (≤69 years), gender, legal marital status, 
socioeconomic classification, educational attainment and region. The model took into account the General Household Survey (GHS) weighting factor and 
the GHS data (2002) was used as the reference group 
c Calculated using Mantel Haenszel Odds Ratio, adjusting for age and sex 
d From a generalised estimating equation logistic regression model, taking into account the General Household Survey weighting factor, controlling for age 
at questionnaire completion, gender and educational attainment. Outcomes reported were survivors doing these at least once vs never as compared to the 
general population 
e Logistic models were adjusted for age and socio-economic status 
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Table 3.7 Differences in mean scores for eight SF-36 scales between CNS childhood cancer survivors and UK 
norms 
SF36 Scale CNS overall CNS overall 
Cranial RT yes 
CNS overall 
Cranial RT no 
Craniopharyngioma Medulloblastoma Astrocytoma 
 difference* 
(95%CI) 
 difference* 
(95%CI) 
difference* 
(95%CI) 
difference* (95%CI) difference* 
(95%CI) 
difference* 
(95%CI) 
Physical 
Function 
-15.7  
(-16.7 to -14.7) 
-19.8  
(-21.1 to -18.4)  
-10.7  
(-12.2 to -9.1) 
-16.3  
(-19.4 to -13.2)  
-19.3  
(-21.7 to -16.9) 
-13.9  
(-15.2 to -12.7) 
Role-Physical 
-14.7 
 (-16.3 to -13.2) 
-17.9  
(-20.0 to -15.7) 
-10.0  
(-12.4 to -7.5) 
-19.6 
 (-24.5 to -14.7) 
-18.3  
(-22.0 to -14.6) 
-12.4  
(-14.4 to -10.5) 
Role-Emotional 
-5.5  
(-7.1 to -3.9) 
-6.9  
(-9.1 to -4.7) 
-4.4 
 (-6.9 to -1.9) 
-5.4  
(-10.5 to -0.3) 
-6.1 
 (-9.9 to -2.2 
-4.1  
(-6.2 to -2.1) 
Social 
Functioning 
-11.6  
(-12.6 to - 10.5) 
-13.5  
(-14.9 to -12.1) 
-9.5  
(-11.1 to -7.8) 
-13.3  
(-16.5 to -10.0) 
-12.5  
(-15.0 to -10.0) 
-10.1  
(-11.5 to - 8.8) 
Mental Health 
-4.4  
(-5.3 to -3.6) 
-4.5 
 (-5.7 to -3.3) 
-4.4 
 (-5.8 to -3.1) 
-4.2  
(-6.9 to -1.5) 
-2.6 
 (-4.7 to -0.6) 
-4.4 
 (-5.4 to -3.3) 
Vitality 
-5.5 
 (-6.5 to - 4.5) 
-6.8  
(-8.2 to -5.5) 
-3.7   
(-5.3 to -2.2) 
-11.4 
 (-14.5 to -8.3) 
-3.9 
 (-6.2 to -1.5) 
-4.8  
(-6.0 to -3.5) 
Pain  
-3.4 
 (-4.4 to -2.3) 
-3.5  
(-5.0 to -2.0) 
-3.8  
(-5.5 to -2.1)  
-7.1  
(-10.5 to -3.7) 
-2.0  
(-4.6 to -0.6) 
-3.0 
 (-4.3 to -1.6) 
General Health 
Perception 
-10.7  
(-11.7 to - 9.6) 
-12.6  
(-14.0 to -11.3) 
-8.4  
  (-10.0 to -6.8) 
-22.1  
(-25.3 to -18.9) 
-10.2 
 (-12.7 to -7.8) 
-9.1  
(-10.4 to -7.8) 
BCCSS: British Childhood Cancer Survivor Study, CNS: Central Nervous System, CI: confidence interval, RT: radiotherapy, SF-36:short form health-status 
survey 
*Linear regression coefficient adjusted for sex and age at questionnaire completion 
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Table 3.8 Directly standardised percentage experiencing specific outcome within the SF-36 for CNS subgroups as compared to the UK normal population  
SF-36 Scale Individual item UK 
norms 
(%) 
CNS 
overall 
(%)§ 
CNS overall 
Cranial RT yes 
(%)§ 
CNS 
overall 
RT no  
(%)§ 
Craniopharyngioma 
(%)§ 
Medulloblastoma 
(%)§ 
Astrocytoma 
(%)§ 
Physical  Vigorous activities 54 68 73 60 83 78 64 
function† Moderate activities* 8 38 46 31 45 48 34 
 Lifting or carrying groceries  22 38 44 31 40 43 34 
 Climbing several flights of stairs 20 44 52 36 53 59 40 
 Climbing one flight of stairs 5 28 35 21 23 44 24 
 Bending, kneeling or stooping 15 41 46 34 38 45 39 
 Walking more than one mile 11 42 49 34 54 53 36 
 Walking half a mile 6 30 37 24 31 41 26 
 Walking 100 yards 3 23 29 17 19 27 19 
 Bathing and dressing yourself 3 22 27 15 24 20 18 
         
Role Cut down the amount of time spent on work/other activities 11 24 28 20 27 28 21 
Limitation- Accomplished less than you would like 18 34 39 28 41 42 30 
Physical† Were limited in the kind of work/other activities 13 35 40 28 45 46 30 
 Had difficulty performing work/other activities 16 34 39 28 43 42 29 
         
Social 
Functioning† 
 
What extent have your physical or emotional  problems 
interfered with your normal social activities with family, 
friends, neighbours or groups 
7 17 20 14 17 16 15 
 How much time in the last month has your health limited 
social activities  
6 24 25 17 23 21 19 
         
General health  % who say their health is 'poor' or 'fair'  12 28 31 25 43 31 23 
perception I seem to get ill more easily than other people ∆ 6 18 20 17 41 16 15 
 I am as healthy as anybody i know ∆ 88 72 33 22 51 75 75 
 I expect my health to get worse ∆ 13 15 17 16 21 8 15 
 My health is excellent ∆  83 67 38 29 48 69 70 
CNS: Central Nervous System, RT: radiotherapy SF-36: Short Form Health Status Survey, UK: United Kingdom   
†For these individual questionnaire items, the percentage is reported as percent limited  
∆ For these individual items, the percentage is reported as percent mostly/definitely agree 
§ Directly standardised for age and sex  
* Moving a table, pushing a vacuum, bowling or playing golf  
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CHAPTER 4 CEREBROVASCULAR DISEASE AMONG 
FIVE-YEAR SURVIVORS OF CHILDHOOD CANCER 
USING HOSPITAL EPISODE STATISTICS: THE BRITISH 
CHILDHOOD CANCER SURVIVOR STUDY 
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4.1 ABSTRACT 
Background: Survivors of childhood cancer are at increased risk of hospitalisation due to 
cerebrovascular disease; however, the extent to which long-term childhood cancer survivors 
have been hospitalised for specific cerebrovascular conditions, including cerebral 
haemorrhage and ischaemic strokes, remains largely unknown.  
Methods: The population-based British Childhood Cancer Survivor Study (BCCSS) cohort, 
comprising 34,489 individuals diagnosed with cancer aged <15 years, between 1940 and 
2006, in Britain and who survived at least five years, was linked to the inpatient Hospital 
Episode Statistics (HES) database for England. The excess risk of hospitalisation due to 
specific cerebrovascular conditions were quantified by standardised hospitalisation ratios 
(SHR) (defined as Observed/Expected) and absolute excess risks (AER) per 10,000 person-
years. Potential explanatory factors for cerebrovascular hospitalisation were investigated 
using multivariable Poisson regression.   
Results: Overall, 299 survivors were hospitalised for a cerebrovascular condition compared 
to 59 expected (SHR=5.1, 95%CI:4.5-5.7) with survivors of a central nervous system (CNS) 
tumour (SHR=11.9, 95%CI:10.3-13.7, AER=8.5, 95%CI:3.9-18.3) and leukaemia (SHR=5.6, 
95%CI:4.2-7.4, AER=2.3, 95%CI:1.0-5.0) at the greatest excess risk. Of the specific 
cerebrovascular conditions, the greatest observed hospitalisations among survivors were for 
cerebral haemorrhage (SHR=8.1, 95%CI:6.7-9.8) and ischaemic stroke (SHR=5.2, 
95%CI:4.3-6.2), with CNS tumour survivors at particular increased risk. Previous treatment 
with cranial irradiation was associated with increased risk of being hospitalised for a 
cerebrovascular condition over that expected (SHR=15.6, 95%CI:13.0-18.9). In absolute 
terms this equated to 58 additional hospitalisations per 10,000 person-years.     
Conclusion: CNS tumours and leukaemia are at the greatest risk of cerebrovascular 
hospitalisations and more specifically hospitalisations due to cerebral haemorrhage and 
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ischaemic stroke. Cranial irradiation is a strong risk factor associated with survivors being 
hospitalised for cerebrovascular complications. A risk-stratified approach to clinical follow-
up, would ensure survivors at highest risk of cerebrovascular complications undergo 
surveillance.  
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4.2 INTRODUCTION 
Survival after childhood cancer has dramatically improved over the last few decades with 
overall five-year survival in the UK now exceeding 80% (220). The number of long-term 
survivors continues to increase due to improvements in treatment but many sub-groups of 
survivors are at an increased risk of developing adverse health outcomes many years after 
treatment (47, 50). In a study by the CCSS, almost 30% of childhood cancer survivors had a 
severe or life-threatening chronic condition by a mean age of 26.6 years, with CNS tumour 
survivors being some of the highest at risk (47). 
As a result of the increased risk of adverse health outcomes, survivors are more likely to be 
hospitalised compared to their siblings and the general population (122, 123, 221). Previous 
studies have reported the excess risks of hospitalisation due to overall circulatory conditions 
with risks estimated up to 9-fold that expected (122, 124, 222). 
However, the estimated excess risks of hospitalisation among childhood cancer survivors 
specifically due to cerebrovascular disease as reported from large scale population-based 
studies remains largely unknown. The exception is a recent study from Scandinavia (Adult 
Life after Childhood Cancer in Scandinavia (ALiCCS)) using 32,308 one-year childhood 
cancer survivors diagnosed between 1943 and 2008 (71). They reported a 4-fold increased 
risk among survivors being hospitalised due to cerebrovascular disease compared to expected 
(71).  
The aims of this study were to: determine the risks of hospitalisations due to a cerebrovascular 
condition among five-year survivors of childhood cancer as compared to that expected from 
the general population through electronic record linkage of the British Childhood Cancer 
Survivor Study (BCCSS) with the national Hospital Episode Statistics (HES) database; 
investigate the risk of specific types of cerebrovascular conditions (cerebral haemorrhage and 
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ischaemic stroke) in the survivors; examine any variation in these risks by cancer type and 
cranial irradiation. 
To our knowledge, this is the only second large scale population-based study that has 
investigated the risk of hospitalisations explicitly due to cerebrovascular conditions among 
childhood cancer survivors. In addition this study had access to whether individuals received 
direct cranial irradiation which the Scandinavian study did not have. Survivors of childhood 
cancer previously treated with cranial irradiation have been shown to be at increased risk of 
developing cerebrovascular disease (182) with the risk showing a linear dose response 
relationship with radiation dose delivered to the brain (110, 111).  
4.3 METHODS 
4.3.1 British Childhood Cancer Survivor Study 
The British Childhood Cancer Survivor Study is a population-based cohort of 34,489 
individuals diagnosed with a childhood cancer between 1940 and 2006 inclusive, before age 
15 years, in Great Britain and who survived for at least five years from diagnosis. Individuals 
in the cohort were identified using the population-based National Registry of Childhood 
Tumours. Ethical approval for the study was obtained from the National Research Ethics 
Committee (10/H1102/86) and legal approval from the Health Research Authority's 
Confidentiality Advisory Group (Section 251) (ECC 2-02 (f)/2011).  
4.3.2 Hospital Episode Statistics 
Hospital Episode Statistics (HES) is a centralised database which contains records from 1st 
April 1997 of all inpatient admissions to National Health Service (NHS) hospitals within 
England (223). HES data was provided by the Health and Social Care Information Centre 
(HSCIC). Records in the HES database are classified into hospital episodes; each of these 
hospital episodes relates to a period of care for a patient under a single consultant. The 
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information contained within a HES record includes an episode start date, an episode end 
date, a primary diagnosis code and additional subsidiary diagnosis codes, which may relate to 
pre-existing conditions or other conditions diagnosed during hospital admission, but there are 
no dates associated with these subsidiary conditions. The primary diagnosis which accounts 
for hospital admission is classified using the International Classification of Diseases 10th 
revision (ICD-10) (224). 
The BCCSS cohort was electronically linked to the inpatient HES database for England for 
the period from the 1st April 1997 to 31st December 2012 using NHS number, date of birth 
and gender. Childhood cancer survivors that were Scottish or Welsh residents were excluded 
as were those who had died before April 1st 1997. Thus the total number of survivors 
excluded from the overall cohort was 6,650.  
4.3.3 Definition of cerebrovascular events  
To identify a cerebrovascular hospitalisation (ICD-10: I60-69), the primary diagnosis code for 
each HES record was used. The following ICD-10 codes were used to classify hospitalisations 
for specific cerebrovascular conditions: subarachnoid haemorrhage (I60), cerebral 
haemorrhage (I61-I62), ischaemic stroke (I63), unspecified stroke (I64) and other 
cerebrovascular disease (I65-I69). The episode start date was used to determine occurrence of 
a first hospitalisation since this corresponds with the primary diagnosis code. For overall 
cerebrovascular hospitalisations, the first occurrence of any cerebrovascular hospitalisation 
per individual was taken. For cerebrovascular subtypes, the first occurrence of the 
cerebrovascular hospitalisation of interest per individual was taken. Only the first occurrence 
of a hospitalisation was ascertained so the same condition was not recorded multiple times.     
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4.3.4 Statistical methods  
Any cerebrovascular hospitalisations that occurred before five-year survival in individuals 
were excluded from the analysis since we were only concerned with hospitalisations 
occurring at five-year survival or beyond. Survivors entered the period of risk at the latest of: 
date of five-year survival or 1st April 1997. Survivors exited the study at the earliest of: date 
of death, date of loss-to follow-up, date of hospitalisation for a cerebrovascular condition (i.e. 
event date) or 31st December 2012 (study end date).  
 
Standardised hospitalisation ratios (SHR) and absolute excess risks (AER) were calculated for 
hospitalisation due to any cerebrovascular condition and for specific types of cerebrovascular 
conditions. The SHR was defined as the number of observed cerebrovascular hospitalisations 
divided by the number of expected cerebrovascular hospitalisations. The AER was defined as 
the number of observed cerebrovascular hospitalisations minus the number of expected 
cerebrovascular hospitalisations divided by the number of person-years at risk multiplied by 
10,000. The AER may be interpreted as the number of additional hospitalisations for each 
year of follow-up per 10,000 survivors attributable to the original childhood cancer diagnosis 
or its treatment.   
To derive the expected number of cerebrovascular hospitalisations, the number of individuals 
with a cerebrovascular hospitalisation in the entire HES dataset for England (N=27,839) was 
calculated for each sex, single year of age and single calendar year stratum. These numbers of 
observed hospitalisations were divided by the relevant mid-year population count estimate for 
England corresponding to each sex, age and calendar year specific stratum from the Office of 
National Statistics (225).   
A multivariable Poisson regression model with the log of the expected as the offset, was used 
to derive relative risks (RR) to determine the simultaneous effect of the following variables on 
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hospitalisation due to cerebrovascular events: gender, childhood cancer diagnosis, attained 
age (<20/20-29/30-39/40-49/ ≥50 years), age at diagnosis (0-4/5-9/10-14 years) and decade of 
diagnosis (<1970/1970-79/1980-89/1990-99/2000-06). A similar multivariable Poisson 
regression model with the log of the person-years as the offset and a special link function was 
fitted to derive excess hospitalisation ratios (EHRs). EHRs are essentially the ratios of AERs 
adjusted for the confounders which were fitted within the model. The effect of previous 
treatment with cranial irradiation on developing a cerebrovascular hospitalisation was 
investigated in survivors diagnosed with childhood cancer between 1940 and 1991 because 
treatment information was available for this period only. Statistical significance was taken at 
the 5% level (two sided tests). Analyses were carried out using Stata statistical software 
(version 13.1; Stata Corp., College Station, TX). 
4.4 RESULTS  
4.4.1 Cohort characteristics  
Of the 34,489 childhood cancer survivors in the cohort, 27,839 (80.7%) were eligible to be 
linked with HES after excluding the Scottish and Welsh residents and those who died before 
the 1st April 1997. The total person-years of follow-up were 312,869 years. The mean and 
median follow-up times were 11.2 years and 13.7 years, respectively (range:0-15.8 years). 
Overall, 299 (1.1%) survivors had been hospitalised for a cerebrovascular condition. When 
cerebrovascular subtypes were investigated, 118 (34%) hospitalisations were observed for 
ischaemic stroke, 104 (30%) hospitalisations for cerebral haemorrhage, 58 (17%) 
hospitalisations for unspecified stroke, 47 (13%) hospitalisations for other cerebrovascular 
conditions and 21(6%) hospitalisations for subarachnoid haemorrhage. 
  82 
4.4.2 Hospitalisation for any cerebrovascular condition (Table 4.1) 
Overall, survivors had 5-fold the expected risk (SHR=5.1, 95%CI:4.5-5.7) of being 
hospitalised for any cerebrovascular condition; this corresponded to an excess of 8 (AER=7.7, 
95%CI:6.9-8.5) hospitalisations per 10,000 person-years. Survivors of CNS tumours 
(SHR=11.9, 95%CI:10.3-13.7) and leukaemia (SHR=5.6, 95%CI:4.2-7.4) were at the greatest 
risk of being hospitalised for a cerebrovascular condition. CNS tumour survivors and 
leukaemia survivors had an excess of 25 and 4 hospitalisations per 10,000 person-years 
respectively. Survivors of soft tissue sarcoma (SHR=2.8, 95%CI:1.7-4.8), neuroblastoma 
(SHR=2.5, 95%CI:1.1-6.1) and Hodgkin's disease (SHR=2.2, 95%CI:1.2-3.8) were also at 
increased risk of being hospitalised for a cerebrovascular condition. The SHR of being 
hospitalised due to any cerebrovascular type declined with increasing attained age (adjusted 
Ptrend<0.01). In contrast the AER increased with increasing attained age (adjusted Ptrend=0.01) 
with the number of additional hospitalisations increasing from 4 (per 10,000 per year) among 
those aged <20 years to 25 among those aged ≥50 years, respectively. 
4.4.3 Hospitalisations due to cerebral haemorrhage (Table 4.2)     
Survivors had 8-fold the expected risk, (SHR=8.1, 95%CI:6.7-9.8) of being hospitalised due 
to a cerebral haemorrhage, corresponding to an excess of 3 (AER=2.9, 95%CI:2.5-3.4) 
hospitalisations per 10,000 person-years. Female survivors had a 1.7-fold risk of cerebral 
haemorrhage relative to males, but both female and male survivors experienced 3 excess 
hospitalisations per 10,000 person-years. CNS tumour survivors (SHR=18.6, 95%CI:14.5-
23.8, AER=8.5, 95%CI:6.5-11.1) and leukaemia (SHR=10.7, 95%CI:7.2-15.9, AER=2.4, 
95%CI:1.5-3.7) survivors had the greatest excess risk in both relative and absolute terms of 
being hospitalised due to a cerebral haemorrhage. The SHR was greatest among those 
diagnosed in more recent decades (adjusted Ptrend=0.01), survivors diagnosed in the 2000’s 
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were at 7-fold the relative risk of cerebral haemorrhage compared with those diagnosed before 
1970 (RR=7.0, 95%CI:1.6-31.0).  
4.4.4 Hospitalisations due to ischaemic stroke (Table 4.3)      
Survivors had 5-fold the expected risk (SHR=5.2, 95%CI:4.3-6.2) of being hospitalised due to 
an ischaemic stroke; this corresponds to an excess of 3 (AER=3.0, 95%CI:2.6-3.6) 
hospitalisations per 10,000 person-years. CNS tumour, leukaemia, NHL and bone sarcoma 
survivors had a 12-fold, 6-fold, 3-fold and 3-fold expected risk respectively of being 
hospitalised due to ischaemic stroke, which equated to AER values of 10, 2, 2 and 2 
respectively. The SHR declined with increasing attained age from 14.3 (95%CI:7.7-26.6) 
among those aged <20 years to 2.8 (95%CI:2.0-4.0) among those aged ≥ 50 years (adjusted 
Ptrend=0.04). In contrast, the AER increased with increased attained age (adjusted Ptrend<0.001) 
with the number of additional hospitalisations increasing from 1 (per 10,000 per year) among 
those aged <20 years to 12 among those aged ≥50 years, respectively. There was suggestive 
evidence that both the SHR and AER declined with increased age at diagnosis (adjusted 
Ptrend=0.04 and adjusted Ptrend=0.05). 
4.4.5 Hospitalisations of any cerebrovascular event among CNS tumour survivors (Table 
4.4) 
Among the CNS tumour survivors, the SHR declined with increased attained age (adjusted 
Ptrend<0.001) from 51 in survivors aged <20 years to 6 among survivors aged ≥ 50 years. 
4.4.6 Hospitalisations associated with treatment with cranial irradiation (Table 4.5) 
In all childhood cancer survivors, cranial irradiation was associated with an excess risk of 
being hospitalised for a cerebrovascular condition of any type over that expected; in that those 
so treated there was a 12-fold increased risk over that expected (SHR=11.7, 95%CI:9.9-13.7) 
whereas survivors not treated with cranial irradiation had a 2-fold increased risk compared to 
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that expected (SHR=1.9,95%CI:1.5-2.5). In absolute terms this equated to 25 and 4 additional 
hospitalisations per 10,000 person-years, respectively.  
Among CNS tumour survivors, cranial irradiation was associated with the risk of being 
hospitalised for a cerebrovascular condition in that those treated with cranial irradiation had a 
16-fold increased risk compared to that expected (SHR=15.6,95%CI:13.0-18.9) with an 
excess of 58 hospitalisations (95%CI:48.0-70.8) per 10,000 person-years. For CNS tumour 
survivors not treated with cranial irradiation, the risk of being hospitalised for a 
cerebrovascular condition was 3-fold over that expected (SHR=3.0, 95%CI:1.9-4.9) with 9 
additional hospitalisations per 10,000 person-years (AER=8.7, 95%CI:4.3-17.7). Within 
leukaemia survivors cranial irradiation was not significantly associated with either a relative 
or absolute increased risk of being hospitalised for a cerebrovascular condition over that 
expected. However, this could relate to insufficient statistical power as there is suggestive 
evidence of an increased risk associated with cranial prophylaxis in leukaemia survivors.   
4.5 DISCUSSION 
4.5.1 Main findings 
In this large scale population-based study we found that survivors of childhood cancer are at a 
5-fold expected risk of being hospitalised for a cerebrovascular condition. With respect to 
specific cerebrovascular conditions, survivors of childhood cancer are at an 8-fold expected 
risk of cerebral haemorrhage and a 5-fold expected risk of ischaemic stroke. Survivors of 
CNS tumours previously treated with cranial irradiation experienced a 16-fold expected risk 
for cerebrovascular disease; also CNS tumour survivors not treated with cranial irradiation 
experienced a 3-fold expected risk.  
 
The 5-fold expected risk of a hospitalisation due to any cerebrovascular condition that we 
observed was similar to the 4-fold excess risk reported in the ALiCCS study, the only other 
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large scale population-based study investigating cerebrovascular hospitalisations (71). In the 
North American Childhood Cancer Survivor Study (CCSS), among 4,828 five-year leukaemia 
survivors, the relative risk of such survivors developing a late-occurring stroke was 6.4 
(95%CI:3.0-13.8) compared to siblings which is consistent with our study (111). The overall 
risk of cerebrovascular disease among 1,367 five-year survivors of childhood cancer 
diagnosed between 0 and 14 years in a English regional study was higher (HRR=7.9) than that 
observed in our study (226). The period of diagnosis in this English regional study however 
ranged from 1991 to 2006 thus in comparison with our study they have a predominantly 
younger cohort, which could be a possible explanation in the difference of overall risk.   
In our study, the SHR for any cerebrovascular condition declined with increasing attained age 
while the AER increased; similar trends were observed in the ALiCCS study (71). A 
reduction in SHR with increasing attained age among survivors is likely to be due to the 
increasing background risk of cerebrovascular disease in older individuals in the general 
population. An increasing AER implies that an additional number of survivors were 
hospitalised, compared with expected, which increased with attained age and again this relates 
to the background risk increasing with age in the general population.  
4.5.2 Hospitalisations due to cerebral haemorrhage and ischaemic stroke  
Survivors of all childhood cancer in our study had an 8-fold expected risk of being 
hospitalised for a cerebral haemorrhage and a 5-fold expected risk of being hospitalised for an 
ischaemic stroke. These findings are similar to the reported 8-fold excess risk of being 
hospitalised due to cerebral haemorrhage and the 4-fold excess risk for ischaemic stroke 
among all childhood cancer survivors in the ALiCCS study (71). In our study, the declining 
SHR with increased attained age with respect to survivors being hospitalised for ischaemic 
stroke is likely to be due to the increasing risk of stroke with age in the general population. 
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For cerebral haemorrhage hospitalisations, the risk of hospitalisation increased with decade of 
diagnosis thus more recently diagnosed survivors appear to be at higher risk; this may be due 
to survival bias between survivors diagnosed decades ago compared with those in recent 
decades. Survivors diagnosed decades ago are more likely to have died before developing the 
adverse outcome of cerebral haemorrhage compared with survivors diagnosed more recently.   
4.5.3 CNS tumour survivors and treatment with cranial irradiation 
CNS tumour survivors in our study were at the greatest risk of any cerebrovascular condition, 
specifically cerebral haemorrhage and ischaemic stroke. High risks of hospitalisation due to 
cerebrovascular disease after a CNS tumour were also reported in the ALiCCS study (71). In 
particular, a very high risk of hospitalisation due to cerebral haemorrhage after a CNS tumour 
was reported in the ALiCCS study, 18-fold that expected which was similar to the 19-fold risk 
found in our study (71). The relative risk of brain tumour survivors developing a stroke 
compared to siblings in a CCSS study was reported to be 29.0 (95%CI:13.8-60.7) (111), 
which is higher than what we report in our study but the confidence intervals for the CCSS 
are wide and our risk estimate of 18.6 (95%CI:14.5-23.8) for cerebral haemorrhage after CNS 
tumours falls within their confidence bounds. As the CCSS is based in North America 
survivors could have been treated more aggressively with cranial irradiation than in our 
British study; over 50% of CNS tumour survivors in the CCSS study were treated with 
radiation doses of ≥30Gy. The risk of stroke among CNS tumour survivors treated without 
cranial irradiation in the CCSS study is similar to the risk of cerebrovascular disease we report 
for all CNS tumour survivors in our study. 
AERs increased substantially with increased attained age among CNS tumour survivors thus 
the absolute number of CNS survivors being hospitalised are in substantial excess to that 
expected, particularly with older survivors.      
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We were also in the position to investigate the risk of hospitalisation associated with cranial 
irradiation among CNS tumour survivors which the ALiCCS study could not do. We found 
survivors of CNS tumours previously treated with cranial irradiation to be at increased risk of 
hospitalisations due to cerebrovascular disease. In the CCSS, survivors of childhood cancer 
previously treated with cranial irradiation have been reported to be at an increased risk of 
developing cerebrovascular disease, notably CNS tumour survivors (110, 111). However, 
CNS tumour survivors who did not receive cranial irradiation in our study still had an 
increased risk of being hospitalised for a cerebrovascular condition compared to that 
expected, suggesting previous treatment with surgery may confer increased risk of 
cerebrovascular disease. The CCSS also found an elevated risk for both CNS tumour 
survivors who had not been treated with cranial irradiation in their risk of stroke compared 
with siblings, although the risks reported were higher than in our study (111).  
4.5.4 Biological mechanisms 
The biological mechanisms by which cranial irradiation may increase the risk of 
cerebrovascular disease in childhood cancer survivors are not clear. Potential mechanisms for 
radiation induced stroke may include the development of atherosclerosis through chronic 
inflammation in the intracranial vasculature, which can either lead to narrowing of the blood 
vessels or formation of blood clots (227-229). Metabolic syndrome is a late effect recognised 
in childhood cancer survivors which encompasses conditions of hypertension, 
hyperlipidaemia, obesity and type 2 diabetes (230, 231). Previous radiation vasculature 
damage combined with metabolic syndrome may influence the development of 
cerebrovascular disease (227, 232) .        
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4.5.5 Study Limitations 
Potential limitations of our study include: (i) the lack of treatment information for those 
survivors diagnosed post 31st December 1991. However, our study did have available 
treatment exposure for survivors diagnosed between 1940 and 1991 which the ALiCCS study 
did not have. The comprehensive effect of treatment (i.e., dose response) is currently being 
investigated through case-control studies in the European funded CEREBRAD study, of 
which the BCCSS is a collaborative partner (233). (ii) We were not able to report risk 
estimates for known modifiable risk factors for stroke such as hypertension and diabetes 
mellitus. Lifestyle factors should also be considered in addition to treatment factors in the risk 
of cerebrovascular conditions as tobacco use, poor diet, inactivity and alcohol consumption, 
are known to increase the risk of stroke (234). (iii) The causes of hospitalisation in HES are 
not validated but there are advantages to using electronic record linkage to ascertain outcomes 
as opposed to self-reported data. For example, we do not have the issue of non-responder bias 
that arises in survivors self-completing questionnaires and by using two population-based 
sources, the numbers of survivors being lost-to-follow-up is likely to be less than non-
population-based ascertainment. An advantage of our study is that we were able to address 
hospitalisations due to more specific diseases with electronic record linkage as such 
information is available in HES. For example, subtypes of cerebrovascular disease whereas 
broad categories are often used in self-reported questionnaires to ascertain outcomes (235). 
(iv) Since entry into HES is from 1997 there is the potential that some of our survivors may 
have had the event of interest before study enrolment, i.e. a hospitalisation due to a 
cerebrovascular condition but the date of such an event would be unknown thus our outcome 
estimates would be under-estimated. In the comparable ALiCCS study, the time of entry into 
the study from childhood cancer diagnosis and linkage with hospital registers has a 
substantially smaller time lag thus due to greater data completeness, left censoring requires 
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less consideration than in our study. However a sensitivity analysis was conducted with 
survivors diagnosed before 1997 and post 1997 in our study and there was no evidence of an 
interaction; between the effect of age at diagnosis and pre- and post-1997 achievement of 5-
year survival on hospitalisation due to a cerebrovascular condition; between the effect of 
decade of diagnosis and pre-and post-1997 achievement of 5-year survival on hospitalisation 
due to a cerebrovascular condition (results not shown). Thus our overall results can be 
reported in confidence despite the issue of left censoring. 
 
Current childhood cancer survivorship guidelines from the UK (CCLG and SIGN) do not 
include cerebrovascular complications as a potential late effect (17, 164). Irradiation ≥18Gy 
given in specified fields such as cranial, ear and nasopharyngeal regions are indicated for 
potential cerebrovascular complications among childhood cancer survivors in North America 
and annual neurological examinations are recommended among survivors who have received 
such treatment (121). The type of surveillance recommended to survivors in the UK requires 
further consideration but the evidence provided in this study should at least highlight survivor 
groups at greater risk of cerebrovascular late effects. It is difficult to monitor cerebrovascular 
late effects, one suggestion has been magnetic resonance imaging scans but these are costly 
investigations and the benefit gained from such a procedure in terms of stroke prevention for 
example, may be minimal. Patients may wish to consider preventative measures in terms of 
lifestyle factors which could increase their risk of developing cerebrovascular conditions, for 
example, stroke. Empowering survivors with such knowledge of preventative measures will 
enable them to take more control over their health, which could provide more long-term 
benefit. Preventative measures may include smoking cessation or a reduction in tobacco 
intake, dietary advice which advocates lower cholesterol and salt intake, regular exercise and 
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a reduction in alcohol consumption. Other preventative measures can involve medication for 
underlying conditions such as statins for hypercholesterolemia and angiotensin-converting 
enzyme (ACE) inhibitors for hypertension, two conditions which are considered risk factors 
for cerebrovascular disease.  
   
4.5.6 Conclusions 
Through the use of electronic record linkage, we have been able to provide empirical evidence 
that childhood cancer survivors of CNS tumours and leukaemia are at the greatest risk of 
cerebrovascular hospitalisations and more specifically hospitalisations due to cerebral 
haemorrhage and ischaemic stroke. Cranial irradiation is a strong risk factor associated with 
survivors being hospitalised for cerebrovascular complications. A risk-stratified approach to 
clinical follow-up, would ensure survivors at highest risk of cerebrovascular complications 
undergo surveillance. Further research is needed in survivors who have been diagnosed more 
recently where the use cranial irradiation may have changed or doses may differ to see if the 
risk of cerebrovascular disease is still elevated. 
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Table 4.1 Observed and expected numbers of cerebrovascular hospitalisations overall, standardised hospitalisation ratios and absolute excess risks, adjusted relative 
risks and excess hospitalisation ratios  
 Number of 5-
year survivors  
Person-years O/E SHR (95%CI) RR (95%CI)† AER (95%CI) EHR (95%CI)† 
Overall  27,839 312868.7 299/59.0 5.1 (4.5-5.7)  7.7 (6.9-8.5)  
Gender        
Male  15216 170155.0 167/35.6 4.7 (4.0-5.5) 1.0 (referent) 7.7 (6.4-9.4) 1.0 (referent) 
Female  12623 142713.7 132/23.4 5.6 (4.7-6.7) 1.2 (0.9-1.5) 7.6 (6.2-9.4) 0.9 (0.7-1.2) 
Pheterogeneity    0.12 0.28 0.92 0.57 
Attained age         
<20 7731 109400.4 52/3.4 15.5 (11.8-20.4) 1.0 (referent) 4.4 (3.3-5.9) 1.0 (referent) 
20-29 8642 93476.3 55/7.2 7.6 (5.9-9.9) 0.5 (0.4-0.8) 5.1 (3.8-6.9) 1.1 (0.6-1.7) 
30-39 5357 61643.4 77/11.3 6.8 (5.5-8.6) 0.6 (0.3-1.0) 10.7 (8.2-13.9) 2.1 (1.1-4.0) 
40-49 3814 32555.1 55/15.8 3.5 (2.7-4.5) 0.3 (0.2-0.6) 12.0 (8.3-17.4) 2.4 (1.1-5.4) 
≥50 2295 15793.5 60/21.4 2.8 (2.2-3.6) 0.4 (0.2-0.8) 24.5 (16.5-36.2) 5.4 (2.0-14.4) 
Ptrend    <0.001 <0.01 <0.001 0.01 
Childhood Cancer        
Leukaemia 8374 91163.7 48/8.6 5.6 (4.2-7.4) 2.3 (1.0-5.0) 4.3 (3.1-6.1) 4.2 (0.8-23.7) 
Hodgkin's disease 1759 20458.6 12/5.6 2.2 (1.2-3.8) 1.7 (0.6-4.3) 3.1 (1.1-9.0) 1.7 (0.2-14.7) 
Non-Hodgkin's lymphoma 1274 15163.4 6/3.7 1.6 (0.7-3.7) 1.2 (0.4-3.7) 1.6 (0.2-11.9) 0.9 (0.0-18.9) 
Central Nervous System 
tumour 
6401 68269.3 186/15.6 11.9 (10.3-13.7) 8.5 (3.9-18.3) 25.0 (21.3-29.2) 19.5 (3.5-106.7) 
Neuroblastoma 1281 14380.7 5/2.0 2.5 (1.1-6.1) 1.5 (0.5-4.7) 2.1 (0.5-9.0) 2.8 (0.4-21.2) 
Non Heritable retinoblastoma 872 11257.4 4/3.0 1.3 (0.5-3.6) 1.0 (0.3-3.5) 0.9 (0.0-41.0) 0.0 (0.0,.) 
Heritable retinoblastoma  604 7680.3 0/2.1 0.0 (.,.) 0.0 (0.0,.) 0.0 (0.0,.) 0.0 (0.0,.) 
Wilms 2034 24756.4 7/4.1 1.7 (0.8-3.6) 1.0 (referent) 1.2 (0.2-7.0) 1.0 (referent) 
Bone sarcoma 968 10948.6 7/3.3 2.1 (1.0-4.5) 1.8 (0.6-5.1) 3.4 (0.8-13.7) 2.4 (0.3-21.2) 
Soft tissue sarcoma 1730 20430.5 14/5.0 2.8 (1.7-4.8) 2.1 (0.8-5.3) 4.4 (2.0-10.0) 4.1 (0.7-25.5) 
Others  2542 28359.9 10/6.4 1.6 (0.9-2.9) 1.2 (0.4-3.1) 1.3 (0.2-7.0) 1.1 (0.1-10.3) 
Pheterogeneity    <0.001 <0.001 <0.001 <0.001 
Decade of diagnosis        
<1970 2488 35815.5 81/29.4 2.8 (2.2-3.4) 1.0 (referent) 14.4 (10.2-20.3) 1.0 (referent) 
1970-1979 3791 56387.2 80/14.6 5.5 (4.4-6.8) 1.6 (1.0-2.5) 11.6 (8.9-15.2) 1.5 (0.8-2.7) 
1980-1989 5761 86651.6 69/9.2 7.5 (5.9-9.5) 1.9 (1.1-3.3) 6.9 (5.3-9.1) 1.5 (0.7-3.0) 
1990-1999 8659 102862.8 55/4.8 11.4 (8.8-14.9) 2.0 (1.0-4.0) 4.9 (3.7-6.5) 1.2 (0.5-2.9) 
2000-2006 7140 31151.7 14/1.0 13.6 (8.1-23.0) 1.9 (0.8-4.6) 4.2 (2.4-7.3) 1.0 (0.4-2.9) 
Ptrend    <0.001 0.11 <0.001 0.47 
Age at diagnosis        
0-4 12885 148050.3 89/19.4 4.6 (3.7-5.7) 1.0 (referent) 4.7 (3.6-6.1) 1.0 (referent) 
5-9 7375 82371.7 112/15.0 7.5 (6.2-9.0) 1.1 (0.8-1.5) 11.8 (9.5-14.6) 1.3 (0.9-1.9) 
10-14 7579 82446.7 98/24.7 4.0 (3.3-4.8) 0.7 (0.5-1.0) 8.9 (6.8-11.6) 0.9 (0.6-1.4) 
Ptrend    0.22 0.03 <0.001 0.64 
AER: absolute excess risk, CI: confidence interval, EHR: excess hospitalisation ratio, O/E: observed/expected, RR: relative risk, SHR: standardised hospitalisation ratio  
† adjusted for gender, childhood cancer, attained age, age at diagnosis and decade of diagnosis 
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Table 4.2 Observed and expected numbers of cerebral haemorrhage hospitalisations standardised hospitalisation ratios and absolute excess risks, adjusted relative 
risks and excess hospitalisation ratios 
 Number of 5-year 
survivors 
Person-years O/E SHR (95%CI) RR (95%CI)† AER (95%CI) EHR (95%CI)† 
Overall  27,839 313793.5 104/12.9 8.1 (6.7-9.8)  2.9 (2.5-3.4)  
Gender        
Male  15216 170710.9 56/8.6 6.5 (5.0-8.5) 1.0 (referent) 2.8 (2.0-3.8) 1.0 (referent) 
Female  12623 143082.6 48/4.3 11.1 (8.4-14.8) 1.7 (1.1-2.5) 3.1 (2.2-4.2) 1.2 (0.7-1.8) 
Pheterogeneity    <0.01 <0.01 0.67 0.54 
Attained age         
<20 7731 109460.4 31/1.5 21.4 (15.1-30.5) 1.0 (referent) 2.7 (1.9-3.9) 1.0 (referent) 
20-29 8642 93622.3 20/2.2 9.2 (5.9-14.2) 0.6 (0.3-1.1) 1.9 (1.2-3.1) 0.8 (0.4-1.6) 
30-39 5357 61894.7 29/2.5 11.4 (8.0-16.5) 1.2 (0.5-2.9) 4.3 (2.9-6.4) 2.4 (0.9-6.2) 
40-49 3814 32745.4 12/3.0 4.0 (2.3-7.0) 0.7 (0.2-2.1) 2.7 (1.3-5.9) 1.9 (0.5-7.6) 
≥50 2295 16070.6 12/3.7 3.2 (1.8-5.7) 1.0 (0.2-4.2) 5.2 (2.3-11.7) 5.4 (0.8-36.8) 
Ptrend    <0.001 0.49 0.21 0.31 
Childhood Cancer        
Leukaemia 8374 91262.8 24/2.2 10.7 (7.2-15.9) 2.1 (0.6-6.9) 2.4 (1.5-3.7) 4.1 (0.3-54.1) 
Hodgkin's disease 1759 20497.9 3/1.2 2.5 (0.8-7.8) 0.9 (0.2-4.6) 0.9 (0.1-5.8) 0.6 (0.0-72.1) 
Non-Hodgkin's lymphoma 1274 15189.0 2/0.8 2.5 (0.6-10.1) 0.9 (0.1-5.2) 0.8 (0.1-7.9) 1.3 (0.0-38.0) 
Central Nervous System 
tumour 
6401 68866.6 62/3.3 18.6 (14.5-23.8) 6.0 (1.9-19.7) 8.5 (6.5-11.1) 13.8 (1.1-177.3) 
Neuroblastoma 1281 14388.8 2/0.5 4.8 (1.1-17.9) 1.3 (0.2-8.0) 1.1 (0.2-6.4) 2.2 (0.1-50.0) 
Non Heritable retinoblastoma 872 11276.4 2/0.6 3.4 (0.8-13.5) 1.4 (0.2-8.6) 1.2 (0.2-9.0) 0.1 (0.0-2260.0) 
Heritable retinoblastoma  604 7680.3 0/0.4 0.0 (.,.) 0.0 (0.0,.) 0.0 (0.0,.) 0.0 (0.0,.) 
Wilms 2034 24774.2 3/0.9 3.3 (1.1-10.3) 1.0 (referent) 0.8 (0.2-4.3) 1.0 (referent) 
Bone sarcoma 968 10986.3 0/0.7 0.0 (., .) 0.0 (0.0,.) 0.0 (0.0,.) 0.0 (0.0,.) 
Soft tissue sarcoma 1730 20474.6 4/1.0 3.9 (1.5-10.3) 1.4 (0.3-6.2) 1.5 (0.4-5.4) 2.7 (0.2-46.0) 
Others  2542 28396.6 2/1.3 1.6 (0.4-6.2) 0.5 (0.1-3.1) 0.3 (0.0-12.3) 0.3 (0.0-74.2) 
Pheterogeneity    <0.001 <0.001 <0.001 <0.001 
Decade of diagnosis        
<1970 2488 36136.0 15/5.3 2.8 (1.7-4.7) 1.0 (referent) 2.7 (1.2-5.9) 1.0 (referent) 
1970-1979 3791 56648.2 23/3.1 7.5 (5.0-11.3) 2.6 (1.0-6.8) 3.5 (2.2-5.6) 2.2 (0.6-8.0) 
1980-1989 5761 86870.5 27/2.4 11.1 (7.6-16.1) 4.4 (1.4-13.6) 2.8 (1.9-4.3) 3.3 (0.8-13.9) 
1990-1999 8659 102975.1 30/1.7 18.0 (12.6-25.7) 6.6 (1.8-24.4) 2.8 (1.9-4.0) 3.9 (0.8-19.4) 
2000-2006 7140 31163.7 9/0.4 22.5 (11.7-43.2) 7.0 (1.6-31.0) 2.8 (1.4-5.5) 3.8 (0.7-22.4) 
Ptrend    <0.001 0.01 0.68 0.18 
Age at diagnosis        
0-4 12885 148277.9 33/4.5 7.3 (5.2-10.2) 1.0 (referent) 1.9 (1.3-2.9) 1.0 (referent) 
5-9 7375 82763.1 41/3.4 12.2 (9.0-16.6) 1.2 (0.8-2.1) 4.5 (3.3-6.3) 1.5 (0.8-2.6) 
10-14 7579 82752.5 30/5.0 6.0 (4.1-8.6) 0.8 (0.4-1.4) 3.0 (2.0-4.6) 1.0 (0.5-2.0) 
Ptrend    0.45 0.35 0.06 0.97 
AER: absolute excess risk, CI: confidence interval, EHR: excess hospitalisation ratio, O/E: observed/expected, RR: relative risk, SHR: standardised hospitalisation ratio  
† adjusted for gender, childhood cancer, attained age, age at diagnosis and decade of diagnosis 
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Table 4.3 Observed and expected numbers of ischaemic stroke hospitalisations, standardised hospitalisation ratios and absolute excess risks, adjusted relative risks 
and excess hospitalisation ratios  
 Number of 5-
year survivors 
Person-years O/E SHR (95%CI) RR (95%CI)† AER (95%CI) EHR (95%CI)†  
Overall  27,839 313674.1 118/22.8 5.2 (4.3-6.2)  3.0 (2.6-3.6)  
Gender        
Male  15216 170661.3 65/14.7 4.4 (3.5-5.7) 1.0 (referent) 2.9 (2.2-4.0) 1.0 (referent) 
Female  12623 143012.8 53/8.2 6.5 (5.0-8.5) 1.2 (0.9-1.8) 3.1 (2.3-4.3) 1.0 (0.7-1.6) 
Pheterogeneity    0.04 0.25 0.79 0.96 
Attained age         
<20 7731 109491.8 10/0.7 14.3 (7.7-26.6) 1.0 (referent) 0.8 (0.4-1.7) 1.0 (referent) 
20-29 8642 93665.9 23/1.9 11.9 (7.9-17.9) 0.7 (0.3-1.6) 2.2 (1.4-3.5) 2.4 (1.0-5.9) 
30-39 5357 61850.2 33/3.6 9.2 (6.5-12.9) 0.6 (0.2-1.6) 4.8 (3.2-7.0) 6.1 (2.1-17.5) 
40-49 3814 32716.4 22/6.0 3.6 (2.4-5.5) 0.3 (0.1-0.9) 5.0 (2.7-8.7) 9.0 (2.5-32.9) 
≥50 2295 15949.8 30/10.5 2.8 (2.0-4.0) 0.2 (0.1-0.9) 12.2 (7.0-21.2) 21.8 (4.6-103.2) 
Ptrend    <0.001 0.04 <0.001 <0.001 
Childhood Cancer        
Leukaemia 8374 91289.8 18/2.8 6.4 (4.1-10.2) 2.2 (0.6-7.6) 1.7 (1.0-2.9) 2.8 (0.7-1.6) 
Hodgkin's disease 1759 20506.2 2/2.2 0.9 (0.2-3.6) 0.7 (0.1-4.4) 0.0 (0.0,.) 0.4 (0.0-26.8) 
Non-Hodgkin's lymphoma 1274 15167.6 4/1.5 2.9 (1.1-7.7) 2.0 (0.4-9.0) 1.7 (0.4-7.8) 2.0 (0.2-22.5) 
Central Nervous System tumour 6401 68787.2 73/6.2 12.0 (9.6-15.1) 8.4 (2.6-27.3) 10.0 (7.8-12.8) 13.1 (2.0-84.5) 
Neuroblastoma 1281 14384.5 1/0.7 1.3 (0.2-9.6) 0.7 (0.1-6.9) 0.2 (0.0-349.7) 0.9 (0.0-20.6) 
Non Heritable retinoblastoma 872 11274.0 2/1.2 1.7 (0.4-7.0) 1.1 (0.2-7.0) 0.7 (0.0-23.2) 0.0 (0.0,.) 
Heritable retinoblastoma  604 7680.3 0/0.8 0.0 (.,.) 0.0 (0.0,.) 0.0 (0.0, .) 0.0 (0.0,.) 
Wilms 2034 24778.7 3/1.5 2.0 (0.6-6.2) 1.0 (referent) 0.6 (0.1-5.8) 1.0 (referent) 
Bone sarcoma 968 10950.1 3/1.3 3.0 (1.1-7.9) 2.5 (0.5-11.6) 2.4 (0.6-10.6) 2.5 (0.2-29.2) 
Soft tissue sarcoma 1730 20464.7 3/2.0 2.5 (1.0-6.0) 1.8 (0.4-7.6) 1.5 (0.3-6.3) 2.3 (0.3-20.6) 
Others  2542 28391.0 4/2.5 1.6 (0.6-4.4) 1.2 (0.3-5.5) 0.5 (0.0-6.8) 0.0 (0.0,.) 
Pheterogeneity    <0.001 <0.001 <0.001 <0.001 
Decade of diagnosis        
<1970 2488 35994.7 39/12.9 3.0 (2.2-4.1) 1.0 (referent) 7.2 (4.5-11.6) 1.0 (referent) 
1970-1979 3791 56635.7 29/5.4 5.4 (3.8-8.0) 1.2 (0.6-2.4) 4.2 (2.7-6.5) 1.5 (0.6-3.6) 
1980-1989 5761 86856.3 32/2.9 10.9 (7.7-15.4) 1.7 (0.7-4.1) 3.3 (2.3-4.9) 2.5 (0.9-7.3) 
1990-1999 8659 103006.8 17/1.3 12.8 (8.0-20.6) 1.3 (0.4-4.2) 1.5 (0.9-2.5) 2.1 (0.6-7.6) 
2000-2006 7140 31180.6 1/0.3 3.5 (0.5-25.0) 0.3 (0.0-3.2) 0.2 (0.0-3.5) 0.5 (0.0-6.5) 
Ptrend    <0.001 0.91 <0.001 0.52 
Age at diagnosis        
0-4 12885 148295.3 34/7.1 4.8 (3.4-6.7) 1.0 (referent) 1.8 (1.2-2.8) 1.0 (referent) 
5-9 7375 82679.9 50/5.7 8.8 (6.6-11.6) 1.2 (0.7-1.9) 5.4 (3.9-7.3) 1.2 (0.7-2.0) 
10-14 7579 82698.9 34/10.0 3.4 (2.4-4.7) 0.6 (0.3-1.0) 2.9 (2.0-4.7) 0.5 (0.3-1.0) 
Ptrend    0.10 0.04 0.05 0.05 
AER: absolute excess risk, CI: confidence interval, EHR: excess hospitalisation ratio, O/E: observed/expected, RR: relative risk, SHR: standardised hospitalisation ratio  
† adjusted for gender, childhood cancer, attained age, age at diagnosis and decade of diagnosis 
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Table 4.4 Observed and expected numbers of cerebrovascular hospitalisation overall among Central Nervous System tumour survivors, standardised hospitalisation 
ratios and absolute excess risks, adjusted relative risks and excess hospitalisation ratios 
 Number of 5-year 
survivors 
Person-years O/E SHR (95%CI) RR (95%CI)† AER (95%CI) EHR (95%CI)†  
Overall 6401 68269.3 186/15.6 11.9 (10.3-13.7)  25.0 (21.3-29.2)  
Gender        
Male  3460 346432.4 108/9.4 11.5 (9.5-13.8) 1.0 (referent) 27.1 (22.0-33.3) 1.0 (referent) 
Female  2941 31836.9 78/6.2 12.6 (10.0-15.7) 1.0 (0.8-1.4) 22.6 (17.7-28.7) 0.8 (0.6-1.2) 
Pheterogeneity    0.54 0.80 0.26 0.30 
Attained age         
<20 1647 21619.0 35/0.7 50.5 (36.3-70.4) 1.0 (referent) 15.9 (11.3-22.3) 1.0 (referent) 
20-29 2056 19284.5 31/1.5 21.1 (14.8-30.0) 0.5 (0.3-0.8) 15.3 (10.6-22.2) 0.9 (0.5-1.6) 
30-39 1064 13458.6 47/2.5 18.9 (14.2-25.2) 0.5 (0.2-1.0) 33.1 (24.5-44.7) 1.8 (0.8-3.9) 
40-49 933 9058.7 34/4.5 7.6 (5.5-10.7) 0.2 (0.1-0.5) 32.6 (22.2-48.0) 1.8 (0.7-4.7) 
≥50 701  39/6.5 6.0 (4.4-8.2) 0.2 (0.1-0.6) 67.0 (45.9-97.6) 3.9 (1.3-11.8) 
Ptrend    <0.001 <0.001 <0.001 0.11 
Decade of diagnosis        
<1970 715 9758.1 54/8.6 6.3 (4.8-8.2) 1.0 (referent) 46.5 (33.9-63.9) 1.0 (referent) 
1970-1979 874 12481.9 46/3.7 12.3 (9.2-16.4) 1.4 (0.8-2.4) 33.9 (24.7-46.3) 1.1 (0.6-2.1) 
1980-1989 1092 15740.0 36/1.9 18.9 (13.7-26.3) 1.5 (0.7-3.0) 21.7 (15.3-30.6) 1.1 (0.5-2.3) 
1990-1999 1979 22698.2 40/1.1 35.1 (25.7-47.8) 1.9 (0.8-4.6) 17.1 (12.4-23.6) 1.1 (0.4-2.8) 
2000-2006 1741 7591.1 10/0.3 36.3 (19.6-67.5) 1.6 (0.5-4.8) 12.8 (6.8-24.2) 0.8 (0.2-2.6) 
Ptrend    <0.001 0.31 <0.001 0.18 
Age at diagnosis        
0-4 1969 20797.0 39/2.8 13.9 (10.1-19.0) 1.0 (referent) 17.4 (12.4-24.4) 1.0 (referent) 
5-9 2246 24311.6 76/5.3 14.5 (11.6-18.1) 1.2 (0.8-1.8) 29.1 (22.9-37.0) 1.5 (1.0-2.3) 
10-14 2186 23160.7 71/7.6 9.4 (7.4-11.8) 0.9 (0.6-1.4) 27.4 (21.1-35.5) 1.2 (0.7-2.0)  
Ptrend    0.02 0.53 0.05 0.59 
AER: absolute excess risk, CI: confidence interval, EHR: excess hospitalisation ratio, O/E: observed/expected, RR: relative risk, SHR: standardised hospitalisation ratio  
† adjusted for gender,attained age, age at diagnosis and decade of diagnosis 
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Table 4.5 Observed and expected number of cerebrovascular hospitalisations overall among survivors diagnosed between 1940 and 1991, standardised 
hospitalisation ratios and absolute excess risks, adjusted relative risks and excess hospitalisation ratios 
 Explanatory factor Number of 5-year 
survivors 
Person-years O/E SHR (95%CI) RR (95%CI)† AER (95%CI) EHR (95%CI)†  
Overall  No cranial irradiation 5775  85945.0 68/34.9 1.9 (1.5-2.5) 1.0 (referent) 3.9 (2.4-6.3) 1.0 (referent) 
 Cranial irradiation  3675 53736.2 147/12.6 11.7 (9.9-13.7) 5.0 (3.7-6.8) 25.0 (21.0-29.8) 8.5 (5.1-14.1) 
Pheterogeneity     <0.001 <0.001 <0.001 <0.001 
         
CNS tumour No cranial irradiation 892 13106.3 17/5.6 3.0 (1.9-4.9) 1.0 (referent) 8.7 (4.3-17.7) 1.0 (referent) 
 Cranial irradiation  1361 18614.4 116/7.4 15.6 (13.0-18.9) 5.0 (3.0-8.3) 58.3 (48.0-70.8) 6.6 (3.3-13.1) 
Pheterogeneity     <0.001 <0.001 <0.001 <0.001 
         
Leukaemia No cranial irradiation 198 2987.4 1/0.9 1.1 (0.2-7.7) 1.0 (referent) 0.3 (0.0-4910.0) 1.0 (referent)† 
 Cranial irradiation 2291 34772.7 31/5.1 6.1 (4.3-8.6) 2.2 (0.3-16.2) 7.4 (4.9-11.4) 2.6 (0.1-63.3) 
Pheterogeneity     0.06 0.39 0.13 0.43 
         
AER: absolute excess risk, CNS: central nervous system, CI: confidence interval, EHR: excess hospitalisation ratio, O/E: observed/expected, RR: relative risk, SHR: standardised hospitalisation ratio 
†  adjusted for gender, attained age, age at diagnosis, decade of diagnosis, cranial irradiation  
 
 
  96 
 
 
 
 
 
 
 
CHAPTER 5 RISK OF GENITOURINARY PRIMARY 
CANCERS SUBSEQUENT TO CHILDHOOD CANCER 
DIAGNOSED THROUGHOUT EUROPE: THE 
PANCARESURFUP COHORT  
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5.1 ABSTRACT 
Background: Survivors of childhood cancer are at increased risk of developing subsequent 
primary neoplasms (SPNs). Cancers of the genitourinary (GU) system predominantly develop 
beyond age 40 years and few previous studies have investigated the long-term risks of 
developing such SPNs in childhood cancer survivors and none had adequate statistical power 
to investigate the risks of specific neoplasms such as bladder cancer or testicular cancer.   
Methods: The European PanCareSurFup cohort comprising 75,217 five-year survivors of 
childhood cancer, diagnosed below the age of 20 years, was investigated to determine the 
absolute and excess risks of genitourinary SPNs. The excess risks of genitourinary SPNs were 
quantified by standardised incidence ratios (SIR) and absolute excess risks (AER) per 10,000 
person-years. Cumulative incidence of developing a first genitourinary SPN was estimated 
treating death as a competing risk. 
Results: After a mean follow-up time of 20.7 years, 277 (0.37%) genitourinary SPNs were 
diagnosed among 75,217 survivors of childhood cancer. The most commonly observed 
genitourinary SPNs were of the kidney (n=70), bladder (n=44) and testis (n=38). Overall, 
survivors were twice as likely to develop a genitourinary SPN of any type than expected 
(SIR=1.7, 95%CI:1.5-1.9, AER=1.0, 95%CI:0.8-1.2). Survivors of retinoblastoma (SIR=3.5, 
95%CI:2.3-5.3) and Wilms' tumour (SIR=3.3, 95%CI:2.3-4.8) were at the greatest risk of 
developing any genitourinary SPN. Overall, survivors had a 5-fold expected risk of 
developing a kidney SPN (SIR=5.2, 95%CI:4.1-6.6) and a 4-fold expected risk of developing 
a bladder SPN (SIR=3.7, 95%CI:2.7-4.9). Male survivors were not at a significantly increased 
risk of developing a testicular SPN (SIR=0.8, 95%CI:0.6-1.0). 
Conclusion: This study, the largest ever undertaken, found survivors of retinoblastoma and 
Wilms' tumour at particular increased risk of developing genitourinary SPNs. The former 
group of survivors are at increased risk of developing bladder SPNs while the latter are at 
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increased risk of developing kidney SPNs. It is important that health professionals involved in 
the long-term follow-up care of childhood cancer survivors are aware of the excess risks of 
genitourinary SPNs as survivors become older so they may provide information accordingly 
and counsel survivors in relation to early symptoms.      
  99 
5.2 INTRODUCTION 
Survival after childhood cancer has continued to improve in recent decades, with the most 
recent overall five-year survival being approximately 80% in developed countries (39, 236). 
Due to advances in treatment, the population of childhood cancer survivors across Europe 
surviving to at least five years is increasing (237-239). It is estimated that the number of 
childhood cancer survivors across Europe is currently between 300,000 and 500,000 (240). 
However, this growing population of survivors of childhood cancer is at risk of a spectrum of 
adverse health outcomes related to the cancer or its treatment (241). The most common cause 
of premature mortality among mature survivors is the development of subsequent primary 
neoplasms (SPNs) (60). Most survivors can now expect to live many decades and increasing 
numbers of survivors are reaching ages at which in the general population the risk of cancer 
typically starts to increase inexorably. Cancers of the digestive tract and genitourinary system 
predominantly develop at older ages and few previous studies have investigated the long-term 
risks of developing such primary neoplasms in childhood cancer survivors. To our 
knowledge, none had adequate statistical power to investigate the risks of specific cancers 
such as bladder cancer or testicular cancer. No large scale study has been conducted 
investigating the risk of genitourinary SPNs collectively. 
In 2011 a large European collaborative study funded by the 7th Framework Programme of the 
European Union called PanCare Childhood and Adolescent Cancer Survivor Care and 
Follow-Up Studies (PanCareSurFup) was established. PanCareSurFup is a consortium of 16 
European institutions in 12 countries established in February 2011 and funded by the 7th 
Framework Programme of the European Commission (www.pancaresurfup.eu) (173). The 
global aim of PCSF consortium is to conduct studies into long-term complications of 
treatment for cancer, to establish guidelines for clinical follow-up of survivors, and to 
disseminate the results and provide training and workshops for stakeholders. One of the 
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objectives of PanCareSurFup was to investigate the risk of SPNs that are common in the 
general population after the age of 40 years through a retrospectively ascertained European 
cohort of childhood cancer survivors from 12 different countries across Europe.   
The aim of the current study was to investigate the risk of developing subsequent primary 
genitourinary (GU) neoplasms in five-year survivors of childhood cancer using the greatest 
number of long-term survivors ever assembled from pooling across the 10 countries involved. 
5.3 METHODS 
5.3.1 PanCareSurFup 
The study comprises 11 European cohorts (across 10 countries) of survivors of childhood 
cancer diagnosed with a first primary neoplasm (FPN) below 20 years of age. A total of 
75,217 individuals surviving at least five years after childhood cancer were included 
ascertained from population-based cancer registries or major treatment centres across 10 
different countries within Europe. Data collected from each cohort was sent to the 
coordinating centre at the University of Mainz, Germany for initial cleaning of the data. The 
entire dataset was subsequently transferred to the University of Birmingham, UK, for further 
consistency checks and statistical analyses. Ethical approval for the study was obtained for 
each contributing cohort separately. Table 5.1 describes the main characteristics of each 
specific cohort forming the overall European PanCareSurFup cohort.   
5.3.2 Case identification, ascertainment & validation  
First primary neoplasms (FPNs) 
First primary neoplasms (FPNs) were mostly coded in International Classification of Diseases 
for Oncology (ICD-O)-1, 2, 3 (242-244) and were aggregated into groups by type of 
childhood cancer as defined in the International Classification of Childhood Cancer (ICCC) 
(12) through a conversion programme developed by the International Agency for Research on 
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Cancer (IARC) (245, 246). A large proportion of FPNs provided by both Norway and 
Slovenia were classified only in International Classification of Diseases (ICD)-7 (247) format 
therefore due to a lack of morphological detail, conversion to ICCC groups was not possible 
and hence these countries were excluded from the current cohort analysis. Furthermore any 
other FPNs with insufficient information for the IARC conversion programme were also 
excluded from the analysis.   
 
Ascertainment of subsequent primary neoplasms (SPNs) 
Since the focus of this study was on genitourinary SPNs, which are solid cancers, known to 
have strong associations with radiation exposure and characterised by latency periods of 10 or 
more years (248), only SPNs developing after five-year survival were considered. SPNs were 
ascertained largely through population-based cancer registries (Denmark, Finland, Iceland, 
Sweden, Switzerland and UK), questionnaires to the survivor and/or their families (France, 
Hungary, Netherlands and Switzerland) or late effect clinics (Hungary and Switzerland). 
Other methods of ascertainment included linkage to health insurance registries (France), 
linkage to hospital data or medical records (Italy, Netherlands), cancer registrations 
(Netherlands) or linkage with mortality statistics (Italy and Switzerland). SPNs were validated 
by obtaining pathology reports or other clinical documentation. For SPNs to be included in 
this study they had to be malignant if developing outside the CNS, benign or malignant if 
developing within the CNS and any tumour of the bladder was included. All ascertained SPNs 
were coded according to the ICD-O (242-244) or ICD (224, 247, 249, 250) or both. Where 
countries provided SPN information in both ICD-O and ICD format, the former took 
precedence. ICD categories were taken from the definition used in Reulen et al (63). Table 
5.2 provides the ICD-O codes used to define site-specific GU SPNs while Table 5.3 provides 
the ICD codes used to define these same SPNs. Only GU SPNs that were malignant were 
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included in the analysis with the exception of bladder SPNs, for which malignant, benign, 
uncertain behaviour and carcinoma in-situ behaviour codes were all included. Problems with 
the histological differentiation of malignant, benign, uncertain behaviour and in-situ histology 
at the site of the bladder are known (251) .    
5.3.3 General population cancer rates 
An attempt was made to obtain site-based (ICD-10) general population cancer rates for each 
country via several different sources. General population cancer rates for specified calendar-
years were downloaded from the European Cancer Observatory (ECO) hosted by the 
International Agency for Research on Cancer (IARC) (252) for Denmark, Sweden (1960-
2009) and Iceland (1955-2007). Finnish cancer rates from 1953-2011 were obtained from 
Statistics Finland (253). The Office for National Statistics (ONS) provided cancer rates from 
1971-2006 for the UK general population (254)   . Cancer rates from the Swiss general 
population were provided by the Swiss National Institute for Cancer Epidemiology and 
Registration (NICER) for the calendar-years 1985 to 2011 (255). The UK cancer rates were 
used for countries for which general population cancer rates were unattainable. For countries 
where the range of calendar-years for the general population cancer rates did not match that of 
the period of SPN ascertainment in the PCSF cohort, rates from the closest available year 
were used as a proxy. 
5.3.4 Statistical methods 
The period at risk of developing a SPN was initiated five years following initial diagnosis of 
childhood cancer until the first occurrence of loss to follow up, death, GU SPN of interest, or 
reaching the end of follow-up. Multiple SPNs per survivor were permitted for comparisons 
with the general population to avoid bias. Standardised incidence ratios (SIRs) were 
calculated as the observed SPNs divided by the expected number of neoplasms in the 
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underlying cohort. The expected numbers of cancers in each cohort were calculated by 
multiplying general population cancer incidence rates (stratified by sex, 5-year age bands, and 
1-year calendar bands) by the accumulated person-years within each corresponding sex, age 
and calendar year stratum in the PCSF cohort and summing as appropriate. Absolute excess 
risks (AERs) were calculated as the observed minus expected divided by the number of 
person-years at risk multiplied by 10,000. Relative risks of developing a SPN by sex, 
childhood cancer type, attained age, country of diagnosis, time since five-year survival, 
decade of diagnosis and age at diagnosis were derived using a multivariable Poisson 
regression model that incorporated the expected number of cancers as the log-offset. Two 
separate multivariable models were fitted, one adjusting for attained age and another adjusting 
for time since five-year survival, because of collinearity between these two factors. 
Cumulative incidence of developing a first GU SPN of interest was estimated by treating 
death as a competing risk. For SPN subtypes that exceeded 30 observed events we also 
evaluated the SIRs and AERs by sex, childhood cancer and attained age. Statistical 
significance was taken at the 5% level (two sided tests). Analyses were carried out using Stata 
statistical software (version 13.0; Stata Corp., College Station, TX). 
5.4 RESULTS 
5.4.1 Cohort characteristics 
Overall, 277 (0.37%) genitourinary subsequent primary neoplasms (SPNs) were diagnosed 
among the 75,217 five-year survivors of childhood cancer. Total follow-up subsequent to 
five-years was 1,179,332 person-years. The mean follow-up time from childhood cancer 
diagnosis was 20.7 years (median, 18.9 years; range: 5.0-66.6 years). The most commonly 
observed genitourinary SPNs were of the kidney (n=70), bladder (n=44) and testis (n=38) 
(Table 5.5). Genitourinary SPNs occurred most frequently in survivors who were originally 
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diagnosed with ‘other’ neoplasms (n=60), CNS tumours (n=47) and soft tissue sarcoma 
tumours (n=33) (Table 5.5).  
5.4.2 Overall Risk of Genitourinary Subsequent Primary Neoplasm (Table 5.4) 
Survivors were twice as likely to develop a genitourinary SPN than expected (SIR=1.7, 
95%CI:1.5-1.9) with an absolute excess risk of 1.0 SPN per 10,000 person-years (95%CI:0.8-
1.2). The SIRs for attained age did not vary significantly across the age-groups however the 
AER increased significantly (Ptrend<0.001) from 0.3 genitourinary SPNs per 10,000 person-
years among survivors aged <20 years to 9.7 genitourinary SPNs per 10,000 person-years 
among survivors aged ≥50 years respectively. Survivors of retinoblastoma (SIR=3.5, 
95%CI:2.3-5.3) and Wilms’ tumour (SIR=3.3, 95%CI:2.3-4.8) were at the greatest risk of 
developing a genitourinary SPN with 3 and 2 excess SPNs per 10,000 person-years 
respectively. Childhood cancer type was a significant factor (Pheterogeneity<0.01) in the risk of 
developing a genitourinary SPN. The AERs showed a decreasing trend (Ptrend<0.01) with 
more recently diagnosed childhood cancer survivors; those diagnosed between 1970 and 1979 
had 1.4 excess SPNs (95%CI:0.8-2.5) per 10,000 person-years while those diagnosed in 2000 
or later had no excess SPNs. Survivors aged between 0 and 4 years at cancer diagnosis were 
twice as likely than expected to develop a genitourinary SPN while survivors aged between 
15 and 19 years at cancer diagnosis were almost comparable with that expected from the 
general population (Ptrend<0.001). When exploring the risk of developing a genitourinary SPN 
by country (of those contributing to the PanCareSurFup cohort), survivors in France 
(SIR=3.4, 95%CI:2.4-5.0), Hungary (SIR=2.7, 95%CI:1.5-5.1) and the Netherlands (SIR=2.3, 
95%CI:1.6-3.4) had the highest risks; the AER was 3.1 (95%CI:1.8-5.1), 1.3(95%CI:0.5-3.4) 
and 1.4 (95%CI:0.7-2.7) per 10,000 person-years in each of these countries respectively. The 
multivariable Poisson models revealed that childhood cancer type, country of diagnosis, 
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decade of diagnosis and time since five-year survival were all significantly associated with the 
risk of developing a genitourinary SPN.  
The cumulative risk of developing a genitourinary SPN increased from 0.14% (95%CI:0.11-
0.18) by 20 years from childhood cancer diagnosis to 0.98% (95%CI:0.82-1.15) by 40 years 
from diagnosis whereas 0.7% was expected from the general population at this time point 
(Figure 5.1). With respect to childhood cancer type, the cumulative risk of developing a 
genitourinary SPN by 40 years from original cancer diagnosis was highest at 1.64% among 
soft tissue sarcoma survivors and 1.54% among NHL survivors respectively. Survivors of 
CNS tumours had the lowest cumulative risk (0.53%) of developing a genitourinary SPN by 
40 years from their original childhood cancer diagnosis (Figure 5.2). Survivors in France had 
the highest cumulative risk by 40 years from childhood cancer diagnosis, 1.51% closely 
followed by survivors from Denmark (1.21%), Finland (1.20%) and Sweden (1.08%). 
Survivors in the UK had a cumulative risk of 0.98% by 40 years from cancer diagnosis 
(Figure 5.3). 
5.4.3 Genitourinary site specific subsequent primary neoplasms (Table 5.6) 
Analyses by site of SPN revealed that compared to expected survivors were at greatest risk of 
developing neoplasms of the kidney (SIR=5.2, 95%CI:4.1-6.6) and bladder (SIR=3.7, 
95%CI:2.7-4.9). Female survivors were also at significantly increased risk of developing 
female site specific neoplasms including corpus uteri (SIR=2.7, 95%CI:1.9-3.9), ovary 
(SIR=1.7, 95%CI:1.2-2.3) and other female sites (e.g. vulva, vagina) (SIR=3.4, 95%CI:2.0-
5.7). Male survivors were however not at significantly increased risks of developing male site 
specific neoplasms including testis (SIR=0.8, 95%CI:0.6-1.0), prostate (SIR=1.3, 95%CI:0.8-
2.0) or penis (SIR=0.9, 95%CI:0.1-6.3). The absolute excess risks for all of the genitourinary 
sites were between 0.1 and 0.5 SPNs per 10,000 person-years. 
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5.4.4 Subsequent primary neoplasms of the kidney (Table 5.7) 
Inspection of the SIRs by childhood cancer type revealed survivors of Wilms’ tumour 
(SIR=25.7, 95%CI:15.7-41.9) and neuroblastoma (SIR=14.4, 95%CI:6.0-34.5) to be at 
substantially increased risk of developing a kidney SPN compared to that expected. Although 
to a lesser extent, survivors of others (SIR=7.0, 95%CI:4.5-10.7), NHL (SIR=6.0, 95%CI:2.5-
14.5), Hodgkin’s disease (SIR=5.3, 95%CI:2.5-11.2), leukaemia (SIR=3.8,95%CI:1.6-9.2) 
and soft-tissue sarcoma (SIR=3.8, 95%CI:1.6-9.2) also appeared to be at increased risk of 
developing a subsequent primary kidney neoplasm. The SIR decreased with increasing 
attained age (Ptrend<0.001), yet the AERs increased with increasing attained age (Ptrend<0.001) 
with survivors aged 50 or older experiencing an excess of 4 kidney SPNs per 10,000 person-
years. The cumulative risks of developing a kidney SPN 50 years from the original childhood 
cancer diagnosis was 0.6% whereas 0.2% was expected based on general population 
incidence rates for kidney neoplasms (Figure 5.4). 
5.4.5 Subsequent primary neoplasms of the bladder (Table 5.7) 
Survivors of retinoblastoma (SIR=19.7, 95%CI:10.2-37.8) were at the greatest risk of 
developing a bladder SPN, with survivors of leukaemia (SIR=11.3, 95%CI:5.7-22.6) and 
neuroblastoma (SIR=10.4, 95%CI:2.6-41.6) experiencing risks greater than 10-fold that 
expected. The SIRs decreased with increasing attained age (Ptrend<0.001), whilst the AER 
increased although the AER remained below 1 excess bladder cancer per 10,000 person-years 
even after age 50 (AER=0.8, 95%CI: 0.1-9.6). The cumulative risks of developing a bladder 
subsequent primary neoplasm 50 years from the original childhood cancer diagnosis was 
0.5% whereas 0.2% was expected (Figure 5.5). 
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5.4.6 Subsequent primary neoplasms of ovary (Table 5.7) 
Although the overall risk of developing a subsequent primary tumour of the ovary was 1.7 
(95%CI:1.2-2.3) the risk was confined to survivors of a CNS tumour (SIR=3.1, 95%CI:1.9-
5.2). The AER was however relatively small, even for CNS survivors (AER= 0.4, 95%CI:0.2-
0.9).  
5.4.7 Subsequent primary neoplasms of testis (Table 5.7) 
The SIR of developing a neoplasm of the testis did not appear to vary with childhood cancer 
type (Pheterogeneity=0.13); in fact, no type of childhood cancer appeared to be at significantly 
increased risk. Similarly, the SIR did not vary by attained age either (Ptrend=0.50). 
5.5 DISCUSSION  
This is the first study ever to satisfactorily investigate the risk of specific genitourinary SPNs 
in survivors of childhood cancer. We show that, relative to the general population, survivors 
of childhood cancer are at increased risk of developing genitourinary SPNs, particularly of the 
kidney and bladder. We further demonstrate, for the first time, that survivors were at similar 
risk of developing neoplasms of the testis as the general population and that survivors of a 
CNS tumour are at increased risk of developing an ovarian subsequent primary neoplasm. 
  
Comparing our findings to previous studies is difficult since very few studies investigated the 
risks of genitourinary SPNs in survivors of childhood cancer and, at least to our knowledge, 
in all previous studies the actual number of SPNs was very limited; the largest previous study 
to date—the North American Childhood Cancer Survivor Study (CCSS)—included 25 
genitourinary SPNs compared to 277 genitourinary SPNs in the current study (67). In this 
study, survivors of retinoblastoma and Wilms' tumour were at the greatest risk of developing 
a genitourinary SPN. However, in the CCSS (67) no genitourinary SPNs were identified 
  108 
among Wilms tumour survivors, but this finding is nonetheless not inconsistent with our 
findings considering the high upper confidence interval limit reported. 
5.5.1 Subsequent primary neoplasm of the kidney 
In this study, the risk of developing a kidney SPN was 5-fold that expected. Wilson et al 
(256) reported an 8-fold expected risk of developing kidney carcinomas after childhood 
cancer which is similar to our findings. In our study, survivors of a Wilms tumour in 
particular were at increased risk. The risk is likely related to previous treatment with flank or 
abdominal irradiation, but exposure to specific chemotherapeutic agents, particularly platinum 
based compounds, might increase the risk as well (256). In our study, survivors of 
neuroblastoma also had a much higher risk than expected of developing a kidney SPN. 
Consistent with this, an elevated risk among childhood cancer survivors developing renal cell 
carcinoma after neuroblastoma has been observed in the CCSS (67, 256). However, the 
pathophysiology between renal cell carcinoma after neuroblastoma has been reported to be 
poorly understood (67). 
5.5.2 Subsequent primary neoplasm of the bladder 
In this study, the multiplicative risk of developing bladder cancer following childhood cancer 
compared to that expected from the general population was substantially elevated; nonetheless 
this substantially elevated risk did not translate into a substantially increased absolute excess 
risk—even beyond age 50 years the absolute excess risk was less than 1 per 10,000 person-
years. We are not able to compare these findings to previous studies since very little literature 
relates to the risk of bladder cancer after childhood cancer, most likely because the risk of 
bladder cancer in the background population only starts to increase beyond age 50 and thus 
most studies would have had very few bladder cancers. To our knowledge, the only study not 
included in the current collaborative study reporting on bladder cancer after childhood cancer 
  109 
was the CCSS study (67), but this study only included five bladder cancers demonstrating the 
clear need for large-scale collaborative studies such as the current one. Both previous 
treatment with high-dose cyclophosphamide and exposure to high dose abdominal irradiation 
have been implicated in causing bladder cancer, but only at high doses and after cancer 
beyond age 40 years (257). Thus far, no study has reported an increase in bladder cancer after 
childhood cancer with the exception of a study by Frobisher et al (258) who reported an 
increased risk of bladder cancer in a British cohort based on 17 bladder cancers, all of which 
were also included in the current collaborative study. Survivors of retinoblastoma had 
particularly high risks of developing a bladder SPN in this study. A BCCSS study previously 
demonstrated high risks of bladder SPNs after heritable retinoblastoma (258). Since we could 
not distinguish between heritable and non-heritable retinoblastoma in the current study, we 
were not able to confirm this, but it is possible that the high risk of bladder cancer observed is 
partially attributable to the genetic predisposition (e.g. RB-1 gene) among survivors of 
heritable retinoblastoma. Previous studies of retinoblastoma survivors have demonstrated the 
influence of genetic predisposition on the risk of developing SPNs (259-262). Another 
possible explanation of such a finding is treatment with cyclophosphamide in survivors of 
heritable retinoblastoma. A Dutch study demonstrated that survivors of heritable 
retinoblastoma treated with chemotherapy, which potentially included cyclophosphamide 
developed bladder cancers and these did not develop until survivors were aged at least 30 
years or older (263). The effect of cyclophosphamide on the bladder is known hence patients 
treated with this drug are given Mesna to protect their bladder lining (164, 264, 265).   
5.5.3 Subsequent primary neoplasm of the testis  
To our knowledge, no previous study satisfactorily evaluated the risks of developing cancer of 
the testis after childhood cancer. Inskip et al (266) reported a 2-fold increased risk compared 
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to expected, but this was only based on 12 observed SPNs. In general, very few 
epidemiological studies have evaluated the association between ionizing radiation and 
development of testicular cancer, but the few studies that did—including studies among 
Japanese atomic bomb survivors—did not find an excess of testicular cancer among 
individuals exposed to ionizing radiation (267). Overall, the available evidence from 
epidemiological studies thus far suggests that the testis is probably insensitive to the 
mutagenic effect of ionizing radiation; however, this has not been empirically demonstrated in 
survivors of childhood cancer. Most previous epidemiological studies have related to adults 
exposed to low doses of radiation from diagnostic procedures (e.g. X-rays), occupational or 
environmental exposures. The risk of developing testicular cancer after exposure of the testis 
to high doses of ionizing radiation in childhood has not been evaluated. Many survivors of 
childhood cancer will have received much higher doses of radiation to the testis than in such 
previous studies. Here we provide, for the first time, evidence for an absence of an increased 
risk of testicular cancer among survivors of childhood cancer. Further studies are, however, 
necessary to evaluate the risk, or lack thereof, by specific cumulative radiation doses to the 
testis and by cumulative doses of specific chemotherapeutic agents. Perhaps, if there is an 
increased risk, it may only become apparent after exposure of the testis to very high doses of 
radiation.  
5.5.4 Subsequent primary neoplasm of the ovary 
We found, to our knowledge for the first time that survivors of a CNS tumour are at increased 
risk of developing a SPN of the ovary. No other types of childhood cancer were at increased 
risk. A possible explanation for this increased risk may be previous treatment with cranial 
irradiation damaging the pituitary gland and affecting the hypothalamic-pituitary-gonadal-axis 
causing hormonal imbalances in luteinising hormone (LH) and follicle stimulating hormone 
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(FSH) subsequently leading to a need for hormone replacement therapy. Treatment with 
hormone replacement therapy is a recognised risk factor for developing ovarian cancer (268, 
269). Nonetheless, the exact reason for the increased risk in CNS tumour survivors remains 
elusive and the possibility of this association being a chance finding should not be entirely 
excluded.  
5.5.5 Study limitations 
A possible limitation of this study is the lack of available treatment information for the 
majority of survivors in the cohort. Many of the countries contributing data to this study are 
based on population-based cohorts using data from cancer registries which generally do not 
routinely collect treatment as part of the cancer registration process.  However, the risks of 
developing a genitourinary SPN in relation to treatment will be further investigated with 
nested-case control studies as part of the PanCareSurFup project whereby detailed radiation 
dosimetry and cumulative doses of chemotherapeutic drugs will be collected for each 
survivor.  
Another potential limitation relates to significant heterogeneity in SIRs and AERs between 
the different countries contributing to this overall study. Survivors treated in France and the 
Netherlands were at greatest risk of developing a genitourinary SPN. Both the French and 
Dutch cohorts were treatment-centre based (as compared to population-based cohorts) with 
major referral centres included. Ascertainment of survivors for inclusion in late effect follow-
up cohorts through treatment centre based hospitals might be problematic because it is not 
inconceivable that survivors previously treated with less intense treatment regimens are more 
likely to be lost to follow-up than those who were treated with more intense treatment 
regimens and regularly attend follow-up clinics at such treatment based centres. There may 
also be international variation between population-based cohort and treatment centre based 
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cohorts in terms of clinical trials that childhood cancer survivors are entered into. The 
biological way in which treatment affects a childhood cancer survivor of the same height and 
weight between a population-based cohort and treatment centre based cohort is unlikely to 
vary, however the total cumulative dose of chemotherapy, type of chemotherapy and 
radiotherapy regimens given between clinical trials could certainly vary, which may account 
for the differences in GU SPN development among survivors in population-based cohorts 
compared to survivors in treatment-centre based cohorts. Differences in treatment regimens 
between population-based and treatment centre based cohorts will be explored further in 
nested case-control studies that are being conducted as part of the PanCareSurFup project.   
A third potential limitation is that we were not able to distinguish between survivors 
diagnosed with heritable and non-heritable retinoblastoma in the current PanCareSurFup 
cohort. Previous studies have reported substantially increased risk of genitourinary SPNs after 
a diagnosis of heritable retinoblastoma, but no increased risks after, or to a much lesser extent, 
after non-heritable retinoblastoma. Therefore, the substantially increased risks of GU SPNs 
we observe after retinoblastoma are most likely to be confined to heritable retinoblastoma 
survivors. 
5.5.6 Conclusion 
In conclusion, this study, the largest ever undertaken to comprehensively investigate 
genitourinary SPNs among childhood cancer survivors demonstrates, for the first time, that 
survivors are at similar risk of developing neoplasms of the testis as the general population 
and that survivors of a CNS tumour are at increased risk of developing an ovarian SPN. We 
further show that, relative to the general population, survivors of childhood cancer are at 
increased risk of developing genitourinary SPNs, particularly of the kidney and bladder. 
Survivors groups at particular increased risk of developing a genitourinary SPN are 
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retinoblastoma and Wilms’ tumour, the former are at increased risk of developing bladder 
SPNs while the latter are increased risk of developing a kidney SPN. It is important that 
health professionals involved in the long-term follow-up care of childhood cancer survivors 
are aware of the excess risks of genitourinary SPNs as survivors become older so they may 
provide information accordingly and counsel survivors in relation to early symptoms. As 
screening is not widely available for all genitourinary cancers, in the UK for instance, there is 
only a national screening programme for cervical cancer, it will also be necessary for 
healthcare professionals to raise awareness among survivors about risk factors such as 
smoking which is strongly associated with bladder cancer and also a risk factor for kidney 
cancer. Promoting healthy lifestyle behaviours in addition to counselling survivors about early 
symptoms ought to be considered simultaneously when advising childhood cancer survivors 
about second primary genitourinary cancers.  
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Table 5.1 Description of cohorts and first primary neoplasm characteristics 
Cohort No. of 5-year 
survivors 
study design period of FPN 
diagnosis 
age at FPN 
diagnosis 
End of 
follow-up 
type of  
FPNs 
inclusion  
criteria 
France 3,037 treatment 
centre 
1946-1986 <16 yrs Sept 2014 all except 
leukaemia 
malignant or 
intracranial 
 
Hungary 4,873 Population-
based 
1971-2008 <16 yrs Dec 2014 all childhood 
cancers 
malignant of 
intracranial 
 
Italy 10,833 Population-
based 
 
1964-2009 <18 yrs Jan 2012 all childhood 
cancers 
malignant or 
intracranial 
Italy 9,136 treatment 
centre 
1960-2008 <18  yrs Dec 2014 all childhood 
cancers 
malignant or 
intracranial 
 
Netherlands 6,075 treatment 
centre 
1963-2002 <18 yrs Dec 2012 all malignant plus 
benign CNS 
malignant or 
intracranial 
 
Denmark 4,781 Population-
based 
1943-2005 <20 yrs Dec 2003 all malignant plus 
benign CNS 
malignant, 
intracranial or of 
bladder 
 
Sweden 7,710 Population-
based 
1958-2003 <20  yrs Dec 2003 all malignant plus 
benign CNS 
malignant, 
intracranial or of 
bladder 
 
Iceland 274 Population-
based 
1955-2003 <20  yrs Dec 2003 all malignant plus 
benign CNS 
malignant, 
intracranial or of 
bladder 
 
Finland 6,150 Population-
based 
1953-2011 <20 yrs Dec 2012 all malignant plus 
benign CNS 
malignant, 
intracranial or of 
bladder 
 
Switzerland 4,390 Population-
based 
1976-2005 <20 yrs Jan 2014 all childhood 
cancers 
malignant or 
intracranial 
 
UK 17,958 Population-
based 
1940-1991 <15 yrs Dec 2006 all malignant plus 
benign CNS 
malignant, 
intracranial or of 
bladder 
FPN: first primary neoplasm 
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Table 5.2 ICD-O topography codes used to classify site specific genitourinary subsequent primary neoplasms 
Subgroups ICD-O-1 ICD-O-2 ICD-O-3 
Bladder 1880-1889 C67.0-C67.9 C67.0-C67.9 
Cervix Uteri† 1800-1809 C53.0-C53.9 C53.0-C53.9 
Corpus Uteri† 1820-1828 C54.0-C54.9 C54.0-C54.9 
Kidney 1890-1899 C64.9-C66.9,C68.0-C68.9 C64.9-C66.9,C68.0-C68.9 
Other female sites† 1799,1819,1840-1849 C51.0-C52.9, C55.9, 
C57.7, C57.8, C57.9, 
C58.9 
C51.0-C52.9, C55.9, C57.7, C57.8, 
C57.9, C58.9 
Ovary† 1830 C56.9 C56.9 
Penis‡ 1871-1874 C60.0-C60.9 C60.0-C60.9 
Prostate‡ 1859 C61.9 C61.9 
Testis‡ 1860,1869 C62.0-C62.9 C62.0-C62.9 
† Female sites only  
‡ male sites only 
 
Table 5.3 ICD codes used to classify site specific genitourinary subsequent primary neoplasms 
Subgroups ICD-7 ICD-8 ICD-9 ICD-10 
Bladder 1810-1819§ 
1880-1889, 223.3, 
237.6 
1880-1889, 223.3, 233.7, 
236.7, 239.4 
C67.0-C67.9, D409.0, D430.3, 
D441.4 
Cervix Uteri† 171 180 180 C53 
Corpus Uteri† 172 182.0 182.0 C54 
Kidney 180 189 189 C64-C66, C68 
Other female 
sites† 
173, 174, 
176 181, 182.9, 184 179, 181, 182.8, 184 
C51, C53, C55, C57.7, C57.8, 
C57.9,C58 
Ovary† 175.0 183.0 183.0 C56 
Penis‡ 179.0 187.0 187.1,187.2, 187.3, 187.4 C60 
Prostate‡ 177 185 185 C61 
Testis‡ 178 186 186 C62 
ICD -International Classification of Diseases  
† Female sites only  
‡ male sites only  
§ In ICD-7, bladder benign and unspecified tumours could not be solely identified since they would have been coded under one main category of kidney and 
other urinary organs- 219 and other genitourinary organs-236 so these categories were not included 
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Table 5.4 Overall genitourinary subsequent primary neoplasms for PanCareSurFup cohort (n=75,217), 
Standardised Incidence Ratios, Absolute Excess Risks, adjusted Relative Risks and Relative Excess Risks 
 Number of 5-
year survivors 
Person-
years 
O/E SIR (95%CI) RR (95%CI) AER (95%CI) RER (95%CI) 
Overall  75,217 1179332.3 277/165.0 1.7 (1.5-1.9)  1.0 (0.8-1.2)  
Gender        
Male  41,075 633240.0 132/84.9 1.6 (1.3-1.8) 1.0 (referent)† 0.7 (0.5-1.2) 1.0 (referent)† 
Female  34,142 546092.2 145/80.0 1.8 (1.5-2.1) 1.2 (0.9-1.5) 1.2 (0.8-1.7) 1.5 (0.9-2.7) 
Pheterogeneity    0.20 0.18 0.12 0.10 
Attained age         
<20 38,361 449746.9 18/6.0 3.0 (1.9-4.7) 1.0 (referent)† 0.3 (0.1-0.5) 1.0 (referent)† 
20-29 25,631 409732.4 69/44.2 1.6 (1.2-2.0) 0.6 (0.4-1.0) 0.6 (0.3-1.2) 3.0 (1.1-8.2) 
30-39 8,356 213615.1 77/46.3 1.7 (1.3-2.1) 0.7 (0.4-1.2) 1.4 (0.8-2.5) 11.2 (4.3-29.5) 
40-49 2,290 78509.1 46/28.3 1.6 (1.2-2.2) 0.8 (0.5-1.5) 2.3 (1.1-4.8) 39.2 (12.8-119.7) 
≥50 579 27728.8 67/40.1 1.7 (1.3-2.1) 1.1 (0.5-2.1) 9.7 (5.3-17.6) 221.7 (53.8-913.6) 
Ptrend    0.34 0.28 <0.001 <0.001 
Childhood Cancer        
Leukaemia 20,414 275716.1 26/22.3 1.2 (0.8-1.7) 0.8 (0.5-1.4) 0.1 (0.0-2.0) 0.5 (0.0-6.7) 
Hodgkin's disease 6,484 93666.2 20/16.1 1.2 (0.8-1.9) 1.0 (0.6-1.7) 0.4 (0.0-3.9) 0.9 (0.1-6.5) 
NHL 3,853 60219.1 17/9.2 1.8 (1.1-3.0) 1.4 (0.8-2.5) 1.3 (0.5-3.6) 3.4 (1.0-11.7) 
CNS tumour 14,211 228906.4 47/36.1 1.3 (1.0-1.7) 1.0 (referent)† 0.5 (0.1-1.6) 1.0 (referent)† 
Neuroblastoma 3,932 61939.0 11/4.5 2.4 (1.3-4.4) 1.5 (0.8-3.1) 1.0 (0.4-2.9) 3.0 (0.8-11.1) 
Retinoblastoma 2,466 57008.8 23/6.6 3.5 (2.3-5.3) 2.4 (1.4-4.2) 2.9 (1.6-5.1) 4.4 (1.3-14.9) 
Wilms 5,313 99323.4 29/8.7 3.3 (2.3-4.8) 1.9 (1.2-3.2) 2.0 (1.2-3.4) 3.7 (1.2-11.3) 
Bone sarcoma 3,376 53342.6 11/11.3 1.0 (0.5-1.8) 0.8 (0.4-1.5) 0.0 (0.0,.) 0.3 (0.0-16.1) 
Soft tissue sarcoma 4,786 83152.5 33/14.1 2.3 (1.7-3.3) 1.8 (1.1-2.7) 2.3 (1.3-4.1) 3.1 (0.9-10.5) 
Others  10,382 166058.2 60/36.1 1.7 (1.3-2.1) 1.3 (0.9-2.0) 1.4 (0.8-2.7) 1.9 (0.6-6.6) 
Pheterogeneity    <0.001 <0.01 <0.001 0.01 
Country        
Denmark  4,781 77714.4 32/24.0 1.3 (0.9-1.9) 0.8 (0.5-1.2) 1.0 (0.3-4.1) 0.1 (0.0-26.1) 
Finland  6,150 103521.6 36/22.1 1.6 (1.2-2.3)  0.9 (0.6-1.4) 1.3 (0.6-3.1) 0.5 (0.1-2.2) 
France  3,037 67352.9 29/8.4 3.4 (2.4-5.0) 1.5 (1.0-2.4) 3.1 (1.8-5.1) 1.9 (1.0-3.7) 
Hungary 4,873 49939.6 10/3.7 2.7 (1.5-5.1) 1.4 (0.7-2.8) 1.3 (0.5-3.4) 2.0 (0.6-6.4) 
Iceland  274 3461.9 0/0.6 0.0 (.,.) 0.0 (0.0,.) 0.0 (0.0,.) 0.0 (0.0,.) 
Italy-population-based 10,833 135183.7 13/15.9 0.8 (0.5-1.4) 0.5 (0.3-0.9) 0.0 (0.0,.) 0.3 (0.0-2.3) 
Italy-hospital-based  9,136 107960.1 7/7.9 0.9 (0.4-1.9) 0.5 (0.2-1.0) 0.0 (0.0,.) 0.0 (0.0-131134) 
Netherlands 6,075 103659.4 25/10.9 2.3 (1.6-3.4) 1.1 (0.7-1.8) 1.4 (0.7-2.7) 1.1 (0.4-2.7) 
Sweden 7,710 115387.6 27/18.7 1.4 (1.0-2.1) 0.9 (0.5-1.4) 0.7 (0.2-2.5) 1.3 (0.4-3.4) 
Switzerland  4,390 46285.6 5/4.1 1.2 (0.5-2.9) 0.6 (0.3-1.6) 0.2 (0.0-28.3) 0.4 (0.0-7.6) 
UK  17,958 368864.8 93/48.6 1.9 (1.6-2.3) 1.0 (referent)† 1.2 (0.8-1.8) 1.0 (referent)† 
Pheterogeneity    <0.001 0.02 <0.001 0.02 
Decade of diagnosis        
<1970 8,682 278892.2 121/80.9 1.4 (1.3-1.8) 1.0 (referent)† 1.4 (0.8-2.5) 1.0 (referent)† 
1970-1979 14,481 333193.9 86/41.3 2.1 (1.7-2.6) 1.9 (1.3-2.7) 1.3 (0.9-2.0) 4.0 (1.6-9.6) 
1980-1989 22,761 363551.0 53/31.2 1.7 (1.3-2.2) 1.8 (1.1-2.8) 0.6 (0.3-1.2) 4.4 (1.4-13.6) 
1990-1999 21,784 178297.7 16/10.6 1.5 (0.9-2.5) 1.9 (0.9-3.7) 0.3 (0.0-1.3) 3.3 (0.4-26.7) 
≥2000 7,509 25397.5 1/0.9 1.1 (0.2-7.7) 1.2 (0.2-9.5) 0.0 (0.0-3790.0) 0.0 (0.0,.) 
Ptrend    0.53 0.03 <0.01 0.04 
Age at diagnosis        
0-4 30,164  495845.6 89/37.3 2.4 (1.9-2.9) 1.0 (referent)† 1.0 (0.7-1.5) 1.0 (referent)† 
5-9 17,630 280272.9 58/32.4 1.8 (1.4-2.3) 0.9 (0.7-1.4) 0.9 (0.5-1.6) 0.8 (0.4-1.6) 
10-14 16,697 264496.5 73/52.5 1.4 (1.1-1.8) 0.7 (0.5-1.1) 0.8 (0.3-1.8) 0.4 (0.2-1.0) 
15-19 10,726 138717.2 57/42.8 1.3 (1.0-1.7) 0.7 (0.4-1.1) 1.0 (0.4-2.9) 0.2 (0.0-0.8) 
Ptrend    <0.001 0.10 0.61 0.01 
Follow-up from 5-
year  
       
Survival        
0-9 52,631 606067.0 51/26.6 1.9 (1.5-2.5) 1.0 (referent)§ 0.4 (0.2-0.7) 1.0 (referent)§ 
10-19 16,114 353523.5 61/46.9 1.3 (1.0-1.7) 0.5 (0.4-0.8) 0.4 (0.1-1.2) 0.7 (0.3-2.2) 
20-29 4,981 157034.8 65/41.2 1.6 (1.2-2.0) 0.7 (0.4-1.1) 1.5 (0.8-2.9) 4.2 (1.9-9.3) 
30-39 1,296 51932.8 65/31.6 2.1 (1.6-2.6) 1.4 (0.8-2.3) 6.4 (4.0-10.3) 38.4 (14.3-103.0) 
≥40 195 10774.2 35/18.5 1.9 (1.4-2.6) 1.3 (0.7-2.4) 15.3 (7.6-30.9) 174.2 (47.6-637.3) 
Ptrend    0.23 0.04 <0.001 <0.001 
AER: absolute excess risk, CNS: central nervous system tumour, CI: confidence interval, NHL: Non-Hodgkin Lymphoma, O/E: Observed/Expected, RER: relative excess risks, 
RR: relative risk, SIR: standardised incidence ratios  
† multivariable Poisson model adjusted for sex, attained age, childhood cancer diagnosis, country of diagnosis, decade of diagnosis and age at diagnosis 
§  multivariable Poisson model adjusted for sex, follow-up from 5-year survival, childhood cancer diagnosis, country of diagnosis, decade of diagnosis and age at diagnosis 
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Figure 5.1 Cumulative risk of developing a genitourinary subsequent primary neoplasm and corresponding 
expected risk. 
 
 
Figure 5.2 Cumulative risk of developing a genitourinary subsequent primary neoplasm of any type by 
childhood cancer diagnosis 
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Figure 5.3 Cumulative risk of developing a genitourinary subsequent primary neoplasm of any type by country 
of diagnosis 
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Table 5.5 Frequency of Genitourinary Site Subsequent Primary Neoplasms by First Primary Neoplasm Diagnosis 
Site of Genitourinary Subsequent Primary Neoplasm 
FPN diagnosis 
Kidney Bladder† Testis Ovary 
Corpus 
 uteri 
Cervix 
 uteri Prostate 
Other  
female  Penis Total (%) 
Leukaemia 5 8 5 2 1 4 1 0 0 26 (9.4) 
Hodgkin's 
Disease 
7 2 1 3 0 2 1 3 1 20 (7.2) 
NHL 5 4 2 1 2 0 2 1 0 17 (6.1) 
CNS  5 4 8 15 5 4 5 1 0 47 (17.0) 
Neuroblastoma 5 2 1 1 0 1 1 0 0 11 (4.0) 
Retinoblastoma 0 9 3 2 6 1 1 1 0 23 (8.3) 
Wilms' 16 2 2 0 5 3 0 1 0 29 (10.5) 
Bone Sarcoma  1 2 1 1 1 3 2 0 0 11 (4.0) 
STS 5 5 3 6 2 2 6 4 0 33 (11.9) 
Others  21 6 13 6 7 3 2 3 0 60 (21.7) 
Total (%)  70 
(25.3) 
44 (15.9) 38 
(13.7) 
37 
(13.4) 
29 
(10.5) 
23 
(8.3) 
21 (7.6) 14 
(5.1) 
1 
(0.4) 
277 
(100) 
CNS: central nervous system; FPN: first primary neoplasm NHL: Non-Hodgkin lymphoma; STS: soft tissue sarcoma  
† malignant bladder only as general population rates are based on malignant codes  
 
 
Table 5.6 Standardised incidence ratios and absolute excess risks of genitourinary subsequent primary 
neoplasms by site. 
SPN Site O/E SIR (95%CI) AER (95%CI) 
Kidney 70/13.4 5.2 (4.1-6.6) 0.5 (0.4-0.6) 
Bladder  44/12.0 3.7 (2.7-4.9) 0.3 (0.2-0.4) 
Other female sites  14/4.1 3.4 (2.0-5.7) 0.1 (0.0-0.1) 
Corpus uteri 29/10.7 2.7 (1.9-3.9) 0.1 (0.1-0.2) 
Ovary  37/22.0 1.7 (1.2-2.3) 0.1 (0.0-0.2) 
Prostate  21/16.4 1.3 (0.8-2.0) 0.0 (0.0-0.2) 
Penis  1/1.1 0.9 (0.1-6.3) 0 
Testis 38/50.2 0.8 (0.6-1.0) 0 
Cervix uteri 23/35.0 0.6 (0.4-1.0) 0 
AER: absolute excess risk, CI: confidence interval, O/E: observed/expected; SIR: standardised incidence ratio, SPN: subsequent primary neoplasm  
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Table 5.7 Standardised incidence ratios and absolute excess risks for bladder, kidney, ovary and testis subsequent primary neoplasms 
 Bladder SPN Kidney SPN Ovary SPN Testis SPN 
Explanatory factor O/E SIR (95%CI) AER (95%CI) O/E SIR (95%CI) AER (95%CI) O/E SIR (95%CI) AER (95%CI) O/E SIR (95%CI) AER (95%CI) 
Sex             
Male 30/8.8 3.4 (2.4-4.9) 0.3 (0.2-0.6) 42/8.4 5.0 (3.7-6.7) 0.5 (0.4-0.8) NA NA NA 38/50.2 0.8 (0.6-1.0) 0 
Female 14/3.1  4.5 (2.6-7.5) 0.2 (0.1-0.4) 28/5.0 5.6 (3.9-8.2) 0.4 (0.3-0.7) 37/22.0 1.7 (1.2-2.3) 0.1 (0.0-0.2) NA NA NA 
Pheterogeneity  0.40 0.22  0.62 0.4       
             
Childhood Cancer             
Leukaemia 8/0.7 11.3 (5.7-22.6) 0.3 (0.1-0.6) 5/1.3 3.8 (1.6-9.2) 0.1 (0.0-0.4) 2/3.0 0.7 (0.2-2.6) 0 5/10.0 0.5 (0.2-1.2) 0 
Hodgkin's Disease 2/1.2 1.7 (0.4-7.0) 0.1 (0.0-2.3) 7/1.3 5.3 (2.5-11.2) 0.6 (0.2-1.5) 3/1.6 1.9 (0.6-5.8) 0.1 (0.0-1.7) 1/6.0 0.2 (0.0-1.2) 0 
NHL 4/0.8 5.3 (2.0-14.1) 0.5 (0.2-1.8) 5/0.8 6.0 (2.5-14.5) 0.7 (0.2-2.0) 1/0.8 1.2 (0.2-8.6) 0 2/3.7 0.5 (0.1-2.1) 0 
CNS  4/2.9 1.4 (0.5-3.7) 0.0 (0.0-1.8) 5/3.1 1.6 (0.7-3.9) 0.1 (0.0-0.8) 15/4.8 3.1 (1.9-5.2) 0.4 (0.2-0.9) 8/10.0 0.8 (0.4-1.6) 0 
Neuroblastoma 2/0.2 10.4 (2.6-41.6) 0.3 (0.1-1.4) 5/0.4 14.4 (6.0-34.5) 0.8 (0.3-1.9) 1/0.7 1.5 (0.2-10.5) 0.1 (0.0-22.8) 1/1.6 0.6 (0.1-4.4) 0 
Retinoblastoma 9/0.5 19.7 (10.2-37.8) 1.5 (0.8-3.0) 0/0.6 0.0 (.,.) 0.0 (0.0,.) 2/0.9 2.1 (0.5-8.6) 0.2 (0.0-2.5) 3/1.9 1.6 (0.5-5.0) 0.2 (0.0-4.0) 
Wilms' 2/0.4 5.0 (1.3-20.1) 0.2 (0.0-0.9) 16/0.6 25.7 (15.7-41.9)  1.5 (0.9-2.6) 0/1.3 0 0 2/3.2 0.6 (0.2-2.5) 0 
Bone Sarcoma 2/1.0 2.0 (0.5-8.0) 0.2 (0.0-3.0) 1/1.0 1.0 (0.1-6.8) 0.0 (0.0,.) 1/1.4 0 0 1/2.8 0.4 (0.1-2.5) 0 
STS 5/1.3 3.8 (1.6-9.2) 0.4 (0.1-1.5) 5/1.3 3.8 (1.6-9.2) 0.4 (0.1-1.4) 6/1.8 0.7 (0.1-5.1) 0.5 (0.2-1.6) 3/3.7 0.8 (0.3-2.5) 0 
Others  6/3.1 1.9 (0.9-4.3) 0.2 (0.0-0.9) 21/3.0 7.0 (4.5-10.7) 1.1 (0.7-1.8) 6/5.7 1.1 (0.5-2.3) 0 12/7.3 1.6 (0.9-2.9) 0.3 (0.1-1.2) 
Pheterogeneity   <0.001 0.02  <0.001 <0.001  0.08 0.07  0.13 0.98 
             
Attained Age             
<20 1/0.2 6.1 (0.9-43.2) 0.0 (0.0-0.2) 9/0.7 12.8 (6.7-24.6) 0.2 (0.1-0.4) 5/1.5 3.4 (1.4-8.1) 0.1 (0.0-0.3) 2/3.4 0.6 (0.1-2.4) 0 
20-29 9/1.1 8.3 (4.3-16.0) 0.2 (0.1-0.4) 15/1.2 13.1 (7.9-21.7) 0.3 (0.2-0.6) 12/4.7 2.5 (1.4-4.5) 0.2 (0.1-0.5) 24/25.4 0.9 (0.6-1.4) 0 
30-39 19/2.0 9.4 (6.0-14.8) 0.8 (0.5-1.3) 17/2.6 6.5 (4.1-10.5) 0.7 (0.4-1.2) 5/5.4 0.9 (0.4-2.2) 0.0 (0.0,.) 10/16.9 0.6 (0.3-1.1) 0 
40-49 7/3.0 2.4 (1.1-5.0) 0.5 (0.1-1.9) 14/3.9 3.6 (2.1-6.0) 1.3 (0.6-2.7) 5/5.5 0.9 (0.4-2.2) 0.0 (0.0,,.) 1/3.9 0.3 (0.0-1.8) 0 
≥50 8/5.8 1.4 (0.7-2.8) 0.8 (0.1-9.6) 15/5.0 3.0 (1.8-4.9) 3.6 (1.7-7.7) 10/5.0 2.0 (1.1-3.7) 1.8 (0.5-6.2) 1/0.6 1.8 (0.3-12.9) 0.2 (0.0-12.6) 
Ptrend  <0.001 <0.001 <0.001 <0.001 <0.001  0.13 0.65  0.50 0.86 
AER: absolute excess risks, CNS: central nervous system, NA: not applicable, NHL: Non-Hodgkin lymphoma, O/E: observed/expected, SIR: standardised incidence ratio, STS: soft tissue sarcoma  
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Figure 5.4 Cumulative risk of developing a kidney subsequent primary neoplasm 
 
 
Figure 5.5 Cumulative risk of developing a bladder subsequent primary neoplasm 
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CHAPTER 6 GENERAL DISCUSSION AND CONCLUSIONS  
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6.1 Principal findings  
Chapter Two investigated which survivors in the BCCSS were on regular long-term hospital 
follow-up. The NCSI has proposed substantial changes to clinical follow-up practices within 
the NHS for the future. Changes proposed are a move away from a one-size fits all model of 
follow-up towards risk stratification, whereby the level of care to be offered corresponds to 
the anticipated level of risk of serious adverse health outcomes. Survivors were assigned to 
proposed NCSI Levels of care (risk stratification levels developed by the BCCSS in 
collaboration with NCSI clinicians and based on cancer type and treatment received). Among 
LEVEL 3 survivors of non-leukaemic cancer only 31% were on regular hospital follow-up, 
despite the NCSI recommendation for all LEVEL 3 survivors to be on regular hospital multi-
disciplinary team review, furthermore this percentage declined from 57% to 16% among 
survivors aged under 20 years to survivors aged at least 50 years, respectively. Among 
LEVEL 1 survivors of non-leukaemia cancers 12% were on regular hospital follow-up, whilst 
the NCSI recommendation for all LEVEL 1 survivors is self-care with support. GPs returns 
indicated that 74% (9595/12978) were willing to discuss survivorship issues with survivors. 
Consideration needs to be given to the potential recall of both NCSI LEVEL 3 survivors who 
are not on regular hospital follow-up for possible establishment of such follow-up, and NCSI 
LEVEL 1 survivors who are on such follow-up for possible discharge to self-care with 
support. 
 
Chapter Three explored which groups of survivors of CNS tumours within the BCCSS were 
at excess risk of adverse health and social outcomes using record-linkage (for causes of death 
and incident SPNs) and the BCCSS study questionnaire data (for non-fatal, non-neoplastic 
outcomes) by comparing risks to that expected from the general population. Between 30 and 
50 years from diagnosis the principal causes of death accounting for most of the total excess 
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deaths observed were: after craniopharyngioma, recurrence (28%) and circulatory (35%); 
after medulloblastoma, recurrence (20%) and SPN (48%); after astrocytoma, recurrence 
(35%), SPN (13%) and respiratory (13%). Consequently, CNS subtype was a strong risk 
stratification factor, as was cranial/craniospinal radiotherapy in that, of the total excess 
number of deaths observed beyond 30 years from diagnosis among those exposed 
(unexposed) to radiotherapy 21% (3%) and 11% (0%) were attributable to SPN and stroke 
respectively. The cumulative risks of developing a meningioma by 35 years from diagnosis 
among those exposed (unexposed) to radiotherapy were 3.9% (0.6%). Educational attainment 
and marriage showed greater deficits among those CNS tumour survivors who had received 
cranial/craniospinal irradiation. CNS subtype and cranial irradiation provide strong risk 
stratification factors which may be used in long-term follow-up clinics to powerfully 
discriminate between groups of survivors in terms of anticipated risk of serious adverse health 
outcomes. 
 
Chapter Four demonstrated through electronic record linkage of the BCCSS cohort with 
Hospital Episode Statistics that overall, 299 survivors were hospitalised for a cerebrovascular 
condition compared to 59 expected (SHR=5.1, 95%CI:4.5-5.7) with survivors of a CNS 
tumour (SHR=11.9, 95%CI:10.3-13.7, AER=8.5, 95%CI:3.9-18.3) and leukaemia (SHR=5.6, 
95%CI:4.2-7.4, AER=2.3, 95%CI:1.0-5.0) at the greatest excess risk. Of the specific 
cerebrovascular conditions, the greatest observed hospitalisations among survivors were for 
cerebral haemorrhage (SHR=8.1, 95%CI:6.7-9.8) and ischaemic stroke (SHR=5.2, 
95%CI:4.3-6.2), with CNS tumour survivors at particular increased risk. Previous treatment 
with cranial irradiation was associated with increased risk of being hospitalised for a 
cerebrovascular condition over that expected (SHR=15.6, 95%CI:13.0-18.9). In absolute 
terms this equated to 58 additional hospitalisations per 10,000 person-years. Hospitalisation 
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due to a cerebrovascular condition and more specifically hospitalisations due to cerebral 
haemorrhage and ischaemic stroke is greatest in survivors who were initially diagnosed with a 
CNS tumour or leukaemia. Cranial irradiation is a strong risk factor associated with survivors 
being hospitalised for cerebrovascular complications. A risk-stratified approach to clinical 
follow-up, would ensure survivors at highest risk of cerebrovascular complications undergo 
surveillance.   
 
Chapter Five, the largest ever cohort study undertaken to comprehensively investigate the risk 
of genitourinary primary cancers subsequent to childhood cancer survivors throughout Europe 
using the PanCareSurFup cohort found that after a mean follow-up time of 20.7 years, 277 
(0.37%) genitourinary SPNs were diagnosed among 75,217 survivors of childhood cancer. 
The most commonly observed genitourinary SPNs were of the kidney (n=70), bladder (n=44) 
and testis (n=38). Overall, survivors were twice as likely to develop a genitourinary SPN of 
any type than expected (SIR=1.7, 95%CI:1.5-1.9, AER=1.0, 95%CI:0.8-1.2). Survivors of 
retinoblastoma (SIR=3.5, 95%CI:2.3-5.3) and Wilms' tumour (SIR=3.3, 95%CI:2.3-4.8) were 
at the greatest risk of developing any genitourinary SPN. Overall, survivors had a 5-fold 
expected risk of developing a kidney SPN (SIR=5.2, 95%CI:4.1-6.6) and a 4-fold expected 
risk of developing a bladder SPN (SIR=3.7, 95%CI:2.7-4.9). Male survivors were not at a 
significantly increased risk of developing a testicular SPN (SIR=0.8, 95%CI:0.6-1.0). 
Survivors of retinoblastoma were at increased risk of developing bladder SPNs while Wilms' 
tumours survivors were at increased risk of developing kidney SPNs. It is important that 
health professionals involved in the long-term follow-up care of childhood cancer survivors 
are aware of the excess risks of genitourinary SPNs as survivors become older so they may 
provide information accordingly and counsel survivors in relation to early symptoms.    
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6.2 Methodological Considerations 
Two principal advantages of using the BCCSS are its large-scale and its population-based 
study design, this provides reliable and unbiased risk estimates with regards to a whole 
spectrum of adverse outcomes that have been studied. The BCCSS was ascertained through 
the National Registry for Childhood Tumours which has a high level of completeness of 
ascertainment ~99% (270). Since all childhood cancer survivors are included, there is unlikely 
to be selection bias present in the population-based BCCSS that is inherent in hospital-based 
studies. In studies such as the CCSS, childhood cancer survivors are ascertained through a 
limited number (twenty-five) of research orientated treatment centres, therefore the survivors 
ascertained are unlikely to be representative of all childhood cancer survivors in North 
America. Furthermore, as the CCSS restrict their inclusion criteria to specific diagnoses (33), 
some childhood cancer survivors are inevitably excluded from their study.    
As a result of including survivors of childhood cancer diagnosed since 1940, the BCCSS has a 
much longer follow-up period compared with studies such as the CCSS (33), SCCSS (32) and 
DCOG LATER study (31). Thus it is possible to investigate late effects among survivors 
many years after their original childhood cancer diagnosis. Extension of the BCCSS cohort 
from 1st January 1992 to 31st December 2006 enables comparisons between survivors 
diagnosed and treated decades ago with survivors diagnosed and treated more recently. 
Further advantages of the BCCSS include its linkage with HSCIC (formerly known as NHS 
Central Registers) and the provision of key information through flagging with respect to 
deaths and second cancers. Every survivor’s vital status is provided by linkage with the 
national death registration system while notification of a survivor developing a SPN is 
through the national cancer registration system. For survivors who are alive, current 
registration with a general practice can be identified through their NHS status. Thus once 
survivors in the BCCSS cohort have been flagged with HSCIC, there is an efficient way to 
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trace these individuals minimising loss-to-follow-up. Tracing individuals in hospital-based 
studies is often more difficult, particularly as survivors move locations and hospital records 
are not updated with key information (271).   
A study questionnaire, based on that used in the CCSS, was developed and distributed by post 
to survivors in the BCCSS via their GP. This study questionnaire was used to ascertain the 
majority of outcomes investigated in Chapter Three. In any self-reported questionnaire, 
response bias needs to be taken into consideration, which is the systematic error caused by 
differences in the outcome being measured between respondents and non-respondents (272). 
The overall response rate for the questionnaire was 70.7%, which is high in research using 
questionnaires, particularly those sent by post (273). The distribution of survivor 
characteristics did not differ substantially between responders and non-responders to the 
questionnaire, which provides some reassurance in relation to potential response bias (30). 
The disadvantage of the BCCSS is its lack of detailed treatment information for each survivor 
within the cohort. Some treatment information is available for cohort members with respect to 
surgery, radiotherapy and chemotherapy which has been recorded discretely as yes, no or no 
record for each treatment type. With a population-based cohort of 34,489 individuals, it would 
be a vast undertaking to locate all the medical records of survivors across the UK as well as to 
collect detailed patient notes in relation to any therapy given during the course of cancer 
treatment for each survivor. One way of addressing this limitation is to conduct nested case-
control studies. The cases and controls are selected from the underlying cohort thus 
minimising selection bias as the cases and controls are selected from the same cohort (271). 
Various outcomes could be investigated and one would only have to gather treatment 
exposure on cases and controls as opposed to the entire cohort. The efficiency of the use of 
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nested case-control studies has been acknowledged when the assessment of exposure is 
resource-intensive such as radiation dosimetry (271).   
The advantages of using Hospital Episode Statistics (HES) to ascertain data with respect to 
hospitalisations are its large size and population-based coverage across England which 
considered together provide robust evidence. The BCCSS questionnaire has been used to 
ascertain various non-fatal and non-neoplastic adverse health and social outcomes up until 
now, however the investigation of cerebrovascular disease among childhood cancer survivors 
in Chapter Four demonstrates another method of ascertaining such information. This 
methodology is less resource intensive than sending out questionnaires and is based on 
medical diagnoses and therefore likely to be valid than outcomes self-reported in a 
questionnaire (235). Hospital record linkage also removes the issue of potential recall bias, 
which is an important consideration of self-reported questionnaires. Linking the BCCSS 
cohort with HES minimises loss-to-follow-up in ascertaining outcomes among survivors as 
they are both population-based sources. The disadvantage of HES is that it is for England 
only, equivalent hospital databases are available for both Scotland and Wales and permission 
is currently being sought to link the BCCSS cohort with these databases.  
There are several advantages of establishing the PanCareSurFup cohort, firstly it is the largest 
ever cohort of childhood cancer survivors in the world. Secondly, the cohort possesses a long-
period of follow-up as it includes the UK and Nordic countries with diagnoses going back to 
the 1940s. Finally, as PanCareSurFup is an international project, there is collaboration with 
experts in the field to work towards providing the best evidence possible for survivors of 
childhood cancer. Due to the long period of follow-up available, survivors in this cohort are 
reaching ages where common diseases occur in mature adulthood in the general population 
(including cancer, cardiovascular, pulmonary and diabetes). This enables a much more 
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informative investigation of such diseases compared with the risk expected from the general 
population. In previous research, it has not been possible to quantify the excess risks of site-
specific genitourinary SPNs comprehensively among childhood cancer survivors as a small 
number of SPNs have been ascertained in previous cohorts (59, 60, 63, 64). Only now with a 
collaborative international study with cases being pooled may the risk of specific SPNs be 
investigated satisfactorily. The age at cancer diagnosis eligibility range for the BCCSS was to 
include individuals diagnosed with cancer between the ages of 0 and 14 years. For the 
PanCareSurFup cohort, the age at cancer diagnosis eligibility range was between 0 and 19 
years since some countries contributing to this cohort had a wider age at cancer diagnosis 
eligibility range. The ICCC was used to classify childhood cancers in the PanCareSurFup 
cohort as the third volume includes the age range of 0 to 19 years (12). Limitations in relation 
to this international cohort include the lack of treatment information which is being addressed 
through nested case-control studies. Standardising data collection has not been without its 
difficulties. For instance, Slovenia and Norway mainly use the ICD (a site-based code) to 
classify their childhood cancers which limits suitable conversions into certain aggregated 
diagnostic groups using the ICCC which requires both site and type information. This is being 
addressed with data providers and although the current cohort excludes these countries in the 
SPN analysis that has been conducted, there is potential to address these issues in the future. 
6.3 Implications on Guidelines  
This thesis has highlighted that a risk stratification tool developed by the BCCSS in 
collaboration with the NCSI may be used to determine the level of clinical follow-up care 
survivors should receive depending on their risk of serious adverse health outcomes. Findings 
from Chapter Two demonstrate which survivors could possibly be discharged from hospital-
follow-up due to their low risk of serious adverse health outcomes and which survivors should 
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probably be on hospital follow-up and may need possible recall to the NHS. Current SIGN 
guidelines propose possible levels of follow-up for survivors based on therapy given to 
survivors and their cancer types (17). These levels are broadly similar to those proposed by 
the BCCSS/NCSI. The risk stratification tool proposed by the BCCSS/NCSI is evidence-
based in that the risk of the total burden of disease from all adverse health outcomes has been 
quantified for each level. Previous studies have proposed levels of follow-up based on risk-
stratification but these have been small-scale studies in hospital-based settings (42, 274, 275). 
Such studies may be prone to selection bias in their inclusion of participating survivors. A 
more recent study based in a single institution in Scotland proposed risk-stratification levels 
but these are based on a younger cohort than the BCCSS (276). Since the cumulative risk of 
many chronic conditions increase substantially with increasing time from diagnosis (49), 
findings from younger cohorts are inevitably rather limited. Thus in proposing levels of 
follow-up using risk stratification, one needs to consider the risks that mature survivors will 
be facing as well as those faced by younger survivors. In suggesting new levels of clinical 
follow-up, it will also be important to ensure survivors are fully informed about their 
childhood cancer diagnosis and the treatment they received as they may have been of ages 
where they were not involved in this exchange of information. Knowledge deficits among 
childhood cancer survivors regarding their cancer diagnosis and previous treatment have been 
reported (277).            
CNS tumour survivors are a heterogeneous group and this thesis demonstrates that CNS 
subtype and cranial/craniospinal radiation are strong risk-stratification factors in determining 
the risks reported for a spectrum of adverse health and social outcomes. The current SIGN 
guidelines state that “many studies lack comparison groups” with regards to psychosocial 
issues (17). Comparison groups outside of the childhood cancer survivor population are 
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essential to quantify the excess risk of an outcome of interest experienced by survivors (271). 
A strength of the findings from Chapter Three are that all comparisons of psychosocial 
outcomes have been made with the general population thus the estimated excess risk among 
childhood cancer survivors can be compared to those individuals who did not have a 
childhood cancer but of a similar age and sex as the survivors. CNS tumour survivors were 
less likely to demonstrate harmful health behaviours such as smoking regularly and drinking 
alcohol compared to the general population. There are however survivors that smoke 
regularly, consume alcohol and have increased risks of BMI, thus health promotion advice 
will be ever more important as a preventative measure for many chronic diseases. Counselling 
survivors about their health risks will continue to be an important goal in empowering 
survivors to make informed lifestyle choices (17).  
The importance of replicating findings across different study populations has been stressed in 
scientific research quantifying risk (151). The study in Chapter Four demonstrated that sub-
groups of survivors at high risk of hospitalisations due to cerebrovascular disease were CNS 
tumours and leukaemia. These findings were in agreement with another large population-
based study investigating the same outcome (71). This can only strengthen the evidence-base 
with respect to this adverse health outcome. The effect of cranial irradiation in the risk of 
survivors being hospitalised due to cerebrovascular disease is notable in this study. This may 
change as treatment protocols evolve over time but how this may impact on the vasculature of 
the brain and risk of cerebrovascular disease is unknown. It is suggested that survivors who 
have received cranial irradiation require closer monitoring with regards to cerebrovascular 
disease. Current CCLG and SIGN guidelines (17, 164) lack recommendations in the areas of 
cerebrovascular disease yet American childhood cancer survivorship guidelines recommend 
annual neurological examinations for those survivors who have received ≥18 Gy to specified 
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fields for monitoring of cerebrovascular disease (121). This highlights the need to harmonise 
guidelines, which is the remit of the International Guideline Harmonisation Group, founded in 
2010 (170).   
The overall risk of SPNs is well documented in guidelines (17, 121). However the risks of 
genitourinary SPNs have not been well documented in these guidelines, possibly as there have 
been few studies with adequate statistical power to investigate the excess risks of such cancers 
in survivors of childhood cancer. This highlights the need for more evidence. The study in 
Chapter Five demonstrated that certain groups of survivors are at increased risk of specific 
types of genitourinary subsequent primary cancers; Wilms' tumour survivors were at 
increased risk of kidney cancer and retinoblastoma survivors were at increased risk of bladder 
cancer. SIGN guidelines recommend GPs should be aware of patterns of presentation for 
SPNs (17). This is ever more important with symptoms such as haematuria which may be 
indicated as a sign of bladder cancer. Thus patients need to be counselled to recognise early 
symptoms and seek health advice as appropriate. Providing survivors with summaries of the 
cancer treatment they received in childhood will equip them with information they may need 
for the future particularly if the adverse late effects they could experience are many decades 
after their original cancer diagnosis as is the case with some of the genitourinary cancers.           
6.4 Future Research 
As the BCCSS cohort has been linked with HES, there is the possibility of ascertaining many 
more non-fatal non-neoplastic adverse health and social outcomes. HES only records data for 
hospitals within England therefore there are plans to link the BCCSS cohort with equivalent 
national databases in Wales (Patient Episode Database for Wales) (278) and Scotland 
(Information Service Division linked database for Scotland) (279) so coverage across the UK 
is maximised. There is also the potential to link the BCCSS cohort with other electronic 
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health record databases such as the Myocardial Ischaemia National Audit Project (MINAP) 
(280) which would enable further investigation of cerebrovascular disease and modifiable 
risk-factors such as smoking status, diabetes, hypertension, hypercholesterolaemia and 
increased BMI. This method of linkage would increase completeness and provide further 
diagnostic validity to ascertained events.    
  
Risk estimates of childhood cancer survivors developing genitourinary SPNs using the PCSF 
cohort were reported in Chapter Five. However a limitation in reporting these risk estimates 
was the lack of exposure information to assess the effect of treatment in the risk of survivors 
developing these SPNs. As mentioned previously, it will be possible to address this limitation 
in nested case-control studies that are being conducted as part of the PanCareSurFup project. 
Selection bias is minimised as the cases and controls will be selected from the underlying 
PanCareSurFup cohort. Data providers are in the process of collecting comprehensive 
treatment information relating to radiotherapy and chemotherapy for cases and controls in 
these nested case-control studies. Multiple exposures can be addressed in the outcome of 
childhood cancer survivors developing genitourinary SPNs on a scale that is unprecedented in 
terms of size of case-control studies. International collaboration is advantageous for 
investigating rare adverse outcomes such as site-specific genitourinary SPNs among 
childhood cancer survivors as the BCCSS alone would not have enough statistical power to 
conduct case-control studies but pooling cases with other countries overcomes this limitation.  
6.5 General Conclusions 
A retrospectively ascertained cohort such as the BCCSS is invaluable in providing empirical 
risk evidence in relation to a spectrum of adverse health and social outcomes. This thesis 
demonstrates that reliable and unbiased evidence can be provided from both the original 
BCCSS cohort, the recently extended BCCSS cohort and working collaboratively with 
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international partners in forming a European cohort. Findings from this thesis provides 
evidence to inform changes to the long-term follow-up practices of childhood cancer 
survivors in the UK; for the first time, follow-up has been approached in an evidence-based 
manner using risk stratification levels. At a time where resources are limited, the current 
stance of providing hospital-based multidisciplinary care will not be feasible for all survivors 
and there is the possibility of some survivors receiving less intensive levels of care. CNS 
tumour survivors and their risks of adverse outcomes differ by CNS sub-type and treatment 
with cranial irradiation. It will be important to consider these factors in providing advice 
regarding late effects and survivorship issues. Overall, childhood cancer survivors are at 
increased risk of hospitalisations due to cerebrovascular disease compared to the general 
population, specifically cerebral haemorrhage and ischaemic stroke. Survivor groups at 
particular increased risk of hospitalisation due to cerebrovascular disease were CNS tumours 
and leukaemia. CNS tumour survivors who had been treated with cranial irradiation were at 
an even greater risk of hospitalisation due to cerebrovascular disease. Survivors of Wilms' 
tumour and retinoblastoma were at the greatest risk of developing any genitourinary SPN; 
Wilms' tumour survivors were at particular increased risk of developing kidney SPNs and 
retinoblastoma survivors were at particular increased risk of bladder SPNs. It is important that 
health professionals involved in the long-term follow-up care of childhood cancer survivors 
are aware of the excess risks of genitourinary SPNs as survivors become older so they may 
provide information accordingly and counsel survivors in relation to early symptoms.    
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